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Thesis Abstract 
We have previously ide~tified antibody-defmed epitopes on the HLA-ORB1 *04 
molecules that are associated with development of rheumatoid arthritis (RA). The 
, -. 
expression of a NFL0.01 f.:defined epitope (011+0401) on B cell lines (BCL) is 
dependent on HLA-OM. NFL0.013 recognizes ORB1 *0404, but not ORB1 *0401 in 
0~ BCL (D13+0404). However, in OM- BCL, NFLD.D13 recognizes an epitope on 
HLA-ORBI *0401 molecules (D13+0401). It was speculated that these epitopes arise 
either through acquisition of peptides from differentiation antigens or through differential 
processing and acquisition of a peptide from a common protein. Initially, we show that 
these epitopes were not detected on the surface of synovial fibroblasts from RA patients, 
despite the up-regulation of DR, OM molecules and compartments necessary for class II 
antigen processing and presentation. Further investigation showed that the expression of 
the 011+0401 and 013+0404 epitopes was restricted to professional antigen presenting 
cells, with the exception of the melanoma cell MDA MD 435.0401, which expressed 
011+0401. To analyze the intracellular mechanisms by which the 011+0401 and 
013+0404 epitopes are generated, we treated normal and OM- BCL with various 
inhibitors, including brefeldin A and protease inhibitors, and employed confocal and 
immunoelectron microscopy to dissect the compartments within the endocytic pathway 
where these epitopes form. We found that both the 011+0401 and 013+0404 epitopes 
form within C063+C082+ lysosomal compartments in normal BCL. The 011+0401 
epitope requires cytoplasmic and endosomal cysteine proteases, whereas 013+0404 
epitope expression is protease independent. Both epitopes appear to require tetraspan 
1 
protein-enriched microdomains for proper surface expression. Interestingly, the 
D13+0401 epitope also ~equired cysteine proteases for its expression, suggesting that a 
I ~ 
unique set of peptides are responsible for the formation of these DRB 1 *04 epitopes. 
' -. 
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1. Introduction 
1.1 The Major Histocompatibility Complex 
1.1.1 Genetic Organization 
The major histocompatibility complex (MHC), a tightly linked cluster of genes 
involved with the adaptive and innate immune systems, is located on the short arm of 
chromosome 6 (band p21.3) in humans and on chromosome 17 in mice [1]. The human 
MHC genomic region, known as human leukocyte antigen (HLA) is 3.6 Mb in length 
with approximately 224 coding and non-coding sequences [ 1-4]. The HLA region 
comprises several loci that encode structurally homologous proteins which are classified 
into HLA class I (HLA-A, -B, and C) and class II (HLA-DR, -DQ, and DP) antigens in 
relation to their structure, tissue distribution and function. MHC molecules were 
originally identified because of their role in tissue rejection following transplantation, but 
upon further analysis their biological function was shown to be involved in presenting 
exogenous and endogenous peptides toT cells [5-8]. The hallmark ofMHC molecules is 
their allelic polymorphism, which increases the total chance of an immune response 
against a given microorganism. This way at least a subset of individuals within a given 
population will respond to the microbe, ultimately increasing the total population's 
chance of survival against infection. 
Based on the search for HLA compatibility required for proper tissue 
transplantation between individuals, the large polymorphism amongst HLA molecules 
was first detected by serology, using typing reagents derived from the sera of multiparous 
women, or blood donors that had received multiple blood transfusions. More recently, 
1 
DNA based typing techniques have further advanced our knowledge of the extensive 
diversity of the HLA complex. For example, at the time of writing, according to the 
European Bioinformatics Institute (EMBL-EBI-www.ebi.ac.uk/imgt/hla) the 100 
serologically-defined HLA-A~ -B, -C, -DR, -DQ and -DP specificities now comprise 
more than 1700 alleles defined at the DNA level. 
In humans the MHC is organized into three distinct, non-overlapping gene-rich 
regions that are designated from centromere to telomere as class II, III and I regions 
(Figure 1 ). In addition to the six major groups of loci mentioned above, the MHC is 
distinguished from other regions of the human genome by the high degree of gene 
density, with about 40% of the genes found within the MHC encoding for proteins with 
immunological functions [9]. There are several functional categories of MHC gene 
products that are expressed, including those involved with antigen processing and 
presentation (HLA-DM, HLA-DO, LMP2, LMP7, and TAP), those involved in innate 
immunity, inflammation and immune regulation, such as the complement components C2 
and C4, TNF and HSP70, as well as genes whose function is other than the immune 
response (Fig 1 ). 
The HLA class I region, found on the telomeric end of the MHC region is 1.8 Mb 
and encodes for 18 HLA class I genes (6 coding and 12 pseudogenes) and several non-
HLA related genes whose functions range from cell growth, DNA replication and repair 
and regulation of transcription [9]. The function of many of the genes within the HLA 
class I region is still unknown. As mentioned above, this region includes genes that 
encode for the heavy chains of the classical class I molecules HLA-A, B and C. 
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Currently, there are 303 known HLA-A alleles, 609 known HLA-B alleles and 150 
known HLA-C alleles [EMBL-EBI]. The HLA class I heavy chain, also known as the a 
chain, pairs with a smaller molecule known as Prmicroglobulin CP2M), encoded on 
chromosome 15, to form mem ane glycoproteins found on the surface of almost all 
nucleated cells [4]. These molecules function by presenting short peptide antigens which 
are mainly derived from endogenous proteins, to CD8+ T lymphocytes [4]. The HLA 
class I region also encodes for non-classical MHC molecules, also known as class lb 
molecules, such as HLA-G, -F and -E. These molecules, which are structurally similar to 
classical HLA class I molecules, also function by presenting peptides to CD8+ T cells and 
have been suggested to have a role in immune recognition [10]. 
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Figure 1. Diagram of the genorruc map of the human lll,A region located on 
chromosome 6, spanning 4000 kb. The lll,A class I genetic region is shown in red, the 
lll,A class II is shown in blue, and the lll,A class ill region is shown in green. (Adapted 
from Kuby Immunology, 4th edition, © W.H Freeman and Company). 
The lll,A class II region is located on the centromeric end of the MHC and covers 
about 0.7 Mb, encoding for 19 lll,A class II genes (11 coding and 8 pseudogenes). This 
region includes genes that encode for the classical MHC class II molecules lll,A-DP, DQ 
and DR in addition to genes that encode for proteins with a variety of immunological 
functions, including lll,A-DM and HLA-DO, two non-classical lll,A class II molecules 
involved in antigen processing and presentation (Fig 1 ). lll,A-DP and lll,A-DQ proteins 
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are formed from the pairing of either the DPA1 and DPB1 or DQA1 and DQB1 gene 
products, and exhibit less polymorphisms then HLA-DR. There are 108 known DPB1 
alleles, 20 known DPA1 alleles, 56 known DQB1 alleles and 25 known DQAl alleles 
[EMBL-EBI-www.ebi.ac.uk/ gt/hla]. DPA2, DPA3, DPB2, DQB2 and DQA2 are 
pseudogenes also found within the HLA class II region. 
The HLA-DR region encodes for a DRA gene, which has 3 known alleles (only 
one is functional) and pairs with a DRB gene product. Much of the polymorphism within 
HLA-DR molecules stems from the DRB1 gene, for which there are approximately 363 
known alleles [EMBL-EBI-www.ebi.ac.uk/imgt/hla] at time of writing. Another reason 
for the increased complexity of the HLA-DR region is due to the fact that a second DRB 
gene may be expressed, depending on the particular MHC haplotype. All individual 
haplotypes contain, with the exception ofDRB1 *01, *10 and *08, a second DRB allele in 
addition to the DRBl allele. For example, DRB3 (DR52) is expressed in individuals that 
are DRBl *11, *12, *13, *14, *17 or *18; DRB4 (DR53) is expressed in individuals that 
are DRB1 *4, *7 or *9; and DRB5 (DR51) is expressed in DRB1 *15 and *16 individuals. 
This further increases the number of HLA-DR molecules that can be expressed on the 
cell surface as the DRa chain can pair with either of the two DRP chains [8]. 
This complexity is reflected in the changes in nomenclature for the HLA over the 
past 20 years. International collaboration has allowed the definition and official 
designation of all HLA specificities (serology) and alleles (DNA), providing a universally 
accepted system. This is necessary since most of the serologically defined specificities 
can be subdivided into many continually growing allelic subtypes. For example, 
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serotypically two people can both be DR4, but contain different DR4 alleles (i.e. ranging 
from HLA-DRBI *0401 through to HLA-DRBI *0438). Despite this diversity, all HLA-
DR molecules are formed from a DRa chain and a DRf3 chain, which form 
heterodimeric, membrane glycoproteins. These molecules are found constitutively on 
antigen presenting cells (APC) such as B cells, macrophages (M<t>) and dendritic cells 
(DC), and can be up-regulated on other cell types where they function by presenting 
peptides derived from exogenous antigens to CD4+ T lymphocytes. 
The MHC class III region is located centrally between the class I and class II 
regions. This region is the most gene rich within the human genome, with 62 genes 
containing more than 500 exons over 706 kb [4]. Although this region does not contain 
classical HLA class I or class II-like molecules, HLA class III genes do encode for 
proteins that have a variety of immune functions such as the inflammatory mediators 
tumor necrosis factor-a (1NF-a), heat shock protein 70 as well as components of the 
complement system, such as C4A. 
1.1.2 General Structure of liLA Class I and Class II Molecules 
HLA class I and class II molecules are closely related membrane bound 
glycoproteins that bind short antigenic peptides and present them to CD8+ and CD4+ T 
cells respectively. Class I molecules (HLA-A, B and C) consist of a large polymorphic a 
chain ( 45 kD) associated with a smaller f32-microglobulin molecule (12 kD) (Figure 2). 
The a chain can be further divided into three smaller domains known as al , a2, and a3, 
along with a transmembrane domain and a cytoplasmic domain. The al and a2 domains 
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form a peptide binding groove, which consists of eight antiparallel ~ strands on the 
bottom and two a-helical regions on the sides. This structure is then able to 
accommodate an appropriate antigenic peptide in its groove. Since the peptide binding 
groove is closed at both ends, c ass I molecules require peptides between 8 and 10 amino 
acids in length [4, 8]. The a3 has an immunoglobulin-like domain and associates non-
covalently with ~2-microglobulin. The CD8 molecule on the T cell contacts the a2 and 
a3 domains of the HLA class I molecule, as well as having some contact with ~2-
microglobulin. 
HLA class II molecules (HLA-DP, DQ and DR) have a similar basic structure, 
although the class II heterodimer consists of a 33-35 kD a-subunit combined with a 25-
30 kD ~-subunit [8]. Both the a and the~ subunits contain two domains. The a2 and ~2 
domains are closest to the cell membrane and like the class I a3 domain, have homology 
to the immunoglobulin fold structure. The membrane-distal a1 and ~1 domains form a 
large peptide binding groove, similar to that seen in the class I molecules. However, 
unlike class I molecules, the peptide binding groove in class II molecules is open at both 
ends, and can therefore accommodate slightly longer peptides consisting of 13-25 amino 
acids [8]. The CD4 molecule on the T cell contacts the HLA class II molecule via the ~2 
domain. The allelic polymorphisms in HLA-DR molecules are located primarily in the 
~1 domain, whereas polymorphism in HLA-DQ and HLA-DP molecules are located in 
both the al and ~1 chains. 
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Figure 2. Diagram of the structure of HLA class I and class IT molecules. Both 
molecules contain external domains, transmembrane segments, cytoplasmic tails and a 
peptide binding cleft which is formed by the a2 and a3 domains for HLA class I and the 
al and PI domains for HLA class IT. (Adapted from Kuby Immunology, 4th edition, © 
W.H Freeman and Company). 
1.1.3 Generation of Cell Surface HLA Class I and II Molecules 
1.1.3.1 HLA Class I 
HLA class I molecules present peptides, derived mostly from intracellular 
polypeptides, to CDS+ T lymphocytes. The assembly of mature, peptide-bound class I 
molecules occurs in the endoplasmic reticulum (ER) and involves several chaperone and 
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accessory molecules (Figure 3). Initially, the HLA class I a chain associates with the 
chaperone molecule calnexin, which promotes proper folding of the protein. Calnexin is 
replaced by calreticulin and tapasin when ~rmicroglobulin associates with the a chain. 
Meanwhile, in the cytoplasm an ATP-dependent multi-subunit protease called the 
proteasome degrades ubiquitinated proteins as a part of normal cell turnover. Most of 
these targeted proteins are misfolded newly synthesized proteins or defective ribosomal 
products, and form the majority of steady-state class I peptides. Other cytoplasmic 
proteases have also been implicated in the formation of class I peptides, including 
calpains, bleomycin hydrolase, thimet oligoendopeptidase, leucine aminopeptidase, and 
tripeptidyl peptidase II [11]. 
Peptides of the appropriate length (8-11 amino acids) are then transported from 
the cytoplasm to the ER by a heterodimeric protein known as transporters associated with 
antigen processing (TAP). This process requires the hydrolysis of ATP and preferentially 
favors the transport of peptides with either hydrophobic or basic carboxyl-terminal amino 
acids, which are preferred as anchor residues for class I molecules. The complex of the 
class I a chain, ~2-microglobulin and calreticulin are brought into close proximity to TAP 
by tapasin, forming the class I peptide-loading complex. The close physical association 
of the molecules in this complex favors the binding of appropriate peptides to the class I 
molecule. After stable binding, the MHC/peptide complex is transported from the ER 
through the Golgi complex to the plasma membrane through small vesicles [8]. 
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Figure 3. Overview of the HLA class I antigen presentation pathway. First, 
Ubiquitinated proteins are degraded by the multi-subunit proteasome to generate 
individual peptides. These peptides are then transported into the ER by the TAP 
complex. Meanwhile HLA class I molecules are associate with various chaperone 
molecules until loaded with the appropriate peptides (Adapted from Kloetzel, Nature 
Reviews Molecular and Cellular Biology, 2001, 2:179-186. ©Nature Publishing Group, 
Macmillan Publishers). 
1.1.3.2 HLA Class ll 
HLA class IT molecules are expressed constitutively on specialized professional 
APC such as B cells, macrophages (M<I>) and dendritic cells (DC). In the presence of 
inflammatory mediators such as interferon-y (IFN-y), expression of these molecules can 
be induced on the surface of a wide variety of cell types collectively known as non-
10 
-professional APC [8]. The formation of HLA class Illpeptide complexes is the result of 
the encounter of two trafficking pathways. Antigens are transported along the endocytic 
pathway where they eventually encounter the class II molecules that have been 
transported there via the ER an · golgi (Figure 4). 
Class II molecules are synthesized de novo in the ER where they associate with a 
co-chaperone molecule known as the invariant chain (Ii). Three class II a~ dimers 
associate with three molecules of the Ii, which is a non-polymorphic type II integral 
membrane protein [8]. Ii plays several critical roles in the production of mature class II 
molecules that are recognized by the TCR; first, Ii binds to the class II molecule in such a 
way that it occupies the peptide-binding groove. This prevents premature association of 
irrelevant peptides with class II in the ER and golgi [12]. Second, the association of the 
Ii with newly synthesized class II molecules ensures that the molecular complex is 
targeted to the endocytic pathway due to a double leucine motif in the cytoplasmic tail of 
the Ii [12]. Because of this, class II/Ii complexes can leave the ER and travel to the Golgi 
apparatus, towards intracellular vesicles within the endocytic pathway, with the majority 
finally accumulating within the low pH environment of late endosomal (multivesicular 
structure) and lysosomal (multilaminar structure) compartments collectively known as 
MHC class II compartments (MIIC) [13-15]. This ensures that class II molecules interact 
with antigenic peptides that are derived from proteins degraded in the endocytic vesicles. 
This process is not 1 00% efficient though, and a fraction of class II/Ii complexes are 
delivered to the plasma membrane directly. These complexes are believed to recycle 
through early endosomes where they can encounter antigenic peptides [16]. 
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HLA class II molecules present peptides derived mainly from the exogenous 
processing pathway. More specifically, the protein source for class II peptides are 
generally proteins that have been taken up by the cell via clathrin-dependent receptor-
mediated endocytosis, clatltrin-independent macropinocytosis or receptor-mediated 
phagocytosis [8]. The antigen then enters the endocytic pathway and is transported along 
a series of compartments from early endosomes (pH 5.5-6.5), to late endosomes (pH 4.5-
5.5), and finally to lysosomes and MIIC (pH 3.0-4.0) [15]. Within these low pH 
compartments the antigen is unfolded and degraded by a variety of proteases. Further 
analyses of natural MHC class II ligands have shown that most class II-associated 
peptides are derived from cellular proteins, predominantly from proteins expressed on the 
plasma membrane [17], such as the transferrin receptor, which recycles constantly 
through the early endosomes from the plasma membrane, Na+K+ATPase and the IL-3 
receptor [17]. Peptides derived from MHC class I molecules are also abundantly 
expressed in the peptide binding groove of MHC class II molecules [17]. Finally, a 
considerable portion of class II peptide ligands originate from proteins found within the 
endosomal and lysosomal compartments, with the majority of them derived from the 
invariant chain [17]. Peptides derived from lysosomal proteases, such as cathepsin Hand 
cathepsin E have also been observed [Reviewed in 17]. 
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Figure 4. The HLA class II antigen processing and presentation pathway. HLA class II 
molecules associate with the Ii and are transported either to the late endosomes or to the 
MHC class II compartments (MIIC). Here the Ii is degraded and CLIP is removed by 
HLA-DM, being replaced by antigenic peptides that are formed from the breakdown of 
exogenous proteins. These complexes are then transported to the cell surface in order to 
interact with CD4+ T lymphocytes. Alternatively, Class II/Ii complexes can be 
transported directly to the cell surface where they can recycle through early endosomal 
compartments. The relative pH levels of each of the intracellular compartments in the 
endocytic pathway are represented by the appropriate litmus color. (Adapted from van 
Ham et al, Immunogenetics 2000, 51(1 0):765-70. © Springer-Verlag Heidelberg). 
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Within the MIIC numerous key processes for the generation of proper class II-
peptide complexes occur. First, the invariant chain is gradually degraded by cysteine 
proteases, notably cathepsin Sin B cells and DC, cathepsins L, S and Fin M<l> [18, 19] 
and cathepsin Lin murine thymic cortical epithelial cells [18]. As shown in Figure 5, the 
stepwise proteolysis of the Ii yields numerous peptide fragment intermediates known as 
Lip23 (Leupeptin-induced peptide; LIP) and Lip10 (Small leupeptin-induced peptide; 
SLIP) and finally a short peptide from residues 88-102 in the class II binding groove 
known as the class II-associated invariant chain peptide (CLIP) [20]. CLIP displays 
variable binding affinities for individual class II alleles [21, 22] and its removal from 
class II molecules involves two co-chaperone molecules HLA-DM and HLA-DO, both 
permanent residents of the endosomal/lysosomal system [23]. The role of HLA-DM in 
the generation of mature class IT/peptide complexes is to facilitate the removal of CLIP, 
while promoting the binding of more stably binding peptides [23-27]. HLA-DM can also 
remove peptides that bind to class II with low affinity, thereby selecting peptides that 
bind to the class IT molecules with higher affinity. This process seems to be due to 
conformational changes in the class II-DM complex, which is different in the presence of 
low and high affinity peptides. As a co-chaperone molecule, HLA-DM also stabilizes the 
peptide-free conformation of the HLA class II molecule, preventing irreversible damage 
in the low pH environment of the MIIC. 
The role of HLA-DO is more controversial. It associates with HLA-DM in 
heterodimeric complexes within the endocytic pathway and is expressed mainly in B 
cells. Although it is clear that HLA-DO modifies the peptide exchange activity ofHLA-
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DM, the physiological relevance of the DM-DO association is still unclear [24]. The 
influence of DO on DM activity appears to be pH-dependent, such that DO inhibits the 
activity of DM at pH above 5.5 [23, 28]. Kinetic analysis has shown that DM-DO 
complexes bind more tightl~o class II molecules compared to DM alone, suggesting 
another potential mechanism of DO function. 
Investigation of pMHC complexes within the endocytic pathway and on the cell 
surface has revealed that the interaction between APC and T cell results in a protein 
reorganization on the surface of both cells known as the immunological synapse. MHC 
molecules can be incorporated into two types of membrane microdomains; cholesterol 
and glycosphingolipid-enriched domains, known as lipid rafts, and microdomains made 
up of 10-30 tetraspan proteins such as CD9, CD63, CD81, and CD82 [15-16]. Lipid raft 
microdomains are smaller in size compared to tetraspan microdomains, and differ from 
other membrane areas in their high cholesterol and high lipid to protein content. 
Tetraspan microdomains, defmed by the B cell activation marker CDw78 may contain up 
to 30 proteins, including non-tetraspan proteins such as HLA-DM. These microdomains 
have been shown to contain class II molecules that are enriched with particular peptides, 
probably due to the presence of DM [15]. Although lipid rafts and tetraspan 
microdomains are distinct structures, they may exist together or separately on the cell 
surface, even though both function to concentrate relevant pMHC complexes for 
interaction with TCR on the surface ofT cells. 
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Figure 5. Diagram of the stepwise breakdown of the invariant chain (li). Full-length Ii 
is shown at the top, followed by the initial breakdown product, Lip23 (LIP), which is 
further degraded into Lip10 (SLIP) and finally into CLIP. (Adapted from Riese and 
Chapman, 2000; Current Opinion in Immunology 12:107-113. © Elservier Science Ltd). 
1.1.4 HLA-DR Structure and Peptide Binding 
As stated above, the primary function of HLA molecules is to bind short peptides 
and present them to T cells. This interaction will influence the selection of the peripheral 
T cell repertoire as well as the specific T cell response to certain antigens. The binding 
capacity of any given peptide to a MHC class II molecule is dependent on the primary 
sequence of the peptide and on the allelic variation of the residues within the peptide 
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binding groove. Knowledge of how class II molecules bind peptides in addition to the 
sequence of these peptides has been aided by in vitro peptide binding and elution studies 
in addition to detailed crystallographic data of class II molecules bound with a specific 
peptide [reviewed in 29 and 30]. 
For HLA-DR molecules, the peptide is bound within a long cleft formed between 
two antiparallel helical structures and a floor formed by an eight-stranded P-sheet [27-
29]. The peptides are held in place by hydrogen bonds between the peptide backbone and 
the residues along the class II molecule itself. As seen from the crystal structure of 
several HLA-DR molecules [31-33], including HLA-DR4 (DRA*0101 , DRB1*0401) 
complexed with a human collagen II peptide [31], class II molecules bind peptides of 
varying lengths, but each peptide contains a core binding region of 7-10 amino acid 
residues, designated P1 through P10. Bound peptide residues that project downwards 
into the peptide binding groove are accommodated by allele-specific pockets found 
within the class II molecule. It is the class II pocket shape and composition that 
determines the amino acid make-up of the peptides that can bind to the class II molecules, 
and these qualities differ greatly amongst HLA-DRB alleles. 
From the crystal structures of several HLA-DR molecules associated with known 
peptides, it has been observed that most MHC class II molecules have 4 major binding 
pockets in their peptide binding groove [31-33]. The majority of the HLA-DR allele-
specific polymorphic residues are located on the surface of the pockets, and this selects 
for a distinct peptide repertoire amongst different HLA-DR molecules due to the amino 
acid composition and the electrostatic charge of the individual amino acids. Pocket 1 is 
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made up from DRJ3 chain amino acids 85, 86, 89 and 90; pocket 4 contains J3-chain amino 
acids 13, 44, 70, 71 and 78; pocket 6 is formed from J3 chain amino acids 11 and 13; 
pocket 7 is formed from J3 chain amino acids 28, 47, 61, 67 and 71, and pocket 9 is 
formed from J3 chain amino aeids 9 and 57 [32]. Both non-polymorphic and polymorphic 
residues contribu~. to peptide binding though, with non-polymorphic residues binding to 
main chain atoms of the bound peptide and polymorphic residues within the different 
pockets binding to the peptide side chains [29]. 
Analysis of the sequence motifs of peptides that bind to HLA-DR molecules 
revealed that as many as 80% of the peptides show an enrichment of aromatic residues 
near the amino terminus [17, 34, 35]. This amino acid residue at position 1, known as P1 
is the general anchor residue. P4 is known as the second general anchor residue, and 
aligned peptide pools from class II molecules show an enrichment of hydrophobic 
residues [34]. The third anchor residue is at P6, which is generally occupied by small 
amino acids such as alanine and glycine for DRB1 *0101 or threonine and serine for 
DRB1 *0401 [34]. P6 also has an important role in determining allelic specificity of 
peptide binding to HLA-DR molecules. P9 also forms an anchor residue which is 
directed inwards towards the class II peptide binding groove pockets. Therefore amino 
acids residues at peptide positions P1, P4, P6 and P9 occupy the class II binding cleft, 
whereas positions P2, P3, P5, P7 and P8 face away from the cleft, ·and are available for 
interaction with the T cell receptor. In fact, amino acid residues P4-P8 are the most 
diverse, mainly because they interact with HLA-DR molecules in areas with the highest 
degree of polymorphism [35]. Of these positions, the P5 environment is the most 
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polymorphic and contains the particularly variable positions ~11, ~13, ~30, ~71 and ~74 
of the DRBI chain. P5, along with P7 have been suggested to play an important role in T 
cell recognition [35]. 
Promiscuity is a common feature of peptides bound to HLA class II molecules, 
meaning that certam peptides are able to bind several or more DR alleles. It is thought 
that this promiscuous binding is because the HLA-DR molecule has both conserved and 
allele-specific residues in the peptide binding groove for the putative peptide to interact 
with. Since HLA class II molecules exhibit both allele-specific and non-specific 
residues, they are able to bind a large range of peptides in both a promiscuous and allele-
specific manner. A good example of peptides that bind HLA class II molecules in a 
promiscuous manner are the invariant chain-derived peptides which bind at variable 
abilities to different class II alleles, since these peptides often exhibit mismatches to the 
allele-specific residues in the peptide binding groove. 
1.1.5 Proteases Involved in the Generation of HLA Class 11-peptide Ligands 
As outlined in section 1.3.2, cysteine proteases are responsible for the degradation 
of Ii in various cell types. This makes HLA class II molecules receptive for interaction 
with HLA-DM, which catalytically removes CLIP. Various proteases found within the 
endocytic pathway are also responsible for degrading protein antigens into short peptides. 
If these peptides contain the correct structural motifs, they should bind the relevant class 
II molecules. Generation of class II peptide ligands within the endocytic pathway is 
thought to be mainly due to cathepsins, which are proteases that are optimally active at 
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acidic pH [20, 36, and 37]. The main categories of cathepsins include cysteine, aspartyl 
and serine proteases, depending on their substrate specificity. In APC the most 
prominent endocytic cysteine proteases are cathepsin B, S and L, whereas the most 
common endocytic aspartyl p teases are cathepsin D and E [20]. 
The breakdown of a particular antigen does not involve one single protease at a 
time, but requires the interplay of the diverse group of endosomal proteases. For 
example, cathepsins D, E, L and S all have potent endoprotease activities and may 
therefore be important in revealing and releasing antigens. Cathepsins B and H have 
weak endoprotease activities, but do have potent carboxypeptidase and aminopeptidase 
activities, respectively [3 8]. The involvement of a diverse group of proteases implies that 
the loss of a particular protease might be tolerated by an organism. This, in fact, has been 
shown in mice deficient for either cathepsin B, D or L [18, 39]. These mice have normal 
T cell development, both in cell numbers and diversity of the T cell response, indicating 
the dispensability of individual proteases in class II peptide ligand generation [18, 39]. 
Recent evidence has suggested that class II peptide ligands can also be generated by 
proteases that are active at neutral pH, namely the proteasome and calcium dependent 
cytoplasmic cysteine proteases collectively known as cal pains [ 40]. 
Once loaded with an appropriate peptide ligand, the class IT-peptide complex 
travels to the cell surface, either through direct fusion of the MIIC with the plasma 
membrane, or through a series of smaller transport vesicles. 
20 
1.1.6 HLA-DRBl *04 Molecules and Rheumatoid Arthritis 
Because of their role in presenting peptides to T cells via the T cell receptor 
(TCR), and since various HLA class II alleles have been associated with autoimmune 
disease in humans it has been hypothesized that HLA class II molecules play an 
important role it}.,.the development of autoimmune disease [41, 42]. For example, HLA-
DQB1 *0302 and HLA-DQB1 *0201 are associated with autoimmune type 1 diabetes and 
Celiac disease. HLA-DR molecules are associated with diseases such as autoimmune 
hepatitis, multiple sclerosis and rheumatoid arthritis (RA) [43]. All RA-susceptible 
alleles possess a homologous short stretch of amino acids (LLEQ(K/R)RAA) at positions 
67-74 ofthe p1 chain, which is often referred to as the shared epitope [41]. In Caucasian 
populations, the major HLA-DR alleles that are associated with increased risk to RA are 
DRB1 *0401 and DRB1 *0404, which differ in the shared epitope region, at positions P71 
(Lys to Arg) and P86 (Gly to Val). 
Studies of Mediterranean and Jewish populations showed that although 
DRB1 *0402 was the most common DR4 allele, it was not associated with RA. Instead, 
DRB1 *01 and *10 were found to be associated with RA [42-44]. Amino acid sequencing 
of these p chains showed that DRB1 *01 and *10 carried the shared epitope, whereas 
B1 *0402 differed conservatively from B1 *0401 and B1 *0404 by negatively charged 
residues at positions P70D and P71E. Interestingly, HLA-DRB1 *0402 confers resistance 
to the development ofRA. The amino acids at positions 67, 70 and 71 which line pocket 
4 appear to be particularly important in disease progression. For example, HLA-
DRB1 *0401 molecules prefer a negatively charged residue to bind in pocket 4 due to a 
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lysine at position p71. In contrast, HLA-DRBl *0402 molecules have negatively charged 
residues (p70-D, p71-E) surrounding pocket 4, causing selection of peptides that have a 
positively charged residue at this position. Positions P70 and P71 have also been shown 
to be important for interacta'ig with the TCR. Therefore it is possible that HLA 
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molecules that carry the shared epitope may select a particular population ofT cells in the 
thymus that lead to RA disease progression [43, 44]. 
Several mAbs that are specific for various epitopes on HLA-DRBI *04 molecules 
were produced and characterized by Drover and Marshall [45-51]. They include 
NFLD.Dl, a mAb that recognizes an epitope on the P2 chain of all HLA-DR4 molecules 
[48] and mAbs that recognize the shared epitope. NFLD.D2 recognizes the amino acid 
sequence of QKRAA/QRRAA on the DRBI chain [48] and NFLD.DlO binds to HLA-
DR molecules that express and Qat position 70 of the p chain [49], with the exception of 
HLA-DRBl *03 and DRB3 products. These mAbs have been useful in studying the 
expression of HLA-DR4 and the shared epitope on a variety of P-APC cell types, 
including HLA-DM negative mutants and NP-APC including synovial fibroblasts 
isolated from patients that have RA. 
Two other mAbs, whose epitopes are the main focus of this thesis, are NFLD.Dll 
and NFLD.Dl3. NFLD.Dll was previously shown to .bind DRBl *0401 molecules on 
EBV-transformed B cell lines [47, 50, 51]. In addition to binding strongly to B cell lines, 
NFLD.Dll was also shown to bind weakly to peripheral blood B cells from normal 
controls and RA patients [47] The formation of this epitope is dependent on the presence 
of the co-chaperone molecule HLA-DM [50 and Chapter 3], as B cells that do not express 
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HLA-DM fail to express the NFLD.Dll epitope (50, 51]. NFLD.Dl3 has an intriguing 
specificity. It recognizes DRBl *0404, but not DRBl *0401 in HLA-DM positive EBV-
transformed B cell lines. However, in B cells that do not express HLA-DM, NFLD.Dl3 
recognizes an epitope on HLA-DRBl *0401 molecules [51 and Chapter 3]. Both the 
NFLD.Dll epitope on DRBI *0401 molecules and the NFLD.Dl3 epitope on 
DRBl *0404 molecules are also expressed on activated macrophages, but not on a wide 
variety of NP-APC, suggesting that an activated phenotype is necessary for their 
formation. This may be due to specific proteases or antigen processing compartments 
present only in P-APC. 
The critical role of HLA-DM in the formation of these DRBl *04 epitopes 
suggests that a different set of peptides may be involved in their generation. 
Alternatively, since the NFLD.Dll and NFLD.Dl3 epitopes are preferentially expressed 
on P-APC, differential antigen processing pathways may be required for their generation. 
For the work described in this thesis, several approaches were used to dissect the cellular 
processes which are involved in the formation of the NFLD.Dll and NFLD.D13 
epitopes. To understand further how these DRBI *04 epitopes may be used to investigate 
basic immunological processes, the following sections will discuss how other mAb 
specific to pMHC have been defined experimentally and used in different aspects of 
immunological research. 
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1.2 MHC Class WPeptide Specific mAbs. 
The first MHC class II-peptide (pMHC) specific antibody was described initially 
in 1989 by Charles Janeway' group and was designated Y Ae. It recognizes a complex 
formed by a self peptide (Ea56_73) bound to J-Ab molecules [52] and is expressed on B 
cells, medullary thymic cells and DC [52, 53]. Studies using Y Ae have led to important 
insights about the antigen processing of endogenous proteins within the endocytic 
pathway in a variety of cell types. Since its description several other pMHC-specific 
mAbs have been described, with each contributing to our overall knowledge of basic 
cellular and immunological processes. 
First, since these mAbs recognize endogenous peptides in the context of MHC 
class II, they have proved useful in assessing the abundance of endogenous pMHC 
complexes on a variety of cell types, including both professional APC and non-
professional APC. For example, identification of specific endogenous pMHC expressed 
within the thymus contributed to our understanding of the role of self peptides in positive 
and negative selection of T cells. By comparing the expression of thymus-expressed 
peptides within peripheral sites, such as the spleen and lymph nodes, these studies 
highlighted the importance of endogenous pMHC in the maintenance of peripheral 
tolerance in a healthy, non-self reactive immune system. 
Second, since many of the described mAbs apparently bind to the pMHC complex 
in a manner analogous to T cell receptor (TCR) recognition of the same complex, they 
have been useful in studying the TCR-MHC interaction both in structural terms and in 
quantifying the number of MHC/specific peptide complexes required for T cell 
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activation. Third, given that these mAbs are specific for a single pMHC complex, the 
intracellular generation of these complexes can be assessed within different cell types 
using subcellular fractionation and various microscopical methods. Lastly, if the mAb is 
directed towards a known a oantigenic pMHC complex, then the possibility of specific 
immunotherapy of the autoimmune disease in question by blocking the autoreactive T 
cell response is tantalizing. This was partly addressed by Aharoni et al, 1991 [54] who 
showed that mAbs specific for myelin basic protein (MBP) peptides in the context ofl-A5 
inhibited the onset of experimental allergic encephalomyelitis (EAE) in mice. 
Unfortunately these promising results presented by the authors have not been followed up 
in a more recent publication. 
1.2.1 Relative Abundance of Self-Peptide/MHC Complexes. 
1.2.1.1 Endogenous Antigen 
Originally it was thought that the majority of cell surface MHC class II molecules 
contained peptides derived from exogenous antigen. Sequencing of peptides eluted from 
class II molecules revealed that the peptide repertoire is actually generated from 
endogenous as well as exogenous proteins [55]. 
Specifically, Rudensky and colleagues found that the majority of peptides isolated 
from the MHC class II molecules (I-A and I-E) from the murine B-cell lymphoma line 
LB27.4 (H-2bxd) were derived from endogenously synthesized membrane proteins [56]. 
The Y -Ae mAb confirmed that class II molecules are loaded with peptides derived from 
endogenously synthesized proteins. Y-Ae, which was generated by immunizing 
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histoincompatible mtce with lipopolysaccharide (LPS) activated spleen cells from 
B1 O.A(5R) (H-2b) mice [52] was found to bind specifically to splenic B cells, and 
medullary thymic cells, in addition to M<I> and DC [52, 53]. Further analysis of the 
peptides eluted from Y-Ae putified molecules showed that the I-A b molecules recognized 
by Y-Ae contained a major self-peptide from another class II molecule; I-Eb [53]. This 
peptide, E~ts2-68 was found to be present in 10-15% of all I-A b molecules on the surface of 
peripheral B lymphocytes [56], and was found to be one of four or five major self 
peptides presented on the surface ofl-A b+ I-Eb+ B cell lines [52]. 
Another major study investigating the percentage of class II molecules bound 
with a known peptide involved mAb 30.2, generated against the Ii processing 
intermediate CLIP bound to I-A b [57]. Its binding was shown to be dependent on a lysine 
residue at position 90, flanking a conserved region of the Ii in hwnan, mouse and rat [58, 
_, 
59]. Similar to the high expression of endogenous Ea52.6s peptide in the contex of I-A b 
recognized by Y-Ae, Eastman et al, 1996 found that 30.2 bound to 13% of l-Ab 
molecules on the surface ofthe human B cell line T1 tranfected with the l-Ab gene [57]. 
A major self-peptide bound to class II was detected with the UL-5A1 mAb [60]. 
In this case, UL-5A1 recognized a conformational epitope on HLA-
DRI(DRAIDRB1 *0101) molecules bound with endogenously-derived HLA-A2 peptides 
or from exogenously provided HLA-A2 peptide 105-117 [60]. It was shown that this 
mAb recognizes an epitope found primarily on activated cells, such as EBV -transformed 
B cell lines. 
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1.2.1.2 Exogenous Antigen 
The mAb Aw3.14, generated against murine 1-Ak molecules bound with peptide 
48-62 from the exogenous antigen hen egg lysozyme (HEL ), was shown to bind to the 
peptide binding groove, contacting both the a-helices and the bound peptide [61]. 
Aw3.14 was also found to block recognition of HEL48-62 by specific T cell hybridomas 
[61]. The authors showed that when the murine B lymphoma cell line M12-Ak was 
incubated overnight with whole HEL, about 9% of the surface A k molecules became 
loaded with the HEL4s-62 peptide, as measured by Aw3.14. By calculating this as a 
percentage of the total class II molecules on the surface of M12-Ak, this amount of 
occupancy of the HEL48-62 peptide corresponded to 2 x 105 out of a possible 2.2 x 106 
molecules on the cell surface [61]. Taken together, these results supported the notion that 
a small number of abundant peptides, either from endogenous or exogenous proteins are 
present within the peptide-binding grooves of class II molecules. Studies of peptides 
eluted from class II molecules have shown that out of the total numbers of peptides, there 
are about 12 peptide species that are present at high levels. In addition to these peptides, 
a cell can present thousands of less abundant MHC/peptide complexes. 
1.2.2 Conformational Changes in MHC Class II Molecules Measured by pMHC 
mAbs. 
MHC class II molecules interact with the co-chaperone molecules HLA-DM and 
HLA-DO in compartments along the endocytic pathway and replace CLIP with antigenic 
peptides [22-26]. This exchange of peptides can be visualized by formation of sodium 
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dodecyl sulphate (SDS)-stable dimers such that class II molecules loaded with CLIP are 
SDS instable and termed floppy. MHC class II molecules loaded with the correct 
antigenic peptides are more stable and do not fall apart in the presence of SDS. The 
question of whether or not stable class II molecules exist in different conformations on 
the cell surface, and if these conformations affect the interaction with T cells has been 
addressed in studies using pMHC-specific mAbs. 
The specificities of some pMHC-specific mAbs are dependent on a certain 
conformation of the class II molecules [ 62, 63]. A study involving a peptide-dependent 
mAb 25-9-17 [62], and the peptide-specific Y-Ae mAb addressed whether the nature of 
the bound peptide affects the conformation ofMHC class II molecules [62]. The epitope 
recognized by the 25-9-17 mAb is dependent on amino acids ~65-67 and ~70, with the 
~65-67 being Pro-Glu-lle, a sequence which is located in a kink in the a.-helix of the ~ 
chain. 25-9-17 appeared to recognize two different conformations, depending on the 
peptide that was bound in the groove of l-Ab, due to this ~65-67 region. For example, it 
did not recognize the 1-A b -Ea.s2-6s, even though it did recognize 1-A b -CLIP. 
Knowing that the I-Ab-Ea.52-68 exists in "tight conformations" on the cell surface, 
and l-Ab-CLIP exists in "loose conformations" on the cell surface, the authors described 
two separate 25-9-17 -recognizable conformations [ 62], which were dependent on the 
peptide which was available to bind in the class II groove. Using a large panel of 
peptides the 25-9-17 mAb was subsequentially shown to discriminate between SDS-
stable (25-9-1 T) and SDS-unstable (25-9-17l. This was further extended by using 25-9-
17 to block the activation of several T cell hybridomas which were specific for various 
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naturally processed l-Ab peptides [62]. It was found that 25-9-17 blocked the activation 
of some but not all of the T eel hybridomas, suggesting that class II molecules acquire 
25-9-17+ and 25-9-1 T confom;1ations, and that T cells are sensitive to these two I -A b 
conformations. 
The results of this study had broad implications for thymic selection and 
autoimmunity, since at the time it was unclear whether T cells were selected on the basis 
of MHC class II structure. According to the 25-9-17 data, T cell recognition is directly 
dependent on the nature of the peptide and the conformation that the MHC molecule 
adopts. According to the studies done by Unanue and colleagues, the I-Ag7 molecules, 
which are implicated in the development of autoimmune diabetes in the NOD mouse, 
exists in a "floppy" conformation [64]. Thus, it is more likely to positively select for 
autoreactive T cells that fail negative selection and this may underlie the increased 
susceptibility to autoimmune disease. 
Another well-studied mAb, 16.23 which recognizes a conformational epitope on 
DR3 molecules, was ftrst described as DR3-speciftc [65], and was later shown to be 
dependent on HLA-DM [24, 63]. It was noticed that 16.23 did not bind to the DM 
negative B cell lines such as .174 [66]. Transfection ofDR3 into the cell line T2, which 
does not express HLA class II genes, did not reconstitute the 16.23 epitope and 
subsequent efforts showed that DM was absolutely required for the generation of the 
16.23 epitope [63]. However, although it initially was thought that 16.23 recognizes 
specific peptide(s) presented in the context of DR3, recent data has shown that 16.23 
actually recognizes a DM-induced conformational change in the DR3 molecule in a 
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peptide independent fashion [63]. This situation is reminiscent of the NFLD.Dll mAb 
which does not bind to DRBl *0101 in DM negative B cells, but which can be restored 
with the introduction ofDM [50] 
1.2.3 Insights into MHC Class ll Antigen Processing and Presentation 
1.2.3.1 The Relationship of CLIP and HLA-DM in Antigen Presentation 
MHC class II molecules bind short peptides found within the endocytic pathway 
for presentation to CD4+ T H cells. As described in section 1.3 .2 above, these proteins 
enter the endocytic pathway via numerous mechanisms, including pinocytosis, 
phagocytosis and receptor-mediated endocytosis. Considerable work has been done to 
dissect the processing of a protein internalized from via these different mechanisms [67, 
68, and 69]. In addition to the classical endocytic pathway, an alternative processing 
pathway is utilized for the production of endogenously-derived peptides for presentation 
on MHC class II molecules [38, 70]. 
The co-chaperone molecule HLA-DM catalytically replaces CLIP with peptides 
that have higher affinity for the class II peptide binding groove. This process was first 
demonstrated using a panel of mutant B cell lines that were defective in their ability to 
present protein antigen to CD4+ T cells, despite normal amounts of class II expression 
[71]. The ability to present antigen to T cells improved after the cells were given 
exogenous peptides. Despite the presence of DR3, these cell lines were not recognized 
by 16.23, a result that provided novel insights into the function of HLA-DM [71, 72]. 
Further genetic analysis of these cells showed that the defect in these cells mapped to the 
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class II region of the MHC [72, 73] and the deficiency could be rescued by transfection 
of functional HLA-DM genes [74 75]. 
Another mAb specific for pMHC, called 30-2 has also been useful in elucidating 
various components of the class II antigen presentation pathway, including the organelles 
where pMHC ligands are formed, and the relevant chaperone and proteases. Rudensky's 
group, using the mAb 30-2, specific for CLIP:I-Ab complexes, confirmed previous 
studies that showed high levels of these complexes on the surface of HLA-DM negative 
cells. For this they used the human antigen presentation mutant cell line T2 transfected 
with l-Ab, which contained significant amounts of CLIP bound to class II due to the 
absence of HLA-DM. They also investigated whether the general cysteine protease 
inhibitor leupeptin, which causes the partial inhibition of Ii degradation and the 
accumulation of LIP and SLIP, modulated the number of 30-2+ complexes on T2- l-Ab. 
They found that leupeptin did not decrease the number of 30-2+ complexes, and actually 
increased the number of these complexes [58] indicating that 30.2 can also recognize l-Ab 
bound with LIP and SLIP. 
1.2.3.2 Intracellular Generation of pMHC Complexes. 
The C4H3 mAb, developed by Germain' s group has been used extensively in the 
study of class II processing and presentation [76]. They produced several mAbs specific 
for various Hen egg lysozyme (HEL) peptides presented in the context of 1-Ak, with 
C4H3 being specific for a subset of these molecules that bind HEL46-61, and weakly cross 
reacting with HELli6-I29 [76]. To study the class II processing and presentation pathway 
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in more detail, they used confocal microscopy to localize the direct intracellular 
formation of the I-A k-HEL46-61 complex after administration of exogenous HEL. C4H3 
staining gave a bright vesicular pattern in A k expressing B cells, co-localizing mainly 
with the lysosomal marker ~-1, and not with a marker for early endosomes, the 
transferin receptor (CD71). This indicates that the major site of generation of this 
specific pMHC complex from exogenous source of antigen is the low pH lysosomal 
compartments and not the early endosomes [76]. 
The Y -Ae mAb was similarly used to study the formation of complexes of class II 
molecules loaded with endogenous peptide [77]. They found that like class II molecules 
loaded with peptides from exogenous protein, the Y -Ae epitope accumulates within 
MHC-enriched compartments before reaching the cell surface ofB lymphocytes. 
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1.3 Thesis Rationale 
The work presented in this thesis is based on the use of several HLA-DRBI *04-
specific mAbs that were produced by S. Drover and W.H Marshall [45-50]. These 
include NFLD.Dll, specific or HLA-DRBI *0401; NFLD.D13, specific for HLA-
DRBI *0404; NFLD.Dl, specific for HLA-DRBl *04; and NFLD.D2 and NFLD.DlO, 
which both recognize determinants on the shared epitope sequence. 
Since NFLD.Dll and NFLD.D13 recognize HLA-DRBl *0401 and DRBI *0404 
molecules respectively, which are strongly associated with the development and 
progression of RA, we questioned whether these epitopes were expressed on synovial 
fibroblasts derived from patients with RA. We know that inflamed synovial tissues 
contain abundant numbers of macrophages and activated transformed-like fibroblasts, 
which secrete a myriad of tissue degrading enzymes [78], but it is presently unclear 
whether HLA-DR expression on fibroblasts plays any role in the immunopathogenesis of 
RA. The presence of the Dll and DB epitopes on a subset of DR4 molecules within 
synovial fibroblasts from RA patients could hold insights into factors necessary for T cell 
activation within the synovium, whether or not these epitopes are truly peptide dependent 
or dependent on the presence of tetraspan microdomains. 
Objectives for Chapter 2 
(1) To phenotype the cultured fibroblast-like synoviocytes (cFLS), derived from patients 
with various forms of inflammatory arthritis. 
(2) To investigate the expression of specific HLA-DRBl *04 epitopes, along with the 
shared epitope on cFLS. 
33 
(3) To characterize the class II pathway in synovial fibroblasts. 
Chapters 3 and 4 deal more extensively with DRBl *04 epitopes defined by the 
mAbs NFLD.Dll and NFLD.Dt3. NFLD.D11 was previously shown to bind a subset of 
DRB1 *0401 molecules on EBV-transformed B cell lines [50, 51]. The formation of this 
epitope is dependent on the presence of the co-chaperone molecule HLA-DM [50] as B 
cells that do not express HLA-DM fail to express the NFLD.D11 epitope [51]. Its 
absence on fibroblasts that up-regulate DM suggested that factors other than DM were 
required for its generation. NFLD.D13 recognizes DRBl *0404, but not DRBl *0401 in 
HLA-DM positive EBV -transformed B cell lines. However, in B cells that do not 
express HLA-DM, NFLD.D13 recognizes an epitope on HLA-DRBl *0401 molecules 
[51]. 
Based on previous results, there are at least two hypotheses to explain the 
restricted pattern of the DRBl *04 epitopes recognized by NFLD.Dll and NFLD.Dl3: 
(a) The epitopes are formed by a combination of allele-specific residues 
and cellular-restricted peptides such as those derived from proteins 
expressed exclusively by P-APC. 
(b) The putative peptides that form these epitopes are derived from 
common proteins that are either differentially processed or loaded in 
P-APC. 
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Objectives for Chapters 3 and 4 
(1) To extend the characterization ofDRBl *04 molecules recognized by NFLD.Dll 
and NFLD.D13 on cell types that include P-APC and NP-APC (Chapter 3). 
(2) To characterize the in acellular pathway and processing mechanisms that are 
involved in generating the NFLD.Dll and NFLD.D13 epitopes in BCL (Chapter 
4) using confocal and immunoelectron microscopy as well as inhibitors of the 
MHC class II pathway. 
(3) To determine if cellular-restricted peptides are involved in forming these epitopes 
by examining the effect of protease inhibitors on the formation of these epitopes 
on BCL (Chapter 4). 
We believe that the study of how these class IT epitopes are generated will yield 
valuable information for our understanding of fundamental immunological processes 
such as the proteolytic generation, and intracellular trafficking of specific HLA class II 
epitopes. 
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Abstract 
HLA-DR positive synqvial fibroblasts are frequently observed in rheumatoid 
arthritis (RA) and may be implicated in the autoimmune reaction since RA is associated 
with certain HLA-DRBI * afleles. The question of whether specific DRB alleles and 
components of tb,_e class II antigen presentation pathway are efficiently expressed by 
synovial fibroblasts is germane to this hypothesis. To address this, cultured fibroblast-like 
synoviocytes (cFLS), were analyzed for constitutive and IFN-y induced expression of 
specific DRB alleles and class II associated co-chaperones. RT -PCR showed DRB alleles 
were differentially expressed in two RA-cFLS, with one also expressing CIITA and 
DRA; none were detected in non-RA-cFLS. Ii and HLA-DOB were detected in all, while 
HLA-DMA and DMB were additionally present in RA-cFLS. IFN-y induction of Ii, DM 
and DR molecules was observed in all cFLS, but expression of specific DR allotypes was 
variable. Interestingly, DM-modulated epitopes on RA-associated DR molecules were 
either absent or delayed, despite strong DM-expression and a paucity of MHC/CLIP 
complexes. In summary, cFLS discordantly express class II genes de novo, but display 
co-ordinate IFN-y induction. Altered expression of specific peptide-dependent epitopes 
on RA-associated HLA-DR molecules suggests differences in antigen presentation by 
cFLS, which may have implications for the immunopathogenesis of RA. 
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2.1 INTRODUCTION 
Synovial tissues from patients with rheumatoid arthritis (RA), psoriatic arthritis 
(PA) and certain forms of osteoarthritis (OA) are characterized by a progressive 
inflammatory reaction [1-31. Although their etiologies are poorly understood, RA and PA 
are hypothesized to have autoimmune elements partly because of large numbers of T-
cells in the inflammatory infiltrates and partly because both diseases are associated with 
particular HLA-DR genes [4,5] . The strongest OR-association is for RAin which most 
patients express an amino acid motif, QKRAA/QRRAA, known as the shared epitope 
(SE). It is found on a subset of HLA-DRJ31 *04, 01 and 14 molecules at J3-chain positions 
70-74, which are crucial for antigen presentation and T-cell recognition [5,6]. The inflamed 
synovial tissues also contain abundant numbers of macrophages and activated 
transformed-like fibroblasts, which secrete a myriad of tissue degrading enzymes and 
which have up-regulated OR-expression [7]. Although OR-expression on non-
conventional antigen-presenting cells (APC) has long been hypothesized as a mechanism 
for developing and/or perpetuating autoimmune diseases [8], the contribution of DR 
expression on synovial fibroblasts to the etiology of autoimmune arthritis has remained 
controversial. 
Several studies have generated adherent cell lines from inflamed synovial tissues, 
and although generally characterized as fibroblast-like, they often possess diverse 
phenotypes and properties including those of pannocytes, follicular dendritic cells and 
nurse cells [7,9-11]. Most cultured fibroblast-like synoviocytes (cFLS) are initially OR-
positive, but lose expression after a few passages andre-express if treated with IFN-y 
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[7,12-14]. Thus in vivo DR-expression on synovial fibroblasts may be a bystander effect 
of IFN -y production in the inflamed synovium. An alternative explanation, based on a 
more recent study demonstrating de novo class II expression on long term cultured 
fibroblasts from RA patients fl-5], is that synovial fibroblasts may already have switched 
on their class II gene expression machinery, thereby potentially functioning as APC in a 
self reactive immune response. 
Conventional APC, which include B-cells, macrophages and dendritic cells, 
express or up regulate various co-stimulatory molecules and possess a highly efficient 
class II antigen presentation pathway (reviewed in [16]). In this pathway endocytosed 
antigens are degraded in the acidic protease-rich endosomal/lysosomal vesicles into 
peptides suitable for loading onto class II molecules. Targeting ofHLA class II molecules 
to the endosomes is aided by the invariant chain (li), which also blocks the peptide 
binding groove, thereby preventing premature binding of peptides en route from the 
endoplasmic reticulum to the endocytic pathway. As HLA class Wli complexes traffic 
through the endocytic vesicles, Ii is progressively degraded leaving only a fragment 
called the class II associated invariant chain peptide (CLIP), bound to the peptide-binding 
groove. Removal of CLIP and its exchange for a stable antigenic peptide is facilitated by 
HLA-DM [17], which in some APC is further regulated by another endosomal resident 
protein, HLA-DO [18]. 
Differences in antigen presenting capabilities of APC from RA patients have been 
reported including reduced HLA-DM expression in B-cells [19], and increased 
expression of RA-associated alleles [20]. Although some studies have examined the 
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ability of HLA class II-positive fibroblasts to activate T-cells [21], little is known 
regarding the presence or :fuJlction of various components of the class II pathway in 
cFLS. To address this, we hJ!,.ve examined cFLS for expression of the HLA class II co-
chaperones Ii, DM and D , as well as selective expression of individual HLA-DRB 
alleles. To deteqpine the efficiency of the class II pathway, we further examined cFLS 
for their ability to express peptide-dependent and HLA-DM modulated epitopes on the 
RA-associated HLA-DR molecules. 
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2.2METHODS 
2.2.1 Patient Samples 
Synovial tissues were obtained by BL, with approval of the local Human Investigation 
Committee, from arthritis patients who were undergoing hip or knee surgery. Tissues 
used for isolation of cFLS were SN41 (hip) and SN50 (knee) from rheumatoid arthritis 
(RA) patients; SN08 (hip) from a psoriatic arthritis (P A) patient; and SN07 (hip) from an 
osteoarthritis (OA) patient. A portion of each synovial sample was stored at -70°C and 
the remainder was digested as described below. HLA class II types of cFLS, determine? 
by DNA-typing using Micro SSP generic HLA Class II DNA typing kits (One Lambda, 
Canoga Park, CA, USA), were as follows: SN41, (DRB1 *0101, 07; DRB4*; DQB1 *05, 
02); SN50, (DRB1 *0401, 1502; DRB4*; DRB5*; DQB*0301, 06); SN08, (DRB1 *0401, 
07; DRB4*; DQBI *0301, 02); and SN07, (DRBI *0402, 0101; DRB4*; DQBl *0302, 
05). 
2.2.2 Preparation of cFLS 
Tissue samples were minced and digested with an enzyme cocktail containing 0.05% 
type IV collagenase, 0.1% hyaluronidase, and 0. 01% deoxyribonuclease in 1. 0% Hank's 
balanced salt solution (HBSS) with 2.5% Hepes (all from Sigma, Oakville, ON, Canada) 
for 3 hr at 3 70C. Mixtures were centrifuged at 20 X g for 3 min to remove excess cellular 
debris. The cell-rich supernatants were collected and washed 2X in HBSS at 400 X g for 
7 min, and resuspended in Iscove's modified Dulbecco's medium (IMDM) supplemented 
with 10% heat inactivated fetal calf serum (FCS), 1 OOU penicillin/ml, 1 OOJ.lg 
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streptomycin/ml, 0.25 f..ig amphotericin B/ml and 2mM L-glutamine (all from Gibco 
BRL, Rockville, ML, USA). Cells were seeded into 25-cm2 tissue culture flasks (Fisher 
Scientific, Halifax, NS, Canada) and incubated in humidified air containing 5% C02 at 
37°C. Non-adherent cells were removed after 24 hr by extensive washing and adherent 
cells were grown to confluency. 
2.2.3 Cell Culture and Interferon-y Treatment 
cFLS were harvested at confluency using 0.25% trypsin (Gibco BRL) in phosphate 
buffered saline (PBS), pH 7.4. A portion was frozen and the remainder was passaged by 
splitting at a ratio of 1:3. For experiments, cFLS were plated in 7 ml CM at I X 105 
cells/25 cm2 flask or in 0.4 ml CM at 5 X 103 cells/well in 8-well chamber slides (Nalge 
Nunc International, Naperville, IL, USA) and allowed to adhere overnight. Cells were 
either left untreated or treated with 500U interferon-y/ml (Pharmingen, San Diego, CA, 
USA) for 6 days at 37°C. Human B cell lines (BCL): SAVC (HLA-DRB1*0401; 
DQB1 *0302), Jesthom (DRBI *0101; DQB1 *0501), PLH (DRB1 *0702; DQB1 *0201) 
and E418 (DRBI *1502; DQB1 *0601), obtained through the lOth International 
Histocompatibility Workshop (IHW) [22], were maintained in IMDM supplemented with 
10% FBS and antibiotics and used as positive controls. 
2.2.4 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from cFLS using Trizol (Gibco BRL) according to the 
manufacturer' s instructions and treated with DNA-free (Ambion, Austin, Texas, USA) to 
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I. 
remove any contaminating DNA. eDNA was prepared from 1 J.tg RNA using the First 
Strand eDNA Synthesis Kit from Pharmacia Biotech (Baie d'Urfe, PQ, Canada), 
according to manufacturer's instructions. All primers (Table 1) with the exception of 
DRB1 *04 [23], (a kind gift from D. Haegert) were synthesized by Gibco BRL. These 
included DRA [24],"'cnTA (25], Ii (26] and DRB1 *01 , 07, 15 allele specific primers [27] 
and P-actin [28]. HLA-DMA, HLA-DMB, HLA-DOA, and HLA-DOB primers were 
devised using sequences acquired from Genbank. The accession numbers of the gene 
sequences used for primer construction were: X76775 for DMA, X76776 for DMB, 
M26039 for DOA and L29472 for DOB. Potential primer sequences were entered into the 
Amplify computer program to ensure primer pairs were compatible and potentially 
proficient for a particular gene amplification. Primer sequences were analyzed using the 
OligoTech program to determine the primer G + C content and melting temperature "-· 
(Tm). 
PCR amplification was performed in a total volume of 50j..tl. PCR Buffer 
consisted of20mM Tris-HCI (pH 8.4), 50mM KCl, 0.2mM dNTPs, 1 Unit ofTaq DNA 
polymerase (all from Gibco) and 1:1 of eDNA or RNA. All PCR reactions used 1.5 mM 
MgCh with the exception of DRB 1 *04 which required 1.25mM MgCh. PCR conditions 
and primer concentrations are given in Table 1. 
49 
Table 1. Primers and experimental conditions used to amplify HLA class II genes by RT-PCR 
Primer 
DRA Sense 
DRA Antisense 
DRB1 *01 Sense 
DRB1 *01 Antisense 
DRB1 *04 Sense 
DRB 1 *04 Antisense 
DRBl *07 Sense 
DRBl *07 Antisense 
DRB1*15 Sense 
DRBl *15 Antisense 
Ii Sense 
Ii Antisense 
DMASense 
DMA Antisense 
DMB Sense 
DMB Antisense 
DOA Sense 
Primer Sequence 5 '-3' 
ega gtt eta tct gaa tee tga cca 
gtt ctg ctg cat tgc ttt tgc gca 
ttg tgg cag ctt aag ttt gaa t 
ctg cac tgt gaa get etc ac 
gtt tct tgg age agg tta aac 
ccg ctg cac tgt gaa get ct 
cct gtg gca ggg taa gta ta 
ccc gta gtt gtg tct gca cac 
ttc ctg tgg cag cct aag agg 
ccg ctg cac tgt gaa get ct 
tee caa gee tgt gag caa gat g 
cca gtt cca gtg act ctt tcg 
cca atg tgg cca gat gac ctg c 
cgc tga aca ctt cag ega tag 
gca gaa gtg act ate acg tgg 
ccg cca get gat cac ace aag 
cca cat ggg etc eta egg ace 
PCR Conditions 
94 °C -lmin, 55 °C -lmin, 72 °C -lmin x 30 
95 °C °C -30sec, 60 °C -30sec, 72 °C -lmin x 30, 72 °C -
5min 
94 °C -lmin, 55 °C -lmin, 72 °C -3min X 30 
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Size 
643 
255 
263 
232 
261 
340 
303 
296 
446 
Primer 
DOA Antisense 
DOB Sense 
DOB Antisense 
CIITA Sense 
CIIT A Antisense 
J3-actin Sense 
J3-actin Antisense 
Primer Sequence 5 ' -3' 
ggc agg tag tgg aac ttg egg 
ctg cac tgc tct gtg aca ggc 
gga cct tag cat gac tga gg 
caa gtc cct gaa gga tgt gga 
acg tee ate ace egg agg gac 
ate tgg cac cac ace ttc tac aat gag ctg cg 
cgt cat act cct get tgc tga tee aca tct gc 
PCR Conditions Size 
94 °C -I min, 55 °C -I min, 72 °C -3min x 30 406 
94 °C -lmin, 60 °C -I min, 72 °C -3min x 30 447 
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2.2.5 Antibodies 
Expression of differentiation and cell lineage markers by cFLS was determined using 
commercially available monoclonal antibodies (mAbs). These included CD14 (clone 
M5E2); CD21 (B-ly4), CD23 (M-L233), CD54 (HA58), CD107a (H4A3) (Pharmingen); 
CD35 (To5), CD68 (EBMll and PG-M1), factor VIII (F8/86) and fibroblast marker 
(5B5) (DAKO Mississauga, ON, Canada); CD63 (CLB-180), CD80 (DAL-1), CD86 
(BU63) (Cedarlane, Hornby, ON, Canada); CD40 (EA-5) (Calbiochem, San Diego, CA, 
USA); CD45 (2Bll) (Medicorp, Montreal, PQ, Canada). HLA-class II expression was 
determined using L243, pan HLA-DR (ATCC); NFLD.D1, pan HLA-DRB1 *04 [29]; 
NFLD.D2 and NFLD.D10, overlapping determinants on the shared epitope [30]; 
NFLD.Dll, DRBI *0401-specific [31]; PL3, HLA-DRB1 *07 + HLA-DRB4* [32] and 
SFR16 [33], pan HLA-DRB1 *07, a kind gift from Dr. Susan Radka. Components of the 
HLA class II processing pathway were determined using DOB.L1, anti-human HLA-
DOB chain, kindly provided by A. Vogt [18]; MaP.DM1, anti-human HLA-DM, kindly 
provided by P. Cresswell [17]; and LN2, invariant chain (Ii) (Pharmingen). Isotype-
matched non-specific mAbs NS "lgM", NS "IgG I", NS "IgG2a" and NS "lgG2b" were 
kindly provided by Terra Nova Biotechnology, St. John's, NF, Canada. Secondary 
antibodies included a peroxidase labeled polymer conjugated to anti-mouse and anti-
rabbit lgs (DAKO Envision) for immunocytochemistry; R-Phycoerythrin (PE)-labeled 
goat anti-mouse (GAM) IgG Fe and PE-labeled GAM lgM Jl chain specific (both from 
Jackson Immunoresearch, West Grove, PN, USA) for cytofluorometry. 
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2.2.6 Immunocytochemistry 
cFLS grown in chamber slides were washed in PBS, fixed in acetone for 15 min at 4°C, 
air dried for 1hr and rehydrated in PBS. Endogenous peroxidase activity was blocked 
using 1% hydrogen peroxide in PBS. Slides were washed in PBS containing 0.5% bovine 
serum albumin (Sigma) + 0.05% Tween 20 (BIO-RAD, Hercules, CA, USA), blocked for 
non-specific binding for 1 hr using 15% human AB serum in PBS, and incubated with 
primary mAbs (optimally diluted in wash buffer) for 1 hr at room temperature (RT) in a 
humid chamber. Slides were washed, incubated with horseradish peroxidase labeled 
conjugate (DAKO) for 30 min at RT, washed again and developed with 
diaminobenzidine + H202 (Sigma) to detect peroxidase, then counterstained with Mayer's 
haematoxylin. The following coding scheme, used by two readers (DS and SD), was 
based on percentage of positive cells and relative staining intensity compared to the 
negative isotype matched control; negative, (0-5% of cells positive, any intensity); (+/-, 
(6-30% weak intensity);+, (6-30% strong intensity or 31-60% moderate intensity or 61-
100% weak intensity); ++, (31-60% strong intensity or 61-100% moderate intensity); 
+++, (61-100% strong intensity). 
2.2. 7 Cytofluorometry 
Antibody binding assays were done as previously described [30]. Briefly, trypsin-
harvested cFLS or controls BCL at 1-5 X 105 cells/tube were incubated with appropriate 
mAbs for 30 min at 4°C. Antibody binding was detected with GAM-PE conjugate 
(Jackson lmmunoresearch), followed by fixation in 1.0% paraformaldehyde (Sigma), and 
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analysis of 5000-10,000 cells using a F ACStarPlus flow cytometer (Becton Dickinson, 
Mississauga, ON, Canada). 
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2.3RESULTS 
2.3.1 Characterization of Cultured Cell Lines Derived from Synovial Tissues 
Adherent cell cultures, prep ed from synovial tissues (SN07, SN08, SN41 and SN50), 
morphologically resembled synovial fibroblasts as described by others [7,12]. To confirm 
and more completely characterize their lineage, they were analyzed with a panel of mAbs 
against several differentiation markers. None expressed CD14, CD45, CD21, CD23 or 
CD35 (data not shown), indicating they were not bone marrow derived or follicular 
dendritic cells. As shown in Table 2 and Figure 1, they lacked the endothelial cell marker, 
Factor VIII, but strongly expressed both the 5B5-defined fibroblast marker, prolyl 4-
hydroxylase and the EBM11-defined macrophage marker CD68. However, they were 
negative for other macrophage markers, PG-Ml and non-specific esterase staining (Table 
2 and Fig la), suggesting they are unlikely to be derived from the type A macrophages 
that are present in the synovial lining. 
Further analysis revealed moderate to strong constitutive expression of the 
adhesion molecule ICAM-1, which was further up regulated by IFN-y on SN41 and 
SN50. Low levels of the co-stimulatory molecule CD40, present in all untreated cells, 
were moderately to strongly up regulated by IFN-y treatment. In contrast, the co-
stimulatory molecules, CD80 and CD86, found on macrophages and other APC, were 
neither present nor inducible by IFN-y (Table 2). Of note, CD63 and LAMP-l, markers 
of endosomalllysosomal vesicles in which peptide loading of MHC class II molecules 
occurs, were strongly and constitutively present in all cFLS. 
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Table 2. Immunocytochemical characterization of cFLS using antibodies against 
differentiation antigens 
Differentiation Antigen s 7 SN08 SN41 SN50 
UTa IFN-y UT IFN-y UT IFN-y UT 
5B5 +++b +++ +++ +++ +++ +++ +++ 
FactorVill 
;:? 
CD68 (EBM II) +++ +++ +++ +++ +++ +++ +++ 
CD68 (PG-Ml) 
ICAM-1 +++ +++ +++ +++ ++ +++ ++ 
CD40 + ++ +/- +++ + +++ + 
CD80 
CD86 
CD63 +++ +++ +++ +++ +++ +++ +++ 
LAMP-l +++ +++ +++ +++ +++ +++ +++ 
a Untreated. 
b codes are: -, 0-5% cells positive;+/-, 6-30% weak intensity; +, 6-30% strong intensity or 31-60% 
moderate intensity or 61-100% weak intensity; ++, 31-60% strong intensity or 61-1 00% moderate intensity; 
+++, 61-100% strong intensity. 
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IFN-y 
+++ 
+++ 
+++ 
++ 
+++ 
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A 
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Control 
Fibroblast 
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(5B5) 
Factor VIII 
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CD68 
(PG-Ml) 
Untreated IFN-y Treated 
Figure lA. Differentiation antigens expressed by cFLS: cFLS, untreated or treated with 500U 
IFN -y/ml for 6 days in chamber slides, were fixed and analyzed by immunocytochemistry using 
antibodies that detected lineage-associated markers. Negative control is irrelevant mouse IgG; 
representative example is SNOS, with original magnification X 400. Similar results were obtained 
in three independent experiments. 
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B 
ICAM-1 
CD40 
(EA-5) 
CD63 
LAMP-l 
Untreated IFN -y Treated 
Figure lB. Differentiation antigens expressed by cFLS: cFLS, untreated or treated with 500U 
IFN-y/ml for 6 days in chamber slides, were fixed and analyzed by immunocytochemistry using 
antibodies that detected antigens typically expressed by conventional antigen presenting cells. 
Negative control is irrelevant mouse lgG as in A; representative example is SN08, with original 
magnification X 400. Similar results were obtained in three independent experiments. 
58 
2.3.2 HLA-Ciass ll Associated Co-Chaperones are Differentially Expressed in cFLS 
cFLS were examined for mRNA and protein expression of Ii, DM and DO, which are 
integral components of the endocytic processing pathway. Using RT-PCR and locus 
specific primers, constitutiv Ii and DMA transcripts were detected in all cFLS (Figure 
2a), while DMB ~as detected in SN41 and SN50, but not in SN07 or SN08. DOA was 
not detected in any cFLS while DOB transcripts were evident in SN08 and SN41, but 
scarcely visible in SN07 and SN50. As expected, IFN-y treatment induced strong 
expression ofDMA, DMB, DOA, DOB and Ii mRNA transcripts in all cFLS (Figure 2a). 
Immunocytochemical analysis of cFLS showed that proteins for DM, DO and Ii 
as well as HLA-DR (Table 3 and Figure 2b) were moderately or strongly expressed in the 
IFN-y treated samples. However, despite constitutive expression of HLA-DMA, DMB, 
and Ii mRNA transcripts in SN41 and SN50, their respective proteins were noted in less 
than 6% of the untreated cells. HLA-DO protein was present in all untreated cFLS, 
probably because the DO mAb recognizes the DO~ chain, which is discordantly 
expressed in a variety of cells [34]. 
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Figure 2. Continued on Next Page. 
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Figure 2. Constitutive and inducible expression of liLA class II chaperone genes in cFLS: 
(A) RT-PCR was used to analyze DMA, DMB, DOA, DOB and Ii mRNA expression in untreated 
(-)or IFN-y (500U/ml) treated(+) cFLS or control BCL; J3-actin served as an internal control. (B) 
Intracellular expression of HLA-DR and class ll co-chaperones by cFLS, grown on chamber 
slides for 6 days was ascertained by immunocytochemistry: Negative control (irrelevant mouse 
lgG); DR (L243); DM (MaP.DMl); DO (DOB.Ll); and Ii (LN2). The representative example is 
SN41, with original magnification X 400. Similar results were obtained in three independent 
experiments. 
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Table 3. Expression ofHLA-DR and HLA class II associated chaperone molecules in 
cFLS 
SN07 SN08 SN41 SN50 
UTa IFN-y UT IFN-y UT IFN-y UT 
HLA-DR +++ +++ +++ 
Ii ++ +++ ++ 
HLA-DM +++ +++ ++ 
++ ++ ++ ++ ++ ++ + 
HLA-DO 
a Untreated. 
b codes are: -, 0-5% cells positive; +/-, 6-30% weak intensity; +, 6-30% strong intensity 
or 31-60% moderate intensity or 61-100% weak intensity;++, 31-60% strong intensity or 
61-100% moderate intensity;+++, 61-100% strong intensity. 
2.3.3 CIIT A and HLA-DRB Alleles are Discordantly Expressed in cFLS 
Most studies have found that HLA-DR is not expressed in long-term cultured synovial 
fibroblasts [7,12], an exception being a study by Navarrete Santos et al., which showed 
constitutive CIITA and HLA-DR expression in long-term cultured fibroblasts from RA 
synovium [15]. We also detected a number of transcripts in RA-derived SN41 and SN50, 
but not in non-RA-derived SN08 (Figures 3a and 3b) nor in SN07, which was only 
available for one assay (data not shown). CIITA and DRA transcripts (Figure 3a) were 
detected only in SN41, which additionally expressed DRB 1 *0 1 (Figure 3c ). However, 
only trace amounts of DRB1 *07 and no transcripts of its associated gene, DRB4* 
(DR53), were detected in SN41 (Figure 3c and data not shown). DRB1 *0401 and its 
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IFN-y 
+++ 
++ 
++ 
++ 
associated DRB4* gene were not detected in SN50, whereas DRBl *15 and its associated 
DRB5* gene were well-expressed (Figure 3d and data not shown) despite the absence of 
detectable CIITA. Interestingly, DQA and DQB were also detected in SN50, but not in 
SN41 (data not shown), suggesting a CIITA-independent mechanism of class II 
regulation in those cells. Although SN41 expressed CIIT A, DRA and DRB mRNA 
transcripts, insignificant amounts of DR proteins were detected in untreated cells by 
immunocytochemistry, whereas high levels were detected in all cells treated with IFN-y 
(Table 2). 
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SN08 SN41 SN50 - + BCL - + BCL 
-== 1111:11:1 - + - + - + BCL DRA IIC IIC IIIC ~ DRB1*04 DRB1*07 
DQA IIII:IIIII:J 1111:1 1:1 c SN41 
DQB 1111:3111; .. liil - + BCL - + BCL 
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CIITA llll:lllii IIC 1:1 - + BCL - + BCL m = 111:1&:1 B-actin 
==== 
DRB1*15 DRB1*04 
Figure 3. Analysis ofmRNA expression ofHLA class ll genes in cFLS using RT-PCR: (A) 
cFLS, untreated(-) or treated with 500U IFNy/ml (+)for 6 days and control BCL were analyzed 
for DRA and CDTA transcripts with ~-actin as an internal positive control. Transcripts for 
specific HLA-DRBl alleles were determined using allele specific primers- (B) SN08, DRB1 *04 
and 07; (C) SN41, DRB1 *01 and *07; {D) SN50 DRBl *04 and DRBl *15. Control BCL were 
SAVC (DRB1 *0401) and PLH (DRBI *07) for SN08; Jesthom (DRBl *0101) and PLH 
(DRB1*07) for SN41; and E418 (DRB1*15) and SAVC (DRB1*04) for SN50. Results are 
representative of2-3 independent experiments per cFLS. 
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2.3.4 IFN-y Teatment of cFLS Induces Variable Expression of Specific HLA-DRBl * 
Molecules 
IFN-y treatment of cFLS induced cell surface expressiOn of HLA-DR molecules, 
although levels were relatively low on SN07 (Figure 4). To assess expression of 
individual HLA-DRB1 * alleles, mAbs capable of discriminating HLA-DR allotypes and 
cytofluorometry were used. HLA-DRBl *04 molecules, determined by pan-DR4 mAb, 
NFLD.Dl, were up regulated on both SN08 and SN50 with approximately 80% cells 
expressing DRB1*0401 compared to 95% for the control BCL. However, only 11% of 
SN07 cells expressed DRB 1 *0402, a result that was comparable to separate experiment 
analyzed by CELISA (data not shown). Interestingly, treatment of SN07 with IFN-y for 
14 days (Figure 3 inset) resulted in significantly increased DRB1 *0402 expression (MFI: 
503 on day 14, compared to MFI of 22 on day 6). By contrast, DRB1 *01 molecules, 
ascertained by NFLD.D10, were expressed almost as well as total DR on SN07. Strong 
NFLD.D10 binding to SN41 indicated abundant expression of DRB1 *01, while its 
binding to SN08 and SN50 reflected known crossreactivity of this mAb with DRB1 *0401 
and 1502 [29]. DRB1 *07 expression by SN08 and SN41 could not be defmitively 
determined as PL3 mAb also binds DR53, both of which are present in these cells. 
However, in subsequent assays using an anti-DRB1 *07 mAb SFR16 (33], kindly 
provided by Dr. Susan Radka, DRB1 *07 was found to be well expressed (data not 
shown). Due to lack of discerning mAbs, DRB1 *1502 and DR51 expression by SN50 
could not be assessed. 
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SN07 SN08 SN41 SNSO Control Cell 
L243 
NFLD.Dl 
NFLD.DlO 
PL3 
Figure 4. Cell surface expression of specific HLA-DRB alleles by cFLS is induced with IFN-
y. cFLS were treated with SOOU IFN-y/ml for 6 days and analyzed by cytofluorometry using 
mAbs: L243, pan-HLA-DR; NFLD.Dl, pan DRB1 *04 (SN07, SN08 and SNSO); NFLD.D10, 
DRB1 *01 (SN07 and SN41); and DRB1 *0401 (SN08 and SNSO). Inset shows NFLD.D1 binding 
to SN07 after a 14 day treatment with SOOU IFN-y/ml. Open histograms = test mAb; filled 
histograms = IgG negative control; percentages at the top indicate the % of positive cells. Control 
BCL was SAVC (DRB1 *0401, DR53). Similar results were obtained in two or three independent 
experiments. 
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2.3.5 Peptide-Dependent Epitopes on HLA-DRBl * Molecules Are Inefficiently 
Expressed on cFLS 
As an indirect means of ascertaini g the functionality of the class IT pathway in cFLS, we 
analyzed IFN-y-treated cFLS for their capacity to express peptide-dependent and/or OM-
modulated epitopes dn their HLA-DRB1 * molecules. Interestingly, a DRB1 *0401-
specific epitope, NFLD.Dll which requires the QKRAA version of the shared epitope 
and which is strongly expressed on conventional APC [35] was not detected on SN08 
and SN50 by cytofluorometry or by immunocytochemistry, despite strong DR expression 
(Figure Sa and data not shown). Even when SN50 was treated with IFN-y for 14 days, 
there was no expression of this epitope. In contrast, the NFLD.D2-specific broadly 
defmed "shared epitope" QKRAA/QRRAA, which is modulated by OM-expression 
[30,35], was detected on SN08, SN50 and SN41; however, its expression was 
comparatively less than levels achieved on SE+ B-celllines, SAVC (DRB1 *0401) and 
Jesthom (DRB1 *0101) (Figure 5). 
To determine whether reduced SE-expression is time dependent and/or related to 
accumulation of intracellular co-chaperones, SN41 and SN50 were cultured with IFN-y 
for 12 or 15 days, and at 3-day intervals, they were analyzed for cell surface expression 
of DR molecules and SE. Since CLIP complexes accumulate when DM-loading is 
deficient, we also determined CLIP expression as well as intracellular expression of Ii, 
DMandDO. 
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Figure 5. Cell surface expression ofBLA-DM modulated epitopes on SE-bearing BLA-DRB 
molecules expressed by cFLS: cFLS (A-C), treated with SOOU IFN-y/ml for 6 days and control 
BCL, (D-E) were analyzed by cytofluorometry using mAbs: L243, pan-~A-DR; NFLD.D2, SE-
specific and NFLD-Dll (DRBI *0401 specific). Similar results were obtained in two or three 
independent experiments. 
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As shown in Figure 6a, DRB1 *0101, which carries the SE sequence in SN41, 
paralleled total DR expression, peaking by Day 6 and maintaining high levels for the 
duration of the experiment. However, expression of SE on these molecules was markedly 
delayed, being barely detectable at day 6 and not reaching a plateau by day 12. In 
contrast, SE expression on SN50 occurred earlier and at higher levels, generally 
paralleling HLA-DR-expression. Interestingly, DRB1 *0401, which carries the SE 
sequence and which was detected by NFLD.D1, peaked between Days 6 and 9, but then 
decreased over the next two time points. Neither SN41 nor SN50 expressed appreciable 
CLIP, although the amounts on SN41 were consistently higher than those on SN50, 
somewhat correlating with increased amounts of CLIP on the DRB1 *01 BCL (Jesthom) 
compared to DRB1 *0401 BCL (SAVC). 
HLA-DM was not detected in SN41 and SN50 at day 3, but by day 6 its 
expression on both cFLS was equivalent or greater than that of the control BCL (Figure 
6b ). In contrast, Ii levels were easily detectable at Day 3 but did not reach BCL levels 
until Day 9. Thus, Ii:DM ratio (Figure 6c) was maximal in both SN41 and SN50 at Day 
3, but then dropped to about the same ratio as for SAVC, but less than that of Jesthom. 
The hierarchy of Ii:DM, SN41>SN50 and Jesthom>SA VC, correlates directly with CLIP 
expression, perhaps explaining the markedly delayed and reduced expression of SE on 
DRB1 *0101 (SN41). As for DO expression, we confirmed low constitutive levels 
previously observed by immunocytochemistry (Figure 2b ), and indeed its expression 
changed little during the duration of the experiment. Similar expression levels on BCL, 
suggest that it is not implicated in the expression of these DR epitopes. 
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Figure 6. Delayed expression of DM-modulated epitopes on HLA-DR molecules in cFLS is 
not due to deficient DM expression by cFLS: SN41 and SN50, treated with 500 U of INF-( 
were harvested at day 0, 3, 6, 9, 12 or 15 (X-axis) and analyzed by cytofluorometry (MFI, mean 
fluorescence intensity on Y-axis). A. Surface expression of generic DR (L243), SE (NFLD.D2), 
MHC class WCLIP complexes (cerCLIP); DRB1*0101 (NFLD.DlO) and 
DRBl *0401(NFLD.Dl); irrelevant mouse IgG, served as a negative control; BCL, Jesthom and 
SAVC served as positive controls for SN41 and SN50, respectively. B. Intracellular expression of 
DM (MaP.DMI), DO (DOB.Ll) and Ii (LN2). Controls were as described above. C. Ratio ofli to 
DM = (MFI of Ii - MFI of IgG) divided by (MFI of DM - MFI-IgG) at various time points (X-
axis) for SN41 (open squares) and SNSO (closed squares) compared to BCL, Jesthom and SAVC. 
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2.4 DISCUSSION 
HLA-class II expression on synovial fibroblasts in inflammatory arthritis is 
believed to be a consequence ofiFN-y, produced by the infiltrating T-cells. In support of 
this, fibroblasts isolated from the inflamed synovium and grown in culture medium, 
quickly lose their expression after a few passages, but re-express if treated with IFN -y 
[7,12]. The existence of an IFN-y independent HLA class II regulatory mechanism was 
suggested by Naverrate Santos et al. [15] who showed that long term cultured fibroblasts 
from the RA synovium constitutively expressed several class II genes including CIIT A, 
DRA and generic DRB. To our knowledge, the study described here is the frrst to explore 
constitutive and inducible expression of specific DRB alleles and associated class II co-
chaperones in cFLS. Our fmdings generally support de novo class II transcription in the 
RA-derived FLS, but additionally demonstrate discordant transcription of DRB alleles. 
Furthermore, various class II co-chaperone genes were transcribed in both RA and non-
RA cFLS, with a greater number present in RA cFLS. However, with the exception of 
HLA-DOB, we observed only trivial expression of class II proteins using either 
cytofluorometry or immunocytochemistry in any of the cFLS. 
The explanation for differential mRNA expression of HLA-DRB and class II co-
chaperones by cFLS is unclear, but it is unlikely an artifact of culture conditions as 
similar results were obtained at both early passages (passage 2-4) and late passages 
(greater than 16). Although all cFLS displayed similar markers, their growth 
characteristics varied with SN07 being the least proliferative and eventually becoming 
senescent. Diverse phenotypes have been ascribed to RA-derived synovial cell lines 
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including properties of follicular dendritic cells, nurse cells and transformed-like cells 
[7,9,11,14,36]. The latter property is associated with expression of over amplified proto-
oncogenes, such as cFos [7,9], wmch has previously been shown to play a role in class II 
regulation [3 7]. Although we did not investigate expression of oncogenes, it was noted 
that the least contact-inhibited and most proliferative cFLS (SN41) expressed the most 
class II genes and was the only one with detectable CIIT A. 
Differential expression of HLA-DRB alleles has been reported in various cell 
types and diseases [38,39]. Particularly interesting is a report by Kerlan-Candon et a/. 
[20] that showed SE-bearing alleles (DRBl *04 and B1 *01) were more highly expressed 
in B-cells from RA patients than in those from healthy individuals. Here we found that 
) 
DRB1 *0101 was constitutively transcribed in SN41, whereas DRB1 *15 and DR51, and 
not DRB1 *0401, were detected in SN50. Differences in HLA-DR expression in cFLS 
could reflect allele specific polymorphisms in the promoter regions, which are known to. 
influence regulation [40-42]. In fact, DRB1 *04 has been reported to be less 
transcriptionally active than alleles such as DRBl *01 and B1 *15 [39,40]. An alternative 
explanation for the lack of DRBI *04 transcription in SN50 is that it may be more 
dependent on expression of CIIT A, than are DRB 1 * 15 and DR51. 
In addition to the CIITA-independent expression of DRB1 *15 and DRB5*, we 
also noted constitutive expression of DQA and DQB transcripts in SN50 (data not 
shown). Although no CIIT A transcripts were detected in three separate experiments in 
these cells, it is possible that the standard RT-PCR used in these experiments is not 
sufficiently sensitive to detect very low levels of CIIT A. Constitutive expression of Ii, 
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DMA and DOB in the three CIITA-negative cFLS was not totally unexpected, as 
although CIITA is required for maximal expression, CIITA-independent expression class 
II genes has been previously reported [43,44]. The HLA molecule markedly expressed in 
untreated cFLS was HLA-DO which is also expressed on thymic epithelial cells in the 
absence of HLA-DR expression [34]. Although its role in B-cells is to regulate DM 
activity [16,18] its function in cFLS and other non-conventional APC remains unclear. 
Several observations in this study support the notion that cFLS can function as 
APC. Abundant levels of constitutive CD63 and LAMP-l indicate the presence of 
endosomal and lysosomal vesicles, while strongly up regulated Ii and DM molecules 
suggest normal class II trafficking and peptide loading. Indeed levels of DM protein in 
IFN-y induced cFLS were significantly higher than those observed for control B-cell 
lines. Unfortunately it was not possible for us to compare DM levels in B-cells from the 
same patients, but these observations are nonetheless intriguing in light of a report 
showing reduced DM levels in B-cells from RA patients compared to those from healthy 
controls [19]. In view of the importance of DM in displacing CLIP from the groove and 
facilitating peptide binding to class II molecules [ 16, 17], the paucity of MHC II/CLIP 
complexes on DR-positive cFLS show that DM is functioning as in conventional APC. 
This is further supported by the expression, albeit delayed, on both SN50 (DRBI *0401) 
and SN41 (DRB1*01) ofthe DM-modulated SE defined by NFLD.D2 [30]. Its delayed 
induction may be due to the initially high Ii:DM ratios observed between Days 3 and 6 of 
the IFN-y induction period. As well, weaker expression of SE on DRB1 *01 compared to 
DRB1 *0401 may be due to greater affinity ofDRB1 *01 for CLIP [45,46]. An alternative 
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mechanism, which was shown for delayed expression of the HLA-DM dependent 
epitope, 16.23 in a non-conventional APC [47], is that DM and DR may be initially 
localized in different endosomal compartments. 
The lack of DM-dependent epitope, NFLD.Dll, on DRB1 *0401 molecules was 
not unexpected, as this epitope was previously shown to require additional but as yet 
undefined factors for its expression [35]. One of these factors could be a cellular 
restricted peptide or alternatively it may require a particular protease that is not present in 
cFLS. Although we did not directly address the issue of protease content, others have 
shown that synovial fibroblasts express a wide array of proteases [48,49]. Cathepsin S, 
which is present in conventional APC and required for degradation of Ii [50,51], is 
strongly up regulated in non-conventional APC by IFN- y [52]. Thus, the very low levels 
of CLIP, despite high levels of Ii, in cFLS suggest that Cathepsin S was up regulated in 
all cFLS. 
In summary this study clearly shows that DR+ synovial fibroblasts possess the 
requisite intracellular components for antigen processing, and based on low CLIP 
expression, they also have the capacity to efficiently display stable MHC/peptide 
complexes. However, the composition of these complexes will likely differ from those 
expressed on conventional APC, possibly due to cell-restricted proteins or processing 
mechanisms. Although their ability to activate CD4+ T -cells was not addressed in this 
study, others have shown that class II positive FLS can activate T -cells by presentation of 
pre-processed peptides or superantigen [21,53]. However, Corrigall et al. [54] found that 
absence of co-stimulatory molecules CD80 or CD86 on DR+ fibroblasts anergized rather 
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than activated naive T -cells. Perhaps other accessory and co-stimulatory molecules such 
as CD40, which was expressed on our cFLS and on fibroblasts in some, but not all, 
studies [54-56], may compensate for CD80/86. It is likely that different subsets of 
synovial fibroblasts exist and as such will differ in their ability to present self-antigens 
and to activate or perpetuate an autoimmune response. 
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Abstract 
The major function of HLA-DR molecules is to bind peptides derived from 
proteins, degraded in the endoc ic pathway, and to present them on the cell surface for 
CD4 T -cell recognition. Peptide binding depends on many factors including the 
particular DRB alleles expressed by the cell, antigen processing machinery, the 
proteolytic environment and contribution of chaperone molecules such as Ii, HLA-DM 
and DO. In this study we investigated expression of allele-specific epitopes on HLA-
DRB1 *0401 and 0404 molecules that differ by two conserved amino acid substitutions, 
K71R and G86V, located on the peptide binding site. We show that an antibody-defined, 
DM-dependent epitope (Dl1+0401) is restricted to DRB1 *0401 molecules, expressed by 
pAPC, notably EBV-transformed BCL. Although DRB1 *0401 and DM were strongly 
up-regulated on various NP-APC, including fibroblast, epithelial and melanoma cells, 
D11 +0401 expression was limited to a putative melanoma line, MDA MB 435. A second 
antibody-defmed epitope (D13+0404) that is not strictly DM-dependent was limited to 
DRB1 *0404 positive B cells and dendritic cells. Most intriguingly, the same mAb 
recognized DRB1 *0401 molecules on DM negative B cells (D13+0401 epitope), and 
introduction of DM into these cells resulted in loss of D13+0401. The limited cellular 
distribution of these epitopes and their different requirements for DM suggest that 
alternative antigen processing or trafficking mechanisms are implicated in their 
generation. 
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3.1 Introduction 
MHC class IT molecules are membrane glycoproteins formed from a non-
polymorphic a chain and a polymorphic~ chain [1-2]. They are expressed constitutively 
on the surface of professional antigen presenting cells (P-APC) such as B cells, 
macrophages (M<l>) and dendritic cells (DC) but can be up-regulated on non-professional 
(NP-APC) by inflammatory mediators such as interferon-y [3]. These molecules bind 
short peptides between 13 to 25 amino acids long [4] which are presented to CD4+ TH 
cells, for T -cell and immune recognition. Since MHC class II molecules bind a wide 
array of peptides, produced by efficient, but fairly ubiquitous antigen processing 
mechanisms, the organism is well equipped to fight infection from a diversity of 
microbial sources. However, because MHC proteins are highly polymorphic with most 
substitutions occurring within the peptide binding groove, each MHC allotype has a 
certain peptide selectivity. The majority of the HLA-DR allele-specific polymorphic 
residues are located on the surface of the pockets, and this selects for a distinct peptide 
repertoire amongst different HLA-DR molecules due to the amino acid composition and 
the electrostatic charge of the individual amino acids. Pocket 1 is made up from DR~ 
chain amino acids 85, 86, 89 and 90; pocket 4 contains P-chain amino acids 13, 44, 70, 
71 and 78; pocket 6 is formed from~ chain amino acids 11 and 13; pocket 7 is formed 
from ~ chain amino acids 28, 47, 61, 67 and 71, and pocket 9 is formed from p chain 
amino acids 9 and 57 [5]. Both non-polymorphic and polymorphic residues contribute to 
peptide binding though, with non-polymorphic residues binding to main chain atoms of 
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the bound peptide and polymorphic residues within the different pockets binding to the 
peptide side chains [ 6]. 
MHC class II molecules are generated in the endoplasmic reticulum (ER) where 
they associate with a chaperone molecule known as the invariant chain (Ii) [7-9]. Three 
MHC a.p dimers bind to three Ii proteins forming a nonomeric complex [1] that travels 
from the ER through the trans-golgi complex to a series of endocytic compartments and 
eventually to lysosome-like structures known as MHC class II peptide loading 
compartments (MIIC), which contain a pH of 3.5-5.5 [10]. Within the MIIC the Ii is 
slowly broken down in a stepwise manner [11], replaced by peptides that have been 
generated either from internalized exogenous or endogenous proteins that are degraded 
within the acidic and protease-rich lysosomal compartments. Although peptide loading 
of MHC class II molecules may occur in early endosomal compartments, it primarily 
occurs with MIIC [12-15], where it is facilitated by the co-chaperone molecule HLA-
DM, which is transported to the MIIC along with its negative regulator, HLA-DO [16]. 
Ii is broken down, mainly by the cysteine proteases cathepsin S and L [11] 
leaving a short fragment called the class II associated invariant chain peptide (CLIP) in 
the peptide binding groove [17]. DM facilitates removal of CLIP [18-20], along with the 
stabilization of the "peptide-free" or empty conformation of the MHC class II molecule 
[21-23] before enhancing the binding of high stability peptides in the groove of the MHC 
class II molecule and editing which peptides bind to form mature pMHC [24-26] within 
MIIC [27]. This mature peptide-MHC complex (pMHC) can now travel to the cell 
surface to interact with the T cell receptor (TCR) on CD4+ cells. 
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Because of their role in presenting peptides to T cells via the TCR, and since 
various HLA class II alleles have been associated with autoimmune disease in humans, it 
has been hypothesized that RLA class II molecules play an important role in the 
development of autoimmune disease (28, 29]. For example, HLA-DQB1 *0302 and 
HLA-DQB1 *0201 are associated with autoimmune type 1 diabetes and Celiac disease 
and HLA-DR molecules are associated with diseases such as autoimmune hepatitis, 
multiple sclerosis and rheumatoid arthritis (RA) [30]. All RA-susceptible alleles possess 
a homologous short stretch of amino acids (LLEQ(K/R)RAA) at positions 67-74 of the 
~ 1 chain, and is often referred to as the shared epitope (28]. In Caucasian populations, 
the major HLA-DR alleles that are associated with increased risk to RA are DRB1 *0401 
and DRB 1 *0404, which differ in the shared epitope region, at positions ~71 (Lys to Arg) 
and ~86 (Gly to Val). Therefore, amino acids within pockets 1 and 4 of the class II 
peptide binding cleft are of vital importance in the differentiation between DRB 1 *040 1 
and DRB1 *0404. 
We previously described three mAb-defined, HLA-DRB1 *04-specific epitopes. 
NFLD.D11 recognizes a OM-dependant epitope on DRB1 *0401 molecules (31], whereas 
NFLD.Dl3 recognizes an epitope on DRB1 *0404 molecules [32], and thus, these mAbs 
are able to distinguish between DRBl *0401 and DRB1 *0404. Both epitopes are strongly 
expressed on normal EBV-transformed B cell lines (BCL) as well as weakly on 
peripheral blood B cells from RA patients and healthy controls [32]. Intriguingly, 
NFLD.Dl3 also recognizes a determinant on HLA-DRB1 *0401 molecules in DM 
negative BCL (33]. 
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We have now extended the characterization of these epitopes to human M<l> and 
DC, as well as numerous NP-APC in order to learn more about processes that lead to the 
generation of these epitopes. Using mAbs with known specificities, we also show that 
the NFLD.Dll and NFLD.D13 recognize determinants located in the peptide binding 
groove of the class II molecule. In regards to the D13+0401 epitope, reconstitution of 
DM by the gene complementation resulted in the loss ofNFLD.D13 binding, confirming 
the antagonistic effect of this molecule in the generation ofthe D13+0401 epitope. 
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3.2 Methods 
3.2.1 Cell Lines 
Human B cell lines (BCL) SAVC (HLA-DRB1 *0401) and MT14b (HLA-
DRB1 *0404), were obtained through the lOth International Histocompatibility Workshop 
(IHW) [34]; 8.1.6 0401, 9.5.3 0401, 5.2.4 0401 and 5.2.4 0404 were all kind gifts from 
Dr. N. Patil and Dr. E. Mellins at Stanford University; Daudi, a class I null Burkitt's 
lymphoma cell line, Daudi Dw4 [31] and Daudi-~2microglobulin (a kind gift from Dr. 
J.R. Parnes at Standford University Medical Center); BLS-1-Dw4, BLS-1-Dw14 and 
SJO-Dw4, three class II negative BCL [35]; the class II null B-T hybrid T2-Dw4 was 
provided by Dr. W.W Kowk at Benaroya Research Institute, Virginia Mason, Seattle, 
WA; and T2-Dw4DM provided thanks to Dr. P. Cresswell and Dr. L. Denzin [36]. 
Adherent human breast cancer cell lines MDA MB 435 Dw4 (endogenous 
DRB1*0405, 13), T47D Dw4 (DRB1*0102) and MCF-7 Dw4 (DRB1*03, 15), all kind 
gifts from Dr. J. Blum at Indiana School of Medicine were selected in CM supplemented 
with either 0.5 mg/ml G418 (Gibco BRL) and/or 0.2 mg/ml hygromycin B (Gibco BRL). 
The human melanoma cells 1359 Mel (DRB1 *0401, DRB1 *0301), DM331 
(DRB1 *0401, DRB1 *01) and DM13 (DRB1 *0404) were kind gifts from Dr. V. 
Engelhard at the University of Virginia. All cells were maintained in complete IMDM 
(CM) supplemented with 10% heat inactivated fetal calf serum (FCS), antibiotics and 
2mM L-glutamine (all from Gibco BRL, Rockville, ML, USA), in humidified air 
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containing 5% C02 at 37°C, except 8.1.6 0401, 9.5.3 0401, 5.2.4 0401 and 5.2.4 0404, 
which were maintained in RPMI supplemented as above. 
3.2.2 Interferon-y treatment 
Adherent breast cancer and melanoma cell lines were harvested at confluency 
using 0.25% trypsin (Gibco BRL) in PBS, pH 7.4 and passaged at a ratio of 1:3. the cells 
were seeded into 25 cm2 tissue culture flasks (Nalge Nunc), allowed to adhere overnight 
and left untreated or treated with 500U interferon-y/ml (Pharmingen, San Diego, CA, 
USA) for the appropriate time period at 37°C. 
3.2.3 Preparation of macro phages and dendritic cells 
Whole blood was collected from a DRB1 *0401, DRB1 *07 healthy donor and 
separated on a Ficoll-Hypaque gradient. The mononuclear cell layer was collected in 
HBSS, washed 2X at 400 x g for 10 min and 2X in 1 0% IMDM ( 400 x g, 7 min), before 
being centrifuged at 150 x g for 5 min to remove platelets. The cells were resuspended 
(at 1 x 105 cells/well) in 10% IMDM, pipetted into 6 well tissue culture plates (Nalge 
Nunc) and incubated in 5% C02 at 37°C for 2 hours before washing them with HBSS 
( 4X) to remove non-adherent cells. The remaining cells were incubated with 10% IMDM 
supplemented with 1000 U/ml human riL-4 (Sigma) and 1000 U/ml human rGM-CSF 
(Sigma), which was refreshed on days 2 and 4. For M<l> isolation, the cells were allowed 
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to adhere to glass 16-well tissue culture chamber slides and either left un-stimulated or 
stimulated with IFN-y for 7 days. 
On day 6, the immature DC were removed from media containing IL-4 and GM-
CSF and treated with 10 :g/ml ofTNF-a. These mature DC were harvested from 6-well 
plates on day 7 and placed in 16-well chamber slides (Nalge Nunc) at 2000 cells/well and 
centrifuged at 400 x g for 7 min. For surface expression analysis of DC, cells were 
cultured as above, and kept in cell suspension for cytofluorometry analysis. FITC-GAM 
lgM (Immunocontact) was used to detect NS lgM, NFLD.Dll, and NFLD.D13 while 
PE-GAM IgG (Jackson ImmunoResearch) was used to detect NS IgG, NFLD.D1, CD1a, 
CD83 and CD86. Approximately 5000 cells were collected for analysis using F ACS, and 
DC were gated based on size and granularity (Forward vs Side Scatter). 
3.2.4 Antibodies 
Commercially available mAbs used to differentiate macrophages and blood 
derived DC included: CD83 (HB 15e ), CD 1 a (HI149) (BD PharMingen, Mississauga, 
Canada), CD86 (BU63) (Cedarlane, Hornby, ON, Canada) and CD68 (EBM11) (DAKO 
Mississauga, ON, Canada). HLA-DR expression was determined using L243, pan anti-
HLA-DR (ATCC). DRBI *04 specific mAbs included NFLD.D1 which recognizes a 
DRBI *04-specific epitope located on the ~2 domain of all DRB1 *04 chains [37]; 
NFLD.D2 which recogmzes a shared epitope that maps to DRB1:70-
74:QKRAA/QRRAA sequence [38]; NFLD.DIO, which recognizes HLA-DR molecules 
that express and Qat position 70 of the HLA-DR~ chain; NFLD.Dll, which binds to a 
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HLA-DM dependent Dw4 determinant on DRBl *0401 molecules [31, 39]; NFLD.D13 
[39] which binds to DRBl *0404 molecules in the presence of DM, while binding to 
DRBl *0401 molecules in the absence of DM [33] while NFLD.M15 was used to 
measure the levels of HLA-B [32]. Antibodies used to identify components of the HLA 
class IT processing pathway included MaP.DMl, anti-human HLA-DM and LN2, which 
recognizes Ii (BD PharMingen) and cerCLIP (BD PharMingen) which recognizes class II 
associated invariant chain peptide (CLIP) associated with class II molecules. Isotype-
matched non-specific mAbs NS "lgM", NS "lgG 1" and NS "IgG2a" [BD Pharmingen] 
were used in all experiments. 
For cytofluorometry, secondary antibodies included goat anti-mouse (GAM) lgG 
Fe fragment specific and GAM lgM Jl chain specific R-Phycoerythrin conjugates 
(Jackson Immunoresearch). For characterization ofMM and DC by confocal microscopy, 
either a Cy3 labeled GAM lgG !-specific antibody, a FITC labeled GAM-IgG2a specific 
antibody, or a FITC-labeled GAM-IgM-specific antibody was used (all from 
lmmunoKontact, Wiesbaden, Germany). 
3.2.5 Antibody Blocking Assay 
The ability of several class IT mAbs to block the expression of the D 11 and D 13 
epitopes on B cell lines was measured by CELISA [31]. SAVC and MT14b were washed 
in PBS, plated in 96-well plates, treated with the appropriate blocking mAb for 1 hr at 
RT. The cells were then washed in buffer (3.X) which contained 0.5% BSA in PBS, and 
incubated with either NFLD.Dll for SAVC or NFLD.D13 for MT14b for 1 hr at RT. 
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The cells were washed again (3X) and incubated with HRP-labeled GAM-IgM for 1 hr at 
RT. After further washing (3X), the cells were transferred to EIA flat bottomed plates 
and incubated with OPD substrate. The reaction time was 30 minutes in the dark, which 
was then stopped using sulfuric acid, and read on a Multiscan Spectrophotometer at 8590. 
3.2.6 Cytofluorometry 
Cell surface expression of HLA-DR molecules and epitopes was determined by 
cytofluorometry as previously described [31]. Briefly, cells were washed in PBS 
containing 0.5% BSA, 0.02% sodium azide (Wash Buffer), and incubated with the 
appropriate test mAb for 30 minutes at 4°C. The cells were then washed 2X with wash 
buffer, and incubated with a GAM-PE labeled conjugate (Jackson Immunoresearch) for 
30 minutes at 4°C. The cells were washed in wash buffer, fixed in 1% paraformaldehyde 
(PF A) (Sigma) and analyzed using a F ACS Star Plus machine. 
3.2. 7 Confocal Microscopy 
M<l> and DC, grown in 16-well chamber slides, were washed with PBS, fixed in 
2% paraformaldehyde for 15 min at 4°C, washed briefly in 10% CM and then 
permeabilized in 0.1% Tween-20 for 10 min at RT followed by blocking with 15% goat 
serum in PBS for 1 hour at RT. These cells were then incubated with the first primary 
mAb for 1 hour at RT. After washing with PBS containing 0.5% BSA (wash buffer) the 
appropriate GAM conjugate, labeled with either Cy3 (lgG !-specific) or FITC (lgG2a-
specific) was then added for 1 hour, washed again in wash buffer followed by PBS. The 
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slides were mounted with aqueous anti-fade mounting media (DAKO) and analyzed 
using the confocal microscope (Olympus Fluo View™ 300 confocal laser scanning 
microscope). 
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Chapter 3.3 Results 
3.1 Allele-specific epitopes, D11+0401 and D13+0404, map to peptide binding pockets 
on the peptide binding groove of DRBl *04 molecules 
The monoclonal antibodies, NFLD.Dll and NFLD.D13 were previously shown 
to be specific for DRBI *0401 (originally called Dw4) and DRB1 *0404 (originally called 
Dw14), respectively [32]. These alleles differ by two conserved substitutions, ~K71R and 
~G86V, which are key residues in pockets 4 and 1 of the peptide-binding groove. Since 
these residues are not unique to DRBI *0401 and 0404 molecules, we compared the mAb 
patterns of recognition on naturally occurring variants of DRB 1 *04 molecules ([31] and 
Table 1). 
Table 1. Key residues in the HLA-DRBl * chain responsible for binding of NFLD.D2, 
NFLD.Dll and NFLD.D13 mAbs. 
DRB1* Amino Acids at DRB 1 Chain Residues Epitope 
~37 ~57 ~67 ~70 P71 ~74 ~86 NFLD.D2 NFLD.Dll NFLD.D13 
*0401 y D L Q K A G + + -
*0413 y D L Q K A v + + -
*0404 y D L Q R A v + - + 
*0408 y D L Q R A G + - -
*0405 y s L Q R A G + - -
*0410 y s L Q R A v + - -
*0101 s D L Q R A G + - -
*0102 s D L Q R A v + - -
*1402 N D L Q R A G + - -
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The extra reactivity of NFLD.Dll with 0413, a dimorphic variant (J386V) of 
0401, clearly places 71K in the context of DRB1 *04 as the critical residue in the 
D 11 +040 1 epitope. The D 13+0404 epitope is more complex as it is not present on 0408, a 
dimorphic variant (J386G) of 0404, thus implicating both J371R and J386V as critical 
residues. Given the role of J386 in anchoring the core peptide and J371 in peptide 
selection and T-cell recognition, we surmised that both 011+0401 and 013+0404 epitopes 
are similar to alloreactive T-cell defined determinants, Dw4 and Dw14, respectively [40]. 
To more definitively locate the D11+0401 and D13+0404 epitopes to the peptide 
binding grooves, we performed antibody-blocking assays. As shown in Figure 1, L243, a 
generic DR-specific mAb, frequently used to block T -cell recognition of allodeterminants 
on class II molecules, completely inhibited binding of NFLD.D11 and NFLD.Dl3 to B 
cell lines, SAVC (B1 *0401) and MT14 (Bl *0404), respectively. Similarly, NFLD.D2, 
specific for the shared epitope, QKRAA/QRRAA at J3-chain positions 71-74, also partly 
inhibited NFLD.Dll and NFLD.D13 binding. However, the pan-DRB1 *04 mAb, 
NFLD.D1, had no effect, most likely because its epitope is located in the J32 domain, and 
binding here may not modulate the conformation of the peptide binding site. Neither 
anti-HLA-DP (NFLD.M67) nor anti-HLA-DQ (NFLD.M36) mAbs inhibited D11 or D13 
(data not shown), further demonstrating that D11+0401 and D13+0404 epitopes are 
located exclusively on DR molecules. 
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Figure 1. The D11+0401 and D13+0404 epitopes bind to DRBl *04 molecules over the 
peptide binding groove. Several lll..A class II mAbs at titrating concentrations were tested for 
the ability to block the binding of NFLD.Dll to SAVC (a) and NFLD.D13 to MT14b (b) by 
CELISA. Briefly, the cells were washed, plated in 96 well plates, treated with the appropriate 
blocking mAb, before being tested for either Dll+0401 or D13+0404 epitope expression. 
Blocking mAbs included L243 (pan-DR), NFLD.Dl (pan-DR4) and NFLD.D2 (shared epitope 
mapping to DRB 1 :70-74:QKRAA/QRRAA). 
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3.2 Role of Class ll Chaperones in Expression ofD11+0401 and D13+0404 Epitopes 
Prior to this study, it was established that the Oll+0401 epitope is dependent on 
co-expression of HLA-OM as it is not expressed on ORB1 *0401 molecules in the OM-
null cells, T2-0w4, BLS.Dw4, and SJO-Ow4 [31]. Interestingly, it was partly restored 
by OM in T2-Dw40M, but more completely reconstituted in the gene complementation 
hybrids, BLS-Dw4 x .174 and SJO-Dw4 x .174, suggesting that additional factors are 
required for its expression. In contrast, we found that NFLO.Ol3 binds to the 
DRB1 *0404 transfectants, T2-0w14 and BLS-Dw14 (Figure 2 and data not shown), 
although its relative expression on these cells is significantly reduced compared to the 
0404+ BCL, MT14. A plausible explanation for reduced 013+0404 and absent 011+0401 
in DM-null cells is the abundant levels of DR/CLIP complexes (Fig. 2) and reduced 
numbers of other OR/peptide complexes [ 41]. 
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Figure 2. NFLD.D13 binding to DRBl *0401 molecules is inhibited by the presence of HLA-
DM. The binding of class 11 mAbs, including L243 (pan-DR), NFLD.Dl (pan-DR4), NFLD.Dll 
(DRBl *0401 in D~ cells), NFLD.D13 (DRB1*0404 in D~ and DRBl *0401 in DM- cells) and 
cerCLIP (DR/CLIP complexes) were tested on MT14b, and the DM null BLS Dw14. The results 
are expressed as a percentage ofL243, with isotype negative controls subtracted. 
3.2.1 Identification of a DM-antagonistic D13+0401 epitope on DM-, DRB1 *0401 
mutant cells 
Analysis of NFLD.Dl3 on various DRB1 *0401 transfectants revealed that the 
DM-null transfectants, T2-Dw4, BLS-Dw4 and SJO-Dw4 express D13+0401 epitopes 
[Figure 3 and data not shown]. This finding was unexpected as NFLD.D13 displayed no 
cross reactivity with DRB1 *0401 PBL B-cells or any homozygous BCL, other than those 
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which expressed DRB1 *0404 ([32]; Table 1). Moreover, unlike the previously described 
OM-dependent D11 +0401 epitope, the D13+0401epitope was abolished in DM-restored 
cells. Intriguingly, its expressiOn correlated with abundant expression of 
DRB1 *0401/CLIP complexes (Fig. 3), suggesting that bound CLIP could form the 
epitope. However, it was not possible to reconstitute this epitope on 0401-positive L-cell 
transfectants using CLIP peptides in standard peptide binding assays (SD, unpublished 
data). 
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Figure 3. The D13+0401 epitope is lost in the presence of BLA-DM. NFLD.Dl, cerCLIP, 
NFLD.Dll and NFLD.D13 binding to DM null cells (SJO Dw4) and D~ cells (SAVC, MT14b, 
SJO Dw4DM and SJO Dw4 x .174) were tested by cytofluorometry. Results are expressed as 
mean fluorescent intensity (MFI) shown with the appropriate isotype negative controls subtracted. 
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3.2.2 DM-dependent and independent epitopes on DRBl *04 molecules are not 
affected by DO expression 
Since T2, BLS and SJO are both no· and DM- we queried whether DO, a known 
regulator of DM, especially in B-cells [ 42, 43], influenced the generation of this epitope. 
To test this we used the hemizygous BCL 8.1.6 (D~, DOl and its daughter lines, 9.5.3 
(DM-, DOl and 5.2.4 (DM-, DO-), all transfected with DRB1 *0401. Despite high levels 
of DRB1 *0401 (NFLD.D1 binding), D11+0401 was not expressed on either 9.5.3-0401 
or 5.2.4-0401, but was reconstituted on 8.1.6-0401 (Fig. 4). Thus if DO has any role in 
forming the D11+0401 epitope, it does so in the presence ofDM. Similarly, expression of 
the DM- D13+0401 epitope on 9.5.3 and 5.2.4, and its absence on 8.1.6 or SAVC, 
suggests that DO has little or no control on expression of this epitope. Only 5.2.4-0404 
was available to analyze expression of D13 (Table 2). By comparing D13 expression, 
normalized to total DRB1 *04 (NFLD.D1) on this mutant to the normal BCL, MT14, it is 
clear that D13 expression is severely decreased. This correlates with our data presented in 
Fig 2 showing reduced DB-expression in the DM-, DO-mutant, BLS-Dw14. Thus, unlike 
D13+0401, expression ofD13+0404 epitope is suboptimal in DM-negative cells. 
Table 2. D13+0404 Epitope is Incompletely Expressed in DM·no· mutant cells. 
mAb 5.2.4 0404 MT14b 
MFI o/o NFLD.Dl MFI %NFLD.Dl 
L243 2963* 525 3226 203 
NFLD.Dl 564 1582 -
NFLD.Dll 0 0 0 0 
NFLD.D13 104 18 1270 80 
cerCLIP 1827 323 260 16 
* lsotype negative controls subtracted and results given in mean fluorescent intensity (MFI). 
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Figure 4. NFLD.Dlt and NFLD.D13 binding to normal and antigen processing mutant 
human B cell lines. Specificity ofHLA-DRB1 *04 allotypic mAbs NFLD.Dll and NFLD.D13 
was measured on the B cell lines SAVC (DRB1*0401), MT14b (DRB1*0404), 8.1.6 0401 
(endogenous DRB1 *03, *52), and the antigen presentation mutants 9.5.3 0401 (DM-) and 5.2.4 
0401 (DM- and DO-) using cell surface cytofluorometry. In addition, total surface HLA-DR4 
(NFLD.D1) and DR/CLIP (cerCLIP) along with intracellular DM (MaP.DM1) was also measured 
on these BCL. A combined cocktail (IgG 1, lgG2a and IgM) of isotype negative controls is 
shown with the grey fill, while the test mAbs are shown by solid blacks lines. Results are 
representative of three independent experiments. 
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3.2.3 D13+0401 and D13+0404 epitopes are not blocked by anti-DRICLIP antibody. 
Although previous attempt to reconstitute these epitopes with CLIP in peptide 
binding assays were not successful, the preceding data were strongly suggestive of a role 
for CLIP the D13+0401 epitope. Therefore, we tested the ability of cerCLIP mAb and the 
blocking mAb, L243, to inhibit binding ofNFLD.D13 and a control mAb anti-B2M. As 
shown in figure 5, L243 significantly blocked expression of both D13+ epitopes and, as 
expected had no effect on the B2M. Surprisingly, pretreatment of the cells with cerCLIP 
increased rather than decreased D13 expression, especially on 9.5.3-0401. This suggest 
that if D13+0401 is formed by CLIP complexes, cerCLIP and NFLD.D13 see different 
epitopes; however, it does not rule out the possibility that cerCLIP binding induces a 
conformational change that further exposes the D 13+040 1 epitope. 
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Figure 5. D13+0401 and D13+0404 epitopes are not formed on DR/CLIP complexes in 
normal and mutant BCL. The ability of class ll mAbs to block D13+0404 epitope expression 
on (a) MT14b and D13+0401 epitope on (b) 9.5.3 0401 was tested by cytofluorometry and shown 
by black bars. The ability of these mAbs L243 (DR), NFLD.Dl (DR4), NFLD.DlO (Q at 
position 70 of the HLA-DR~ chain) and cerCLIP (DR/CLIP) to block ~2-microglobulin 
(irrelevant IgM control-open bars) was also tested on each of the cell lines. 
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3.3 Variable Expression ofD11+0401 and D13+0404 Epitopes on pAPC 
Both D11+0401 and Dl3+0404 epitopes are expressed at reduced levels on 
peripheral blood B-cells but are up regulated by activation in culture (data not shown, and 
[32]). This, together with their high expression on EBV -transformed BCL, prompted us 
to study their expression on a variety of pAPC. 
3.3.1 All DR-expressing DRBl *0401 lymphoid cells do not express the D11+0401 
epitope 
Experiments, addressing D11+0401 expression on other types of lymphoid cells 
were done mainly by using cells that were transfected with DRB1*0401 and ifnecessary 
DRA eDNA constructs. Non-DRBI *04 EBV-transformed BCL transfected with 
DRB1 *0401, such as 8.1.6-0401 (shown in Figure 4) and PLH.Dw4 expressed the 
D11+0401 epitope whereas the T-cell line transfectant, Jurkat-Dw4 did not [31]. This 
latter finding correlated with studies showing no expression on PHA-activated and DR-
positive T-cells from DRB1 *0401 individuals (data not shown). 
Intriguingly, D11+0401 epitope was present on Raji-Dw4 (unpublished data), but 
not on Daudi-Dw4 [31], although both are Burkitt's lymphoma derived B cell lines. 
Daudi differs from Raji and EBV -transformed lines in its complement of EBV genes and 
CD markers and moreover, is HLA-class I null due to a deletion of Chromosome 15 
combined with a mutated P2 microglobulin (B2M) gene on the remaining chromosome 
[44]. This, combined with the fact that substantial numbers of DRB1 *04 molecules 
expressed by EBV -transformed BCL contain peptides derived from class I molecules 
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[45], suggested the possibility that the D11+0401 epitope was formed on 
DRBl *0401/class I peptide complexes. 
I D MT14 9 SAVC 0 DaudiB2M • DaudiDw4 ~ Daudi-B2M/Dw4 1 
10000 .-----------------------, 
~ 100 -+--- --i 
Figure 6. The class I null Burkitt's lymphoma cell line Daudi fails to express the Dll +0401 
epitope. Cell surface expression of DRBI *04 (NFLD.Dl), DR/CLIP (cerCLIP), 011+0401 
(NFLD.Dll), 013+0404 (NFLD.D13) and HLA-B (NFLD.Ml5) was measured on SAVC, 
MT14b, Daudi transfected with; DRBl *0401 (Daudi Dw4), beta-2-microglobulin (Daudi-B2M), 
and DRBI *0401 and beta-2-microglobulin (Daudi-B2M-Dw4) using cell surface 
cytofluorometry. Non-specific lgG is given as the negative control for this assay, with error bars 
measuring standard deviation from the mean of two experiments. Results are expressed as mean 
fluorescent intensity (MFI). 
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To test whether lack ofD11+0401 on Daudi-Dw4 was related to its HLA class I 
null status, we used Daudi-B2M, co-transfected with DRB1 *0401. As shown in Figure 6, 
this was not proven correct, as despite HLA class I reconstitution (NFLD.M15l and 
expression of the DRB1 *0401 transgene (NFLD.D1l, the D11+0401 epitope was not 
restored. This was not due to DM insufficiency as Daudi contains copious amounts of 
DM (data not shown). Daudi.Dw4 also lacked the D13+0401 epitope although abundant 
DR/CLIP were complexes expressed (Fig. 6). Most likely, these CLIP complexes are on 
endogenously expressed class II complexes as there is little difference between cerCLIP 
binding to Daudi-Dw4 and to Daudi-B2M. Lack ofD11+0401 on Daudi could be due to 
any number of reasons (see discussion), but further experiments, described below, 
demonstrating D11 +0401 expression on other types ofP-APC and a limited subset ofNP-
APC, would argue against a role for EBV associated proteins. 
3.3.2 Investigation ofD11+0401 and D13+ epitopes on M<l> and DC 
Cytofluorometric analysis ofD11+0401 and D13+0404 epitopes on CD14 positive 
mononuclear cells from DRB1 *0401 and DRBI *0404 positive individuals expression on 
CD 14+ monocytes revealed that less than 2% of these cells were positive for either 
epitope. Using confocal microscopy and/or cytofluorometry, we further investigated 
whether the epitopes are expressed on cultured M<l> and DC. 
3.3.2A Cytoplasmic expression ofD11+0401 epitope in activated Mfl) and DC 
DRBI *0401+ blood derived M<l> and DC were analyzed by immunofluorescence 
and confocal microscopy with a panel of anti-CD mAbs to check the cell lineage. As 
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shown in Fig 7 A, M<I>, treated or untreated with IFN-y, correctly expressed the 
conventional myeloid marker CD68 but not the DC marker, CD83; however, they weakly 
expressed CDla after activation with IFN-y. As expected, all DC expressed the myeloid 
marker CD68, but TNF-a treated DC additionally up-regulated CDla and CD83, 
indicating they are mature DC. Both sets of M<I> and DC strongly expressed HLA-DM 
and up-regulated HLA-DR after stimulation with either IFN-y or TNF-a respectively (Fig 
7A). DRBl *0401 (NFLD.D1) was expressed at higher levels in the DC compared with 
the M<I> (Fig 7B) and interestingly, most DRB1 *0401 was found intracellularly in M<I> 
(Fig 7B), whereas, both cytoplasm and membrane staining (Fig 7B) is evident in the DC 
The D11+0401 epitope staining pattern differed between the two sets of pAPC. 
First it was barely expressed in untreated M<I>, which reflected overall reduced DR-
expression (see L243 and NFLD.D1) in non-stimulated M<I> (Fig 7B); however, it was 
significantly up regulated by IFN-y treatment, with most of the staining appearing 
intracellular. Although the D11 +0401 epitope was expressed in both immature and mature 
DC (Fig 7B), the staining was weaker and most of it appeared to be intracellular. In a 
separate experiment done on IDC and DC from the same donor, NFLD.Dll produced a 
homogenous staining pattern throughout the cytoplasm of MDC, while most of it 
appeared perinuclear in IDC. Importantly, no non-specific staining was observed with 
lgM or any other irrelevant immunoglobulins (Fig 7 A and 7B), D 11 did not bind DC 
from non-DRB1 *04 individuals (data not shown). 
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Figure 7A. Characterization of human DRBl *0401+ Mel) and DC with differentiation 
markers. Human M<l> and DC were isolated from a DRB1 *0401+ healthy donor and assayed for 
differentiation markers by confocal microscopy to confirm their identity. Inactivated and 
activated M<l>, derived by treating the cells either with or without IFN-y and immature and mature 
DC, derived from cells treated with and without TNF-a, were stained for CD1a (non-classical 
class II molecule), CD68 (myeloid cell marker), CD83 (marker for mature DC) and DM. The 
negative control is non-specific mouse IgG 1. All pictures were taken at 400x (x2) and are 
representative examples of 80-100% of the cells tested. 
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Figure 7B. Analysis ofD11+0401 expression on DRBl *0401+ M«<» and DC. M<ll treated with 
and without IFN-y, and DC treated with and without 1NF-a were tested for the 011+0401 epitope 
using confocal microscopy. Other mAbs used were L243 (pan-DR) and NFLD.Dl (pan-
DRBl *04). Isotypes of the test mAbs are IgG2a for L243, IgGl for NFLD.Dl and IgM for 
NFLD.Dll. Negative controls included non-specific mouse IgGl followed by GAM-IgGl, Cy3 
labeled (Figure 7A), non-specific mouse IgG2a-FITC labeled, and NS IgM-FITC labeled. All 
pictures were taken at 400x (x2) and are representative examples of 80-100% of the cells tested. 
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3.3.2B Differential expression ofD11+0401 and D13+0404 epitopes on the cell surface 
of DC 
Since the above experiments indicated most (or all) Dll+0401 expression was 
within the cytoplasm, cytofluorometry was performed on unfixed IDC and DC, harvested 
from the same DRBl *0401 donor. IDC and DC were also prepared from a DRBl * 0404 
donor. As shown in Figures SA, CD83 was not expressed on IDC from both individuals, 
but was strongly expressed on 1NF-a. treated cells; both CD86 and HLA-DRBl *04 were 
also up regulated, indicating a transition from immature to mature DC phenotype. All 
cells expressed CDla (Figure 8B), and CD68, but lacked CD14, CD3 and CD19 (data not 
shown). 
In contrast to the confocal analysis shown in Fig 7B, no D11+0401 was evident in 
any of the combinations (Fig. 8B). However, D13+0404 epitope was weakly expressed on 
IDC (about 10% of the gated cells) and was strongly up regulated on MDC (30-40% of 
gated cells). As expected it was co-expressed on DRBl *04-positive in both IDC and 
MDC from the DRBl *0404 donor; as well, it was present on about 1/2 of the CD I a-
positive and 2/3 of the CD83+ cells. The negative control lgM mAb stained less than 1% 
of the cells and interestingly, the D13+0401 epitope was not expressed on IDC or MDC. 
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Figure 8. Surface expression of Dll +0401 and D13+0404 epitopes on immature and mature 
DC. (A) DRB1 *0401 and DRB1 *0404 DC were stimulated with (mature DC) or without 
(immature DC) 10 :g/ml TNF-a, and assayed for surface DR4, CD1a, CD83 and either 
D 11 +040 1 (left) or D 13+0404 (right) by cytofluorometry. (B) Surface expression of DR4, CD83 
and CD86 also shown for DRB1 *0401 (top) and DRB1 *0404 (bottom) immature and mature DC. 
In both (A) and (B), lgG is shown as the isotype negative controL 
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3.4 Cellular-restricted expression of Dll +0401 and D13+0404 epitopes on NP-APC 
An early indication that these epitopes may be restricted to pAPC was their 
absence on mouse L-cells, transfected with either DRA or DRB1 *0401 or 0404; this was 
subsequently confirmed for this study (unpublished data). As reported in Chapter 2, a 
collaboprative effort revealed no cell surface or intracellular expression of D 11 +040 1 or 
D13+0404 on DRB1 *04+ cultured synovia] fibroblasts or on class II positive fibroblasts 
in diseased synovial tissues. Interestingly, class II positive fibroblasts co-expressed class 
II chaperones and several endosomal and lysosomal markers, suggesting that either 
cellular specific peptides or proteases might be necessary for their expression. To further 
investigate their cellular specificity, we extended the study to include carcinoma and 
melanoma cell lines, which expressed either endogenous or transfected DR genes. 
3.4.1 Carcinoma cell lines do not express Dl1+0401 or D13+0401 epitopes 
Since carcinoma cells express little or no endogenous class II or chaperone genes, 
the cells, whether or not they expressed endogenous or transfected DRB1 *04 genes, were 
treated with IFN-y. The breast cancer cell lines, T47D Dw4 and MCF-7 Dw4 up 
regulated DR after IFN-y treatment, but did not express D11+0401 (Fig 9). The control 
BCL SAVC expressed copious amounts of DR (L243) and DRB1 *04 (NFLD.Dl) on its 
cell surface, as well as abundant D 11 +040 1 epitope. Lack of D 11 +040 1 on the BCCL is · 
not due to DM insufficiency as significant amounts were found in both BCCL, 
comparable to that found in SAVC (Fig. 9 and data not shown). Similarly, the Dl1+0401 
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epitope was not expressed on the human intestinal epithelial carcmoma cell line 
transfectants HT29 Dw4 treated with IFN-y (data not shown). 
The cell line MDA MB 435 transfected with DRA and DRBl *0401 (MDA MB 
435 Dw4, previously described as a BCCL but more recently suggested to be of 
melanoma origin [46] showed strong up-regulation of total DR, and DRB1 *04 (Fig 9), 
supposedly due to expression of the transfected DRB1 *0401 and endogenous 
DRB1 *0405 alleles. As expected the D11+0401 epitope was not found on the surface of 
the un-transfected MDA MB 435, even though there was abundant DM present (data not 
shown). Surprisingly, both stimulated and un-stimulated MDA MB 435 Dw4 cells 
expressed the D11 +0401 epitope, although it was increased in the presence of IFN-y (Fig 
9). Therefore this demonstrated for the first time the expression of the D11+0401 epitope 
onaNP-APC. 
The DRBl *0401-positive melanoma cells 1359 Mel and DM331 expressed 
significant amounts of constitutive DR and DRB1 *04 which were further up-regulated by 
IFN-y (Fig 9b ). Interestingly, stimulation with IFN-y resulted in slight expression of the 
D11+0401 epitope on both 1359 Mel and DM331 (Fig 9). As seen in Fig 9c, these 
melanoma cells also expressed abundant DM, DO and Ii, although at levels slightly less 
than SA VC. This indicates that although DM is required for D11 +0401 epitope 
expression, other, currently unknown factors are also required for its expression. 
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Figure 9. Continued on Next Page. 
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Figure 9. Expression of the D11+0401 epitope on DRBl *0401+ h~man breast cancer and 
melanoma ceU lines. The Dll+0401 epitope, DR (L243), DRB1*04 (NFLD.D1) and DR/CLIP 
(cerCLIP) expression was tested on (a) MDA MB 435 Dw4 (endogenous DRB1 *0405, 13), T47D 
Dw4 (endogenous DRB 1 *0 102), MCF-7 Dw4 (endogenous DRB 1 *03, 15) and (b) DM331 
(endogenous DRBl *0401, DRBl *01) and 1359 Mel (endogenous DRB1•0401, DRB1 *0301) by 
cell surface cytofluorometry. Cells were either left untreated(-) or treated with 500U interferon-
y/ml (+) for 4 days. Intracellular expression of DM, DO and li (LN2) was measured by 
intracellular cytofluorometry (c) in DM331 and 1359 Mel. The DRB I *0401 + BCL SAVC was 
used as a control for class II epitope expression, with results presented as means of two separate 
experiments. 
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3.4.2 Dll +0401 epitope expression on MDA MB 435 Dw4 shows differential effects 
ofiFN-y. 
To investigate the kinetics of D11+0401 epitope formation, MDA MB 435 Dw4 
was treated with IFN-y for 24 hour increments, ending with 120 hours, or left untreated 
(Fig 10). Total DR expression on these cells did not change significantly over the test 
period and was comparable to total DR expression on the control B cell line SAVC (Fig 
lOa). Similarly, expression of DRBl *04 on untreated MDA MB 435 Dw4 was not 
significantly different from the IFN-y treated cells, and in fact was greater than that 
expressed by SAVC (Fig lOb). 
D11+0401 epitope expression on the melanoma cell line showed a different 
pattern than the total DR and DRBl *04. SAVC consistently expressed this epitope 
throughout the assay, peaking at 72 hours (Fig lOc). There was a delay in the formation 
ofthe D11+0401 epitope on the surface ofMDA MB 435 Dw4 treated with IFN-y, with 
the lag period being between 24 and 48 hours. After 48 hours, the D11+0401 epitope was 
expressed, peaking at 72 hours, similar to total DRB1 *04 expression. Therefore the 
maximal presence of the D11 +0401 epitope at 72 hours may be explained due to 
increased DRB1 *04 expression, or perhaps due to an increase in an IFN-y inducible 
cellular component which is involved in the epitope formation. 
On the untreated MDA MD 435 Dw4 cells there was a drop in D11 +0401 epitope 
expression at 48 hours, although it continued to increase until 120 hours (Fig lOc). At 
this time point, D11 +0401 expression was comparable to the treated cells, indicating that 
the un-stimulated cells were producing a factor that was behaving in a manner similar to 
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IFN-y. This factor is not DM, with intracellular DM failing to accumulate within the 
untreated MDA MB 435 Dw4 cells (Fig 1 Od). The expression of DM throughout the 
assay was similar between the melanoma cells and SA VC, indicating that DM is not 
responsible for the differential kinetics of the D11 +0401 epitope in the three groups of 
cells. 
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Figure 10. The D11+0401 epitope on MDA MB 435 Dw4 untreated and IFN-y treated shows 
differential expression. The cell surface expression of DR (a), DRBI *04 (b), the Dll+0401 
epitope (c) and intracellular DM (d) was tested on the BCL SAVC (.&), MDA MB 435 Dw4 
untreated (•), and treated with 500U interferon-y/ml (•) by cytofluorometry. Expression was 
measured at 24, 48, 72, 96 and 120 hours after IFN-y stimulation. The results are expressed as 
mean fluorescent intensity (MFI), with the appropriate isotype negative controls subtracted. 
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3.4.3 The D13+0404 Epitope is not expressed on NP-APC 
As previously shown, the D13+0404 epitope is strongly expressed on EBV-
transformed B cells and DC. However, it was not expressed on human synovial 
fibroblast cell lines (T Frost, BSc. Honors Thesis) and mouse fibroblasts transfected with 
DRA + DRB1 *0404 (data not shown). Similarly, immunohistochemical studies 
performed on synovial tissues containing large numbers of DR positive fibroblast cells 
from DRBI *0401 and 0404 RA patients lacked these epitopes (S. Oldford, BSc. Honors 
thesis). To address whether other cell types might express this epitope, we analyzed its 
expression on a DRB 1 *0404 positive breast carcinoma cell line BT20 and a melanoma 
cell line DM13. Unfortunately, since BT20 poorly up-regulated DRB1 *04, determined 
by mAb NFLD.D1 (data not shown), we cannot state unequivocally that D13+0404 was 
not expressed. However, analysis on DM13 (Figure 11) clearly shows that despite good 
expression of DR, DRB1 *04 and DM, the D13+0404 epitope was absent. 
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Figure 11. DRBl *0404+ melanoma cells do not express the D13+0404 epitope. The 
expression of total cell surface DR (L243), DRB1 *04 (NFLD.D1), DR/CLIP (cerCLIP), and the 
D 11 +040 1 and D 13+0404 epitopes was measured by cytofluorometry on the BCL MT14b and the 
DRB 1 *0404+ melanoma cell line DM13 untreated (-) and treated with SOOU interferon-y/ml for 4 
days (+), as shown in (a). Intracellular DM, DO, and Ii (LN2) was also measured by 
cytofluorometry as shown in (b). All results are presented as mean fluorescent intensity (MFI), 
with the appropriate isotype controls given as either NSG or NSM. 
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3.4 Discussion 
We have previously described HLA-DRB1 *04-specific epitopes defmed by mAbs 
NFLD.D11 and NFLD.D13. NFLD.D11 recognizes an HLA-DM dependent epitope on 
HLA-DRB1*0401 molecules expressed on normal BCL, but not on DM- BCL [31]. 
NFLD.D13 recognizes DRB1 *0404 on D~ BCL and DRB1 *0401 on DM- BCL [33]. 
In normal BCL, NFLD.Dll and NFLD.D13 are specific for DRB1 *0401 and 
DRB1 *0404, respectively, two DRB1 *04 alleles that differ by two conserved 
substitutions, f3K71R and f3G86V, which are key residues in pockets 4 and 1 of the 
peptide binding groove, respectively. The lack of binding of NFLD.Dll to non-
DRB1 *0401 BCL indicates that 71K of DRB1 *04 is the only critical residue for 
D11+0401 epitope generation [31]. The D13+0404 epitope is dependent on both f371R 
and f386V. Given the role of f386 in anchoring the core peptide and f371 in peptide 
selection and T-cell recognition, we believe that the D11+0401 and D13+0404 epitopes 
are similar to the alloreactive T -cell defmed determinants, which are influenced by 
recognition of MHC-peptide complexes [31]. 
The DM-dependent specificity of D11+0401 is similar to a Dw4-specific T cell 
clone LG.BlO, which was also dependent on DM for recognition and proliferation [31]. 
Interestingly, LG.B10 proliferative responses to Daudi Dw4 was reduced compared to 
other T cell clones, providing further evidence that NFLD.Dll is recognizing a similar 
determinants as the T cell clone LG.B10. Supporting this, the absence of the D11+0401 
and D13+0404 epitopes on mouse L-cell transfected with either DRB1 *0401 or 
DRB 1 *0404 also suggests that bound peptide, as well as critical residues on the peptide 
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binding groove contribute to the generation of these epitopes. This was supported by the 
fact that D 11 +040 1 and D 13+0404 epitopes were both blocked by m.Abs that bind over or 
in the peptide groove, but not by mAbs that bind to the ~2 domain, which confirms that 
these epitopes are located on the class II peptide binding groove 
Both the D11+0401 and D13+0404 epitopes are preferentially expressed on EBV-
transformed BCL, reminiscent ofthe UL-SAl mAb described by Wolpl et al, 1998 [47]. 
UL-5A1, which distinguishes DRB1 *0101 molecules bound with HLA-A2 derived 
peptides was found to specifically bind to activated BCL, and not on NP-APC, 
suggesting that the antigen processing pathway within these cells may be paramount for 
the generation of this epitope. Likewise, preferential expression of D11+0401 and 
D13+0404 on EBV-transformed B cells suggests that an activated phenotype, either by 
the expression of cellular-specific proteins or the mobilization of necessary 
compartmentalization and antigen processing mechanisms, is important for the 
expression of the D 11 +040 1 and D 13+0404 epitopes. In addition to BCL, expression of 
the D11+0401 and D13+0404 epitopes on IFN-y activated M<l> and TNF-a activated 
HLA-DRB1 *0401+ DC supports the notion that an active cell phenotype, perhaps 
specific to P-APC is required for the formation of these epitopes. 
Although DM is required for D11 +0401 epitope formation, its absence on NP-
APC, which express copious DM suggests that other factors are necessary for epitope 
formation. One possibility could be that the proteolytic environment within activated B 
cells, M<l> and DC is changed in response to different exogenous stimuli. For example, 
DC are known to increase proteolysis [ 48], lysosomal function [ 49] and presentation of 
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exogenous antigen [50] after activation. We found that lysosomal and cytoplasmic 
cysteine proteases are required for the generation of the Dll +0401 epitope in BCL 
(Chapter 4), so it is possible that the same proteases are required for the generation of the 
D11+0401 epitope in M<l> an DC. Having said this, the lack of blocking of NFLD.D11 
and NFLD.D13 binding to normal and DM- BCL by cerCLIP indicates that these epitopes 
are not formed on DR/CLIP complexes. This does not disprove however, that other sets 
of peptides are involved in forming the D11+0401, D13+0404 and D13+0401 epitopes. 
This could be due to conformational changes induced by DM, as with the 16.23 epitope 
[51], or through direct recognition of class IT-associated peptides. The involvement of 
specific peptides in the formation of these epitopes is currently under investigation. 
Another possibility is that the cellular organization of intracellular compartments 
or cell surface microdomains such as lipid rafts and tetraspan microdomains may be 
different between cells that are positive and negative for these epitopes. Related to this, 
the P-APC-restricted UL-5Al epitope is present within CDw78-defined tetraspan 
microdomains on the surface of B cells [52] and DC [53], suggesting that these 
microdomains may differ between P-APC and NP-APC. Similarly, we have found that 
the D11+0401 and D13+0404 epitopes are substantially decreased by tetraspan-disrupting 
chemicals such as saponin (Chapter 4), indicating that these microdomains may be the 
additional factor responsible for the presence of these epitopes on P-APC. Related to 
this, we have observed that CDw78 microdomains are significantly reduced on D11+0401 
epitope negative cells such as 9.5.3 0401 and T2.Dw4 (data not shown). 
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Unlike B cells, M<l> and DC, which constitutively express co-stimulatory 
molecules and MHC class IT on their cell surfaces, non-professional APC, must up-
regulate these molecules in the presence of inflammatory stimuli. For example, in the 
presence of IFN-y, microglial cells [54], intestinal epithelial cells [55], and keratinocytes 
[56] have all been reported to increase co-stimulatory and HLA class II expression. 
Interestingly, we found that the Dll +0401 and D13+0404 epitopes were not expressed on 
human breast carcinoma and melanoma cell lines expressing abundant DRB1 *04 and 
DM. Also, human fibroblasts from patients with rheumatoid arthritis, which express 
copious amounts ofDM (Chapter 2), and murine fibroblasts transfected with DRB1 *0401 
or DRB1 *0404 failed to express the D11+0401 and D13+0404 epitopes. Although it is 
possible that the requisite proteases are not up-regulated in these cells, this seems 
unlikely since published data indicate that various cell lines, including human breast 
cancer cell lines [57, 58], colon carcinoma cell lines [59], and HT29 [60] express 
abundant levels of cathepsin B, D and L. Also, a human keratinocyte cell line up-
regulates cathepsin S [61] and gastric epithelial cells up-regulate cathepsins B, L, Sand D 
[62] after IFN-y treatment. Another possibility could be that the source of the putative 
peptide(s) may not be present in these cells. Further analysis of the proteolytic 
environment within these cells should answer these questions. 
The fmding that the melanoma cell line MDA MB 435 Dw4 expressed the 
D11+0401 epitope even without IFN-y treatment suggests that these cells may have 
phenotypic features comparable to P-APC. In the presence of IFN-y there was more 
surface D 11 +040 1, which peaked earlier than the D 11 +040 1 epitope on the un-stimulated 
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cells. Both treatments produced equivalent amounts ofDM, confirming that other factors 
in addition to DM are required. These factors may include proteases, expression of cell 
specific proteins shared between melanoma cells and P-APC, or similar organization of 
tetraspan microdomains. 
DM negative cells, such as 9.5.3 0401, T2 Dw4, BLS Dw4 and SJO Dw4 express 
copious amounts of MHC class II/CLIP complexes [63], and the 013+0401 epitope. The 
presence of the D13+0401 epitiope on these cells suggests that CLIP is somehow 
implicated in the formation of this epitope. However, the cerCLIP rnAb did not block the 
expression of the D13+0401 epitope, suggesting that CLIP is not involved in the 
formation of this epitope. Interestingly, we have observed that cells that express 
D13+0401 are also CDw78 microdomain negative, which may explain the presence of 
this epitope on DM- cells. 
Daudi, a Burkitt's lymphoma cell line, which is class I null, and class II positive, 
including DM and Ii, may provide some insight regarding HLA-DRB1 *04 epitopes. For 
example, Daudi transfected with DRB 1 *040 1 failed to express the D 11 +040 1 and 
D13+0401 epitopes. Its high expression ofDM likely explains the absence ofD13+0401, 
but the absence of D 11 +040 1 suggested the possibility of an epitope derived from class I, 
a result that was not changed by the stable transfection of beta-2-microglobulin into these 
cells. Related to this, we found that a rnAb that recognizes HLA-B caused partial 
inhibition of Dll+0401 and D13+0404 epitope expression on normal BCL. This 
inhibition suggests two possible mechanisms for the involvement of class I in the 
formation of the Dll+0401 and D13+0404 epitopes. One possibility is that Dll+ and 
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D13+ DRB1 *04 molecules are presenting HLA-B derived peptides in their peptide 
binding grooves. As discussed above, another possibility is that the HLA class II 
molecules that form the D 11 and D 13 epitopes are located within large tetraspan-protein 
complexes that also include HLA class I. It has already been shown that these protein 
microdomains are disrupted in the antigen processing mutant cell T2 [53]. It is possible 
that a similar defect in Daudi is the reason why it is D 11 +040 1 null. Related to this, 
CD82 has been found associated with HLA class I within normal BCL [64], so it is 
conceivable that a complex between either of these molecules with DRB1 *0401 results in 
formation of the D 11 +040 1 epitope. 
We have shown that mAb-defmed D11+0401 and D13+0404 epitopes, which are 
similar toT cell epitopes, are preferentially expressed on P-APC, suggesting that factors 
unique to these cells are responsible for generating these epitopes. This may involve the 
up-regulation of unique proteases or cellular proteins that are broken down within the 
class II processing pathway differently than in non-professional APC. The involvement 
of DM and the location of key residues for NFLD.Dll and NFLD.D13 recognition of 
DRBI *04 molecules strongly suggests that class 11-associated peptides are involved in 
epitope formation. This may be due to direct recognition of MHC-peptide, or through 
recognition of peptide-dependent conformational determinants on the class II molecules. 
Alternatively, there is evidence that the DRB1 *04 molecules that these mAb are binding 
are located within tetraspan microdomains. These are active areas of research, and 
should lead to further knowledge of these DRBI *04 epitopes. 
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Abstract 
The expression of MHC class 11/peptide complexes on the cell surface results 
from a complex intracellular process involving HLA-DM and numerous proteases. We 
have previously described antibody-defined epitopes on DRB1 *0401 and DRB1 *0404 
molecules which are largely restricted to professional antigen presenting cells. The 
DRB1 *0401-specific epitope, defined by NFLD.D11, is dependent on the presence of 
DM, whereas the DRB1 *0404-specific epitope, defmed by NFLD.D13 is less dependent 
on DM for its expression. Intriguingly, NFLD.D13 also recognizes an epitope on 
DRB1 *0401 molecules in DM-negative mutant B cells. The limited cellular distribution 
of these epitopes and their different requirements for DM suggest alternative antigen 
processing or trafficking mechanisms are implicated in their generation. We performed 
co-localization studies using confocal microscopy for markers for class II antigen 
processing pathway compartments and protease inhibitors to identify the intacellular 
mechanisms that generate these epitopes. The D11+0401 and D13+0404 epitopes both 
follow the classical endocytic pathway en route to the cell surface in normal B cell lines 
(BCL) and are implicated in tetraspan protein microdomains on the cell surface. In 
normal and mutant BCL the DRB1 *0401 epitopes recognized by NFLD.Dll and 
NFLD.D13 are influenced by endosomal and cytoplasmic cysteine proteases, but not 
aspartyl proteases. Unlike the DRB1 *0401 epitopes, the D13-defmed DRB1 *0404 
epitope was not affected by the protease inhibitors tested here. 
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4.1 Introduction 
MHC class II molecules are membrane glycoproteins formed from a non-
polymorphic a chain and a polymorphic~ chain [1-2] and are expressed constitutively on 
the surface of professional antigen presenting cells (P-APC) such as B cells, macrophages 
(M<I>) and dendritic cells (DC). They also can be up-regulated on non-professional (NP-
APC) by inflammatory mediators such as interferon-y (IFN-y) [3]. MHC class II 
molecules bind short peptides between 13 to 25 amino acids long [ 4] with 
polymorphisms in the peptide binding groove making it possible for the MHC class II 
molecules to bind a wide array of peptides. The binding capacity of any given peptide to 
a MHC class II molecule is dependent on the primary sequence of the peptide and on the 
allelic variation of the residues within the peptide binding groove. For HLA-DR 
molecules, the peptide is bound within a long cleft formed between two antiparallel 
helical structures and a floor formed by an eight-stranded ~-sheet [4]. The peptides are 
held in place by hydrogen bonds between the peptide backbone and the residues along the 
class II molecule itself. Bound peptide residues that project downwards into the peptide 
binding groove are accommodated by allele-specific pockets found within the class II 
molecule. It is the class II pocket shape and composition that determines the amino acid 
make-up of the peptides that can bind to the class II molecule, and these qualities differ 
greatly amongst HLA-DRB alleles. 
MHC class II molecules are generated in the endoplasmic reticulum (ER) and 
associate with the invariant chain (li) [5-7]. Three MHC a~ dimers bind to three Ii 
proteins forming a nonomeric complex [1] that travels from the ER through the trans 
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golgi complex to a series of endocytic compartments and eventually to lysosome-like 
structures known as MHC class II peptide loading compartments (MIIC) [8]. Within 
these MIIC, Ii is slowly degraded in a stepwise manner leaving a small peptide known as 
CLIP, an acronym for class II associated invariant chain peptide, in the class II peptide 
binding groove [9]. HLA-DM facilitates the exchange of CLIP [10-12], for a peptide 
generated from exogenously-derived proteins or from endogenous proteins that intersect 
the class II pathway. DM is also important in the stabilization of the "peptide-free" or 
empty conformation of the MHC class II molecule [13-15] before enhancing the binding 
of high stability peptides in the groove of the MHC class II molecule [16-18]. This 
mature peptide-MHC complex (pMHC) moves to the cell surface to interact with the 
CD4+T H T cell receptor (TCR). 
Recent studies suggest that mature MHC/peptide complexes (pMHC) travel to the 
cell surface as large protein aggregations that include the tetraspanin proteins CD81, 
CD82 and CD63 as well as DM [19]. Although the function of these aggregates is still 
unclear, they may stabilize the pMHC or participate in signal transduction by surface 
receptors [20]. These tetraspan complexes have been shown to exist on the cell surface 
where they likely concentrate specific pMHC complexes, better enabling T cell activation 
[21]. This concentration of relevant pMHC on the APC, and the TCR specific for these 
pMHC on the surface of the T cell results in the formation of the immunological synapse, 
which also includes a variety of costimulatory, accessory and signaling molecules. 
As stated above, proteolytic events play dual roles in the generation of mature 
pMHC complexes. In addition to digesting endocytosed antigen into small peptides that 
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bind class II molecules within lysosomal compartments, cellular proteases also gradually 
destroy Ii. Depending on the cell type, different proteases have been implicated in the 
breakdown of Ii. For example, cathepsin S is the major protease in B cells and DC [22], 
whereas cathepsin Lis implicated in Ii degradation in mouse thymic epithelial cells [23]. 
Recently cathepsin S, and not cathepsin L, has been shown to degrade Ii in NP-APC such 
as epithelial cells [24], suggesting that the cellular processing machinery differs between 
cell types. 
The majority of class II associated peptides results from degradation of proteins in 
the highly acidic and protease-rich endocytic compartments [25]. The major groups of 
proteases in these compartments are cathepsins, which can be divided into two major 
species, cysteine and aspartyl. The dispensability of individual cathepsins has been 
shown by knock-out mice, which have normal immune cell numbers and as broad peptide 
arrays as wild type mice [26-27] and the ability of numerous proteases to degrade the 
same antigen [28-30]. Recent data indicate that class II peptides can be generated from 
cytoplasmic processing of endogenous antigen, confirming that there is more than one 
pathway for class II processing [31-32]. 
We have previously described allele-specific epitopes on DRB1 *0401 and 
DRB1 *0404 molecules which are constitutively expressed on EBV-transformed B cell 
lines (BCL) (Chapter 3). The expression of the DRB1 *0401-specific epitope, defined by 
the mAb NFLD.D11 is dependent on the presence of DM, but requires other unknown 
cellular factors for its expression [33 and Chapter 3]. In contrast, the DRBI *0404-
specific epitope, defmed by NFLD.D13 is less dependent on DM for its expression. 
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Intriguingly, NFLD.D13 also recognizes an epitope on DRB1 *0401 molecules in DM 
negative BCL, which is completely lost when DM expression is restored [34 and Chapter 
3]. The limited cellular distribution of these epitopes and their different requirements for 
DM suggest alternative antigen processing or trafficking mechanisms are implicated in 
their generation. To identify the intracellular location of D11+ and D13+ DRB1 *04 
molecules, we performed co-localization experiments using confocal microscopy, where 
NFLD.D11 and NFLD.D13 were used in combination with m.Abs recognizing markers 
for various intracellular compartments and MHC class II-associated molecules. To 
address the influence of antigen processing mechanisms, we used brefeldin A and 
protease inhibitors to identify whether intracellular trafficking of DRB 1 *04 molecules 
and proteases were implicated in forming these epitopes. 
We found that treatment of the cells with the ER-golgi transport inhibitor 
brefeldin A reduced expression of all three epitopes. Also, in normal and DM null BCL 
expression of the D11+ and D13+ DRB1 *0401 were influenced by endosomal and 
cytoplasmic cysteine proteases, and not by aspartyl proteases. The D11 and D13 epitopes 
in normal BCL appeared to follow similar intracellular trafficking routes, although, 
unlike the DRB1 *0401 epitopes, the D13-DRBI *0404 epitope was not affected by the 
protease inhibitors tested here. 
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4.2 Methods 
4.2.1 Cell Lines 
Human EBV-transformed B cell lines (BCL) SAVC (HLA-DRB1 *0401) and 
MT14b (HLA-DRB1 *0404) were obtained through the lOth International 
Histocompatibility Workshop (IHW) [35] and maintained in complete media (CM) 
consisting of Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% 
heat inactivated fetal calf serum (FCS), antibiotics and L-glutamine (all from Gibco BRL, 
Rockville, ML, USA). BCL 8.1.6 0401 (DRB1 *0401, DRB1 *0301) and 9.5.3 0401 
(DRB1 *0401, DRB1 *0301) were a kind gift from Dr. N. Patil and Dr. E. Mellins at 
Stanford University, and kept in complete RPMI media supplemented as above. All BCL 
were maintained in humidified air containing 5% C02 at 370C. 
4.2.2 Antibodies 
Total HLA-DR expression was determined with L243 (ATCC), while DRB1 *04 
specific mAbs included NFLD.D1, specific for an epitope on the P2 domain of all 
DRB1 *04 chains [36]; NFLD.D11, specific for a HLA-DM dependent Dw4 determinant 
on DRB1 *0401 molecules [33 and 37] and NFLD.D13, which binds DRB1 *0404 
molecules in the presence ofDM and DRB1 *0401 molecules in the absence ofDM [34]. 
Antibodies used to identify components of the HLA class II processing pathway included 
anti-DM, MaP.DM1 (BD PharMingen); cerCLIP (BD PharMingen) specific for MHC 
class II/CLIP complexes and anti-Ii, LN2 (BD Pharmingen). Other markers included 
anti-CD71 (M-A712), anti-CD82 (50F11) (BD PharMingen) and anti-CD63 (CLB-180) 
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(Cedarlane, Hornby, ON, Canada). Isotype-matched non-specific mAbs NS "lgM", NS 
"IgG 1" and NS "lgG2a" [BD Pharmingen] were used in all experiments. 
Secondary antibodies included a peroxidase-conjugated F(ab)2 fragment goat anti-
mouse (GAM) IgG + IgM (H + L) (Jackson Immunoresearch, West Grove, PN, USA) for 
CELISA assays and either GAM lgG Fe fragment specific R-Phycoerythrin conjugate or 
GAM lgM ~ chain specific R-Phycoerythrin conjugate (Jackson lmmunoresearch) for 
cytofluorometry. FITC-labeled IgG Fe fragment specific conjugate (Jackson 
Immunoresearch) and Texas Red dye conjugated lgM ~ chain specific (Jackson 
Immunoresearch) antibodies were used for co-localization experiments. 12nm colloidal 
gold-AffmiPure GAM lgM, ~-chain specific and 18nm colloidal gold-Af:finiPure goat 
anti-mouse lgG, y-chain specific (Jackson ImmunoResearch) were used for electron 
microscopy studies. 
4.2.3 Inhibitor Treatments 
BCL were treated for 18 hours at 37°C with the following inhibitors: Brefeldin A 
(BfA) (Sigma) at 0.5ng/ml, Leupeptin (Sigma) at 25~M, Pepstatin A (Sigma) at 25~M, 
Cathepsin B inhibitor IT (CBI) (Calbiochem) at 1 OO~M, Lactacystin (Sigma) at 250nM 
and Calpeptin (Calbiochem) at 50~M. The concentration of all inhibitors used was 
predetermined and had no effect on cell viability, as assessed by Trypan Blue exclusion. 
After incubation, the cells were either fixed with 2% paraformaldehyde (PFA) (Sigma) in 
PBS, pH 7.4, for 15 minutes at 4°C and washed with cold CM followed by PBS, and 
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assayed by CELISA (for SAVC and MT14b), or alternatively kept cold and assayed by 
cytofluorometry (for SAVC, 8.1.6 0401 and 9.5.3 0401). 
4.2.4 Saponin and Methyl-fJ-cyclodextrin Treatments 
The existence of DRB1 *04 epitopes within lipid rafts or tetraspan microdomains 
on the cell surface was tested as described in [21]. Briefly, BCL SAVC and MT14b were 
washed in PBS, fixed in 1% PF A for 15 min at RT and washed again with CM followed 
by PBS. The cells were then either treated with 0.1% saponin (Sigma) in PBS containing 
2% FCS (Gibco BRL) for 20 min at 4°C or with 5mM methyl-~-cyclodextrin (Sigma) 
diluted in CM for 10 min at 37°C. The presence of various class II epitopes was then 
assayed by cytofluorometry. 
4.2.5 Cytofluorometry 
Cell surface expression of HLA-DR molecules and class II epitopes was 
determined by cytofluorometry as previously described [33]. Briefly, cells were washed 
in PBS containing 0.5% BSA, 0.02% sodium azide (Wash Buffer), and incubated with 
the appropriate test mAb for 30 minutes at 4°C. The cells were washed twice with wash 
. . 
buffer, and incubated with a goat anti-mouse PE labeled conjugate (Jackson 
Immunoresearch) for 30 minutes at 4°C followed by two more washes in wash buffer. 
The cells were fixed in 1.0% PF A and analyzed using a F ACS star plus flow cytometer 
(BD PharMingen), acquiring 1 x 105 events per mAb treatment. For assessment of 
intracellular antigens, cells were fixed in 2% PFA for 15 min at RT, washed in CM 
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followed by PBS and permeabilized with 0.2% saponin for 10 min at RT and assayed as 
described above. 
4.2.6 Confocal Microscopy 
BCL cytocentrifuge preparations (at 2.5 x104 cells/prep) were washed with PBS, 
fixed in 2% PFA for 15 min at 4°C, washed briefly in CM and permeabilized in 0.2% 
Tween-20 for 10 min at RT followed by blocking with 15% goat serum in PBS for 1 hour 
at RT. Cell preps were incubated with the first test mAb for 1 hour at RT, removed using 
wash buffer (PBS containing 0.5% BSA) followed by application of second test mAb for 
1 hour. After washing, the appropriate GAM conjugates were applied for 1 hour, 
followed by washing once in wash buffer and PBS before being mounted with aqueous 
anti-fade mounting media (DAKO) and viewed under the confocal microscope (Olympus 
FluoView™ 300 confocal laser scanning microscope). 
4.2. 7 Immunoelectron Microscopy 
2 x 106 B cells were washed in PBS before being fixed in 2% EM-grade PF A 
(Sigma) for 15 mins at 4°C. The cells were then washed in CM followed by PBS and 
permeabilized with 0.2% saponin in PBS for 15 min at RT. The cells were then 
incubated with the appropriate test mAbs diluted in PBS containing 0.05% saponin for 1 
hr at 4°C, rotating constantly. After 3 washes with PBS containing 0.05% saponin, the 
cells were incubated with 12nm colloidal gold GAM IgM, fl chain specific, followed by 
18nm colloidal gold GAM IgG, y chain specific for 1 hr at 4°C. The cells were washed 
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2x in PBS containing 0.05% saponin and pelleted before being fixed with Karnovsky's 
fixative for 20 min at RT and resuspended in 0.1 M sodium cacodylate buffer overnight. 
The pellets were cut and placed on copper grids before membrane enhancement with 
uranyl acetate followed by osmium vapor treatment. 
4.2.8 Cellular Enzyme-Linked Immunosorbent Assay (CELISA) 
2.5 x 104 B cells/well were fixed in 2% PF A, washed in CM followed by PBS, 
and added to a 96 well round-bottom plate containing the appropriate test antibodies. 
After a 1 hour incubation at RT the cells were washed 3x with wash buffer (0.5% BSA, 
0.05% Tween 20 in 1x PBS) and then incubated with the secondary antibody for 1 hour 
at RT. After 3 washes with buffer, the cells were transferred to EIA flat bottomed plates 
and incubated with OPD substrate for 30 min in the dark. The reaction was stopped 
using sulfuric acid, and read on a Multiscan Spectrophotometer using a 490nm filter. All 
assays were performed in triplicate, with means calculated and backgrounds subtracted 
using the appropriate isotype negative controls. Means and standard deviation were 
calculated from two assays in each case and the results expressed as treated/untreated. 
D11 and D13 epitope expression was also expressed as a percentage of the pan-DRBl *04 
mAb NFLD.Dl. 
4.2.9 Statistical Analysis 
To analyze statistical significance of inhibitor treatments, Paired Two Sample for 
Means, t-Tests were performed, with significance assigned for p-values < 0.05. 
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4.3 Results 
4.3.1 Dll+ DRB1*0401 molecules traffic through the endocytic pathway in B cell 
lines. 
To identify the intracellular location of Dll +and D13+ DRB1 *04 molecules, we 
performed co-localization experiments using confocal microscopy. mAbs NFLD.D11 
and NFLD.D13 in combination with mAbs recognizing markers for various intracellular 
compartments and MHC class 11-associated molecules were reacted with SA VC 
(DRB1 *0401) and MT14b (DRB1 *0404) respectively. 
The staining pattern shows abundant co-localization of the Dll+0401 and D1 
epitopes (Fig 1a), suggesting that the subset of DRB1 *04 molecules bearing the 
Dll+0401 epitope reside within the total DRB1*04 population or that D1+ and Dll+ 
DRB 1 *04 molecules traverse the same intracellular compartments in SA VC. Having 
said this, there is evidence of discrete staining of both epitopes within SA VC. Also, the 
presence of the epitopes was more abundant intracellularly compared with on the cell 
surface, probably because of permeabilization of the plasma membrane by Tween-20. 
The D11 +0401 epitope partially co-localized with HLA-DM, although independent 
binding ofNFLD.Dll and MaP.DM1 was apparent (Fig 1b). This suggests that the Dll+ 
DRB1 *0401 molecules exists within DM positive intracellular compartments and diverge 
from these compartments en route to the cell surface. In contrast;the Dl1+0401 epitope 
did not co-localize significantly with Ii (Fig 1c), indicating that either the Dll+0401 
epitope exists within compartments where the invariant chain has already been degraded, 
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such as post-golgi compartments, or that there is no association with Dll+ DRBI *0401 
molecules with DR/Ii complexes within SA VC. 
The D 11 +040 1 epitope also partially co-localized with CD63 (Fig 1 d) and Lamp-l 
(data not shown), which are markers of late endocytic compartments, where DM is 
typically located [8, 38 and 39]. Complete co-localization of Dll +0401 epitope with the 
tetraspan molecule CD82 (Fig le), suggests that Dll+ DRBl *04 molecules may reside in 
large molecular complexes, as reported by Hammond et al, 1998, or may simply exist 
within the same intracellular compartments as CD82. CD71, which is located in early 
endosomal compartments and on the plasma membrane did not co-localize with the 
D11+0401 epitope (Fig If) demonstrating that the D11+ DRBl *04 molecules are not 
formed on recycling class II molecules. Since the D11+ DRBl *0401 molecules co-
localized primarily with markers for late endosomes and lysosomes (DM, CD63, CD82, 
LAMP-l) without co-localizing with CD71 and Ii, this indicates that the D11+0401 
epitope forms primarily within MIIC, and may require proteases that are active at this 
acidic pH [2, 8, and 9]. 
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(a) NFLD.Dll NFLD.Dl Overlay 
(b) NFLD.Dll 
HLA-DM Overlay 
NFLD.Dll Invariant Chain Overlay 
(c) 
Figure 1. Continued on Next Page. 
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NFLD.Dll CD82 Overlay 
(e) 
NFLD.Dll CD71 Overlay (f) 
Figure 1. Characterization of the D11+0401 epitope within the class II antigen processing 
pathway. mAbs that recognized components of the class II antigen processing pathway were 
used in double labeling studies in conjunction with NFLD .D 11. The normal human B cell line 
SAVC (DRB1 *0401 positive) was used in all panels. m.Abs included those against (a) Ill.,A-DM, 
(b) pan-DR4 (NFLD.D1), (c) the invariant chain, (d) CD63, (e) CD82 and (f) CD71. All test 
mAbs were IgG1, whereas NFLD.Dll is IgM. The conjugates used were GAM IgG FITC 
labeled and GAM IgM Texas Red labeled. Overlays of the two m.Abs are shown on the left, with 
co-localization seen as yellow to greenish-yellow in color. All pictures were taken at 400x (x2) 
and are representative of 90-100% of cells viewed. 
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4.3.2 Dll+ DRBl *04 molecules co-localizes with DM, CD62 and CD82 within 
multilaminar MHC class II compartments in B cell lines. 
To further determine the ultrastructural location of the D 11 +040 1 epitope within 
SAVC, IEM studies were performed. As shown in Fig 2a, the 011+0401 epitope 
appeared on the cell surface as clusters, often within aggregates which resemble 
exosomes described by Escola et al, 1998 [40]. The majority of the intracellular 
D 11 +040 1 epitope positive DRB 1 *04 molecules were located within multilaminar 
structures (Fig 2b) similar to MIIC that most resemble lysosomes [8]. Using different 
size colloidal gold for immunolabeling, it was apparent that the Dll+0401 epitope co-
localized with DM, CD63 and CD82 within these multilaminar structures (Fig 2c ). These 
fmdings correlate with those from the confocal analysis, indicating that the interaction of 
these lysosomal proteins with D 11 + DRB 1 *04 molecules occur within lysosomal 
compartments along the endocytic pathway. 
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(a) 
NFLD.Dll within MllC 
(b) 
NFLD.Dll + HLA-DM NFLD.Dll + CD63 
(c) . . 
Figure 2. The D11+0401 epitope is located on exosome-like structures on the cell surface 
and within multilaminar MDC within the B cell line SAVC. (a) The localization of the 
Dl1+0401 epitope (black arrows) on the surface of SAVC was measured by immunoelectron 
microscopy (IEM), using cells fixed with 2% paraformaldehyde before m.Ab treatment. 
Micrographs shown here are at a magnjfication of 58,000x. (b) and (c) Expression of 
intracellular D 11 +040 1 epitope within the endocytic pathway of SA VC was also shown using 
IEM with permeabilized cells (black arrows). NFLD.Dll (12nm gold-black arrows) was used in 
conjunction with mAbs to either HLA-DM, CD63 or. CD82 (18nm gold-red arrows). All 
micrographs in (b) and (c) are taken at 172,000x. 
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4.3.3 D13+ DRBl *0404 molecules traffic through the endocytic pathway in B cell 
lines. 
Confocal microscopy studies with the DRB1 *0404+ BCL MT14b showed that the 
Dl3+0404 and D1 epitopes partially co-localized, indicating that as expected, Dl3+ 
DRBl *0404 molecules exist within the total DRB1 *04 population (Fig 3a). The 
D13+0404 epitope co-localized incompletely with DM (Fig 3b), which is not surprising 
since it is expressed in DM- BCL and does not require DM for its expression. These 
results imply that although the D 13+0404 epitope is not DM dependent, it still exists 
within D~ compartments. Interestingly, in contrast to the Dll+0401 epitope, the 
D13+0404 epitope co-localized strongly with Ii (Fig 3c), suggesting that Ii is either 
directly involved in the formation of the D13+0404 epitope, or alternatively, the 
Dl3+0404 epitope is formed on DRB1 *0404 molecules that traffic through the same 
intracellular compartments as Ii. 
In addition to this, co-localization of the D 13+0404 epitope with CD63 (Fig 3d) 
indicates that the Dl3+ DRB1 *0404 molecules are also present in lysosomes, just as the 
D11+0401 epitope. The association between the Dl3+0404 epitope and CD82 (Fig 3e-
yellow color), shows that like the Dll +0401 epitope, the D13+0404 epitope may interact 
with this tetraspan molecule within intracellular compartments. · The lack of association 
of the D13+0404 epitope with CD71 (Fig 3f), indicates that this epitope is not present 
within early endosomes and is not expressed on recycling class II molecules. Taken 
together, this confocal microscopical analysis suggests that the D 13+0404 epitope follows 
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a similar intracellular trafficking pathway as the D 11 +040 1 epitope. Unfortunately 
however, although immunoelectron microscopy studies were performed using the 
NFLD.D13 mAb, IEM staining was poor, and therefore no further information could be 
collected in regards to its ultrastructural location. 
NFLD.D13 NFLD.Dl Overlay 
(a) 
NFLD.D13 HLA-DM Overlay 
(b) 
NFLD.D13 Invariant Chain Overlay 
(c) 
Figure 3. Continued on Next Page. 
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NFLD.D13 CD71 Overlay 
(f) 
Figure 3. Characterization of the D13+0404 epitope within the class II antigen processing 
pathway. mAbs that recognized components of the class II antigen processing pathway were 
used in double labeling studies in conjunction with NFLD.D13. The normal human B cell line 
MT14b (DRBI *0404 positive) was used in all panels. mAbs included those against (a) .fll,A-
DM, (b) pan-DR4 (NFLD.Dl), (c) the invariant chain, (d) CD63, (e) CD82 and (f) CD71. All 
test mAbs were lgGl, whereas NFLD.D13 is lgM. The conjugates used were GAM lgG FITC 
labeled and GAM lgM Texas Red labeled. Overlays of the two mAbs are shown on the left, with 
co-localization seen as yellow to greenish-yellow in color. All pictures were taken at 400x. (x2) 
and are representative of 90-100% of cell viewed. 
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4.3.4 D11+0401 and Dl3+0404 epitopes are effected by tetraspan domain, but not 
lipid raft disrupting chemicals. 
The strong co-localization of the D11 +0401 and D13+0404 epitopes with the 
tetraspan molecules CD63 and CD82 suggested that tetraspan microdomains may be 
involved in the surface expression of these epitopes. To test this, we used the tetraspan 
microdomain and lipid raft disrupting chemicals saponin and methyl-P-cyclodextrin 
(MBCD), respectively, as described by Kropshofer et al, 2002 [21]. Although the 
detergent saponin can be used to permeabilize cellular membranes, it also has been 
shown to disturb surface tetraspan microdomains of paraformaldehyde-fixed cells when 
used at low concentrations [21]. As shown in Fig 4a, total DR, measured by L243, and 
the D11+0401 epitope were dramatically decreased by saponin (D11+0401 MIF of 448.5 
in untreated compared with 56.5 in saponin treated), whereas DRB1 *04, measured by 
NFLD.D1 slightly increased. MBCD did not destroy the D11+0401 epitope or 
significantly reduce total DR expression, although it did slightly decrease the D 1 epitope 
(Fig 4b). Saponin caused a slight increase in binding ofNFLD.D13 to SAVC (MIF of2 
in untreated compared with 13.5 in saponin treated). Taken together, this suggests that 
the DRB1 *0401 molecules that form the D11+0401 epitope are present within tetraspan 
microdomains, but not lipid rafts. Related to this, we did not observe co-localization of 
the D11+0401 epitope with FITC-labeled cholera toxin subunit B (data not shown) on 
SAVC, which is reported to be located within lipid raft domains on the surface ofhuman 
BCL [41]. 
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Similarly, DR and D13+0404 epitopes were also disrupted by saponin, but not 
MBCD on MT14b (Fig 4c and d). Interestingly, as seen with SAVC, the Dl epitope 
increased slightly after saponin treatment while decreasing in the presence of MBCD on 
MT14b (Fig 4c and d). TH.ken together, this shows that the D13+0404 epitope is also 
present within tetraspan microdomains, and not lipid rafts on the surface of BCL. 
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Figure 4. Localization of D11+0401 and D13+0404 epitopes within cell surface 
microdomains. The normal human BCL (a and b) SAVC (DBRl *0401) and (c and d) MT14b 
(DRB1 *0404) were treated with 0.1% saponin (a and c), 5 mM methyl-f3-cyclodextrin (MBCD) 
(b and d), or left untreated. The expression of total surface HLA-DR (L243), lll..A-DR4 
(NFLD.D1), and D11+0401 (NFLD.D11) and 013+0404 (NFLD.D13) epitopes were measured by 
cytofluorometry. The results are expressed as total mean fluoresc~nce intensity (MFI), given 
above the appropriate bar, for both the untreated (black fills) and the treated cells (no fill), with 
standard deviation resulting from a combined two experiments. 
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4.3.5 Endosomal and cytoplasmic cysteine proteases are necessary for the generation 
of the D11+0401 epitope. 
The observations that the expression of the D11 +0401 epitope on BCL is DM 
dependent, but is not expressed by several NP-APC that have up-regulated HLA-
DRB1 *04 and DM (Chapter 3) suggests that either specific peptides or proteases are 
required for its generation. Since we could not analyze the peptide repertoire from D 11 + 
molecules as NFLD.Dll is not useful for immunoprecipitation, we elected to study the 
contribution of particular proteases to its generation. For these experiments, SA VC was 
treated with several protease inhibitors for 18 hr and the expression of the D11+0401 
epitope and various other class II-related molecules were then assayed by CELISA. In 
addition, SA VC was also treated with Brefeldin A (BfA), which blocks trans-golgi 
protein transport and inhibits the formation of class II epitopes that require late 
endosomes and lysosomes [42], making it a useful indicator ofthe contribution of newly 
synthesized molecules and the endocytic pathway for D11+0401 epitope formation. 
Since 0.05% Tween-20 was used in the washing buffer throughout the assay, it is likely 
that we measured both intracellular as well as surface expression of the various class II 
molecules. 
BfA treatment resulted in decreased levels of total HLA-DRB1 *04, -DR and class 
I (Fig 5a and data not shown) on SA VC, which is not surprising since it blocks ER-golgi 
protein transport. In contrast, the protease inhibitors used had little effect on the 
expression of HLA-DRB1 *04, -DR and class I molecules (Fig 5a and data not shown) 
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probably because of the redundancy in generating class I and class II epitopes, where one 
group of pro teases can likely compensate for the lack of another. 
We observed decreased D11+0401 expression after BfA treatment (Fig 5b), which 
partly reflects the overall decrease in DRB1*04; however, D11+0401 loss was greater 
than D1 loss. 1bis finding suggests that the D11 +0401 epitope is formed from a pool of 
newly synthesized molecules, but also supports the data showing the existence of the 
D 11 +040 1 epitope within lysosomal compartments. It further suggests that the D 11 +040 1 
epitope is not formed on recycling DRB1 *04 molecules, which correlates with its lack of 
association with CD71 in the confocal studies in Figure 1. However, the general cysteine 
protease inhibitor leupeptin markedly reduced NFLD.D11 binding, whereas pepstatin A, 
which inhibits aspartyl proteases did not. This indicates that cysteine, but not aspartyl 
pro teases are implicated in generating the D 11 +040 1 epitope (Fig 5b ). Specific inhibitors 
of the endosomal cysteine protease cathepsin B and calpain, a group of cytoplasmic 
cysteine proteases, also decreased Dll +0401 expression on SAVC (Fig 5b). Therefore, 
both endosomal and cytoplasmic cysteine proteases are involved in the generation of the 
D 11 +040 1 epitope on DRB 1 *040 1 molecules. 
Interestingly, the expression pattern of DR/CLIP complexes somewhat mirrored 
D11+0401 in the presence of BfA, leupeptin and cathepsin B inhibitor II (CBI) (Fig 5c). 
In contrast, pepstatin A and lactacystin did not affect CLIP expression (Fig 6c and data 
not shown) suggesting that the same proteases are likely responsible for the formation of 
the D11 +0401 epitope and the degradation ofli into CLIP. The possibility that CLIP, or a 
longer version is responsible for forming the D11 +0401 epitope is unlikely since cerCLIP 
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does not block the binding of NFLD.Dll to SAVC, and the D11+0401 epitope is not 
present on DM negative cells that express abundant amounts of CLIP [Chapter 2]. 
Ii!DR complexes were relatively unchanged, although BfA and pepstatin A 
treatments both caused slight increases in LN2 binding (Fig 5d). Since BfA affects total 
protein transport, it may have resulted in the accumulation of li/DR by blocking the 
production of proteases and chaperone molecules needed for Ii degradation and CLIP 
removal. 
4.3.6 Combined cysteine protease inhibitor treatments reduce the Dll +0401 epitope 
on BCL additively. 
Since individual cysteine inhibitors resulted in partial loss of the D 11 +040 1 
epitope, we questioned whether particular protease inhibitor combinations would be 
additive. As shown in Figure 6, the D11+0401 epitope was significantly decreased by 
treatment with the combinations of leupeptin + CBI (p value = 0.00137), leupeptin + 
calpeptin (p value= 0.0191) and calpeptin + CBI (p value= 0.00189). Partial loss ofthe 
D11+0401 epitope with treatment of leupeptin + pepstatin A (Fig 6b), provided further 
evidence that aspartyl proteases are not involved in forming the D11+0401 epitope. In 
contrast, expression of NFLD.D1, which is not peptide-dependent, was only slightly 
decreased with these protease inhibitor treatments. Taken together, these results strongly 
suggest that both endosomal and cytoplasmic cysteine proteases are required for 
generating the D11 +0401 epitope. 
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Figure 5. Inhibition of the D11+0401 epitope in the presence of protease inhibitors and 
brefeldin A. SA VC (DRB 1 *040 1) was incubated with various inhibitors (O.Snglml Brefeldin A , 
25~ Leupeptin, 25~ Pepstatin A, 100~ Cathepsin B inhibitor II and 50~ Calpeptin) or 
DMSO alone (vehicle control) for 18 hrs at 37°C. The cells were then fixed and assayed for the 
expression of class II epitopes by CELISA using the following mAbs; (a) NFLD.D1 (DR4), (b) 
NFLD.Dll (c) cerCLlP (DR/CLlP complexes) and (d) LN2 (DR/Ii complexes). Triplicate 
optical densities were averaged, backgrounds subtracted and combined for two separate 
experiments. Results were then presented as treated/untreated for each of the inhibitors used. 
Error between experiments was measured using standard deviation of the mean. 
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Figure 6. Effect of various combinations of protease inhibitors on the expression of the 
D11+0401 epitope. SAVC (DRBl *0401) was incubated with combinations of inhibitors (25J.LM 
Leupeptin, 25J.LM Pepstatin A,100JJM Cathepsin B inhibitor II and SO!JM Calpeptin) or DMSO 
alone (vehicle control) for 18 hrs at 37°C. The cells were then ftxed and assayed for the 
expression of several epitopes by CELISA using the mAbs; (a) NFLD.D1 (total DR4), (b) 
NFLD.Dll, (c) cerCLIP for (DR/CLIP complexes), (d) LN2 (DR/Iicomplexes). Triplicate 
optical densities were averaged, backgrounds subtracted and .combined for two separate 
experiments. Results are presented as treated/untreated for each inhibitor. Error between 
experiments was measured using standard deviation of the mean. Significant p values as assessed 
by Paired Two Sample for Means t-Tests; * p value = 0.00137, ** p value= 0.0191, *** p value 
= 0.00189. 
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4.3. 7 BfA treatment reduces the D13+0404 epitope, though inhibition of cysteine and 
aspartyl proteases has little effect. 
Since cysteine proteases are involved in generating the D11+0401 epitope, we 
queried whether the D 13+0404 epitope was affected by the same inhibitors. BfA, but not 
protease inhibitors reduced total DRB1 *04 levels (Fig 7a). Like the D11 +0401 epitope, 
the DRBl *04 molecules that form the D13+0404 epitope also appear to come from a pool 
of newly synthesized molecules, since BfA decreased the expression of the epitope by 
about 55% (Fig 7b). The only loss of the D13+0404 epitope with the protease inhibitors 
was with leupeptin, by less than 20% (Fig 7b ), suggesting that cysteine proteases may 
weakly influence the production of this epitope. If any of the proteases tested here are 
required for the generation of the D13+0404 epitope, there is likely a redundancy in the 
cleavage specificity, such that the loss of one protease is compensated for the loss of 
another. 
As with the D11+0401 epitope, the loss of the D13+0404 by the BfA treatment 
paralleled the decrease in DR/CLIP expression (Fig 7c). This indicates that both these 
epitopes require lysosomal/late endosomal compartments for their production. Leupeptin 
and CBI also caused a slight accumulation of Ii complexes in MT14b (Fig 7d), 
presumably due to inhibition of li breakdown. 
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Figure 7. Effect of brefeldin A and proteases inhibitors on the D13+0404 epitope. MT14b 
(DRBl *0404) was incubated with various inhibitors (0.5ng/ml Brefeldin A, 25~ Leupeptin, 
25~ Pepstatin A, 100~ Cathepsin B inhibitor ll and 50~ Calpeptin) or DMSO alone 
(vehicle control) for 18 hrs at 37°C. The cells were then fixed and assayed for the expression of 
several epitopes by CELISA. The following mAbs were used; (a) NFLD.Dl (DR4), (b) 
NFLD.Dl3, (c) cerCLIP (DR/CLIP complexes) and (d) LN2 (DR/invariant chain complexes). 
Triplicate optical densities were averaged, backgrounds subtracted and combined for two separate 
experiments. Results were then presented as treated/untreated for each of the inhibitors used. 
Error between experiments was measured using standard deviation of the mean. 
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4.3.8 Leupeptin-induced loss of the Dll +0401 epitope is not due to decreased DM 
expression. 
Since DM is required for expression of the D11+0401 epitope on DRB1 *0401+ 
BCL, and leupeptin treatment decreased D11+0401 expression, we questioned whether 
leupeptin treatment reduced intracellular DM levels. Leupeptin treated SAVC cells were 
analyzed for intracellular and surface DRB1 *04 and DM using cytofluorometry. As 
shown in Fig 8a, DRB 1 *04 expression was not altered by leupeptin, while surface 
expression of D11+0401 was significantly decreased (MIF of 602 on untreated cells) 
compared to 156 on leupeptin treated cells (Fig 8a). This surface expression agrees with 
the results of total expression presented in Figs 4 and 5. As expected, there was little 
NFLD.D13 binding and no DM on the surface of SAVC before or after treatment (Fig 
8a). 
The results of the intracellular cytofluorometry displayed in Figure 8b confirmed 
that the level of DRB 1 *04 molecules (NFLD .D 1) was unaffected by leupeptin treatment. 
Strangely, there was little detectable intracellular NFLD.Dll binding, in contrast to the 
intracellular microscopy results in Figs 1 and 2. Certainly, the differences in 
permeabilizers (Tween-20 for confocal microscopy, saponin for intracellular flow 
cytometry) could explain this. It is possible that saponin, at the concentrations used for 
this experiment, disrupted NFLD.Dll binding. Intriguingly, intracellular binding of 
NFLD.D13 moderately increased in the presence of leupeptin (MIF = 56 in the untreated 
compared with 145 in the treated cells), whereas this treatment did not affect the 
expression of intracellular DM (Fig 8b ). Therefore the loss of surface expression of the 
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Dll +0401 epitope by leupeptin treatment is not due to a decrease in total DRB1 *0401 or 
DM levels. Together with the data presented in Figs 5 and 6, this further suggests that 
cysteine proteases strongly influence the generation of the D 11 +040 1 epitope. 
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Figure 8. Treatment of the B cell line SA VC with leupeptin does not cause the depletion of 
intracellular HLA-DM. SAVC was treated for 18 hrs at 37°C with 25J.IM leupeptin (red 
histograms) or treated with DMSO in 10% complete media (control- green histograms). The cells 
were either: (a) kept on ice and assayed by cell surface cytofluorometry, or (b) fixed, 
permeabilized and assayed for intracellular flow cytometry. mAbs to various molecules included; 
NFLD.Dl (total DR4), NFLD.Dll, NFLD.D13 and MaP.DMl for total HLA-DM. Appropriate 
isotype negative controls are shown with a solid black line. 
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4.3.9 Treatment of SA VC with cysteine protease inhibitors generates the D13+0401 
epitope. 
Previously we described a 013+0401 epitope on OM negative B cells [34 and 
Chapter 2]. Here, we found that treatment of the normal BCL SA VC with either 
leupeptin, CBI or calpain, decreased the 011+0401 epitope, also generated a NFLO.D13-
recognizable epitope on DRBl *0401 molecules. In contrast, treatment of these cells with 
pepstatin A, lactacystin or BfA did not (Fig 9a and data not shown). When these 
inhibitors were used in combination, BfA + pepstatin A had no effect, whereas various 
combinations of cytsteine protease inhibitors resulted in an additive effect (Fig 9b and 
data not shown). Thus, the same inhibitors that caused a loss of the D11+0401 epitope on 
ORB1 *0401 molecules also resulted in an increase in a D13+0401 epitope. The greatest 
increase in this 013+0401 epitope resulted from the combination of leupeptin + calpeptin 
indicating that endosomal and cytoplasmic proteolysis is necessary for its generation (Fig 
9b). 
Since normal NFL0.013 binding to untreated SAVC was quite low, any increase 
in binding may be interpreted as artificially large when presented as treated/untreated. To 
exclude this potential artifact, NFLO.D13 binding was also expressed as a percentage of 
NFLD.D1, which was not altered by these inhibitors. As shown in Fig 9c, the protease-
induced D13+0401 epitope was clearly not present in the untreated cells, but was 
moderately to strongly expressed in all cells treated with a cysteine protease inhibitor. 
Maximal expression of 40% of NFLD.01 was observed with either combination of 
leupeptin, CBI or calpeptin (Fig 9c ). 
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Figure 9. Treatment of the HLA-DM positive B cell line SA VC with cysteine protease 
inhibitors results in a gain of a D13+0401 epitope. SAVC (DRB1 *0401) was incubated with 
(a) inhibitors (25J.!M Leupeptin, 25f.!M Pepstatin A, 100f.!M Cathepsin B inhibitor II and 50J.LM 
Calpeptin), (b) and (c) various combinations of the above protease inhibitors, or DMSO alone 
(vehicle control) for 18 hrs at 37°C. In all cases the cells were then fixed and assayed for the 
expression of the D13+0401 epitope using CELISA. Triplicate optical densities were averaged, 
backgrounds subtracted and combined for two separate experiments. The results in (a) and (b) 
were then presented as treated/untreated for each of the inhibitors used, and the results in (c) are 
presented as NFLD.D13 as a percentage of the pan-DR4 mAb NFLD.Dl. Error between 
experiments was measured using standard deviation of the mean. 
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4.3.10 The DM antagonistic D13+0401 epitope on antigen processing deficient BCL 
also requires cysteine proteases. 
Finally, we queried if proteases also contributed to generation of the D13+0401 
epitope on DM negative cells. We used the DM negative BCL 9.5.3 0401, which 
expresses abundant DR/CLIP complexes [34] and the D13+0401 epitope, as well as the 
parent cell 8.1.6 0401, which is competent for all components of the antigen processing 
pathway and expresses the D11+0401 epitope but not the D13+0401 epitope [Chapter 2 
and 34]. Because the I-ILA-DR and DRB1 *04 expression on 8.1.6 0401 and 9.5.3 0401 
was sensitive to fixation, these experiments were performed using cytofluorometry and 
not CELISA, as had previously been done with SAVC and MT14b. As shown in Fig 10, 
treatment of the cells with leupeptin, calpeptin and CBI reduced NFLD.D11 binding to 
SA VC and 8.1.6 0401, although this effect was more prominent with SA VC (Fig 1 Oa and 
b). This result confirms the requirement of cysteine proteases for D11+0401 epitope 
formation on normal BCL. 
As seen with the normal BCL, the inhibitors did not cause significant fluctuation 
in DR and DRB1 *04 levels on the surface of 9.5.3 0401, with the exception of BfA, 
which caused a reduction in the binding of L243 and NFLD.D1 (Fig lOc). BfA also 
caused a significant reduction in the D13+0401 epitope on 9.5.3 0401, which coincided 
with a substantial loss of DR/CLIP complexes, DR and DRB1 *04 (Fig 10c). Leupeptin, 
CBI and calpeptin diminished the D13+0401 epitope on 9.5.3 0401 (Fig lOc) whereas 
pepstatin A (Fig 1 Oc) and lactacystin (data not shown) did not. This shows that, like the 
DM-dependent D11+0401 epitope, the D13+0401 epitope partially require newly 
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synthesized molecules in the endocytic pathway, in addition to endosomal and 
cytoplasmic cysteine proteases. For both of these epitopes, the most common lysosomal 
cysteine protease, cathepsin B and calpain are prime candidates. 
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Figure 10. Expression of the D13+0401 epitope on the HLA-DM negative BCL 9.5.3 0401 in 
the presence of protease inhibitors. The (a) normal BCL SAVC (DRB1 *0401), (b) 8.1.6 0401 
(DRB1 *0401, DRB1 *0301) and (c) the HLA-DM negative BCL 9.5.3 0401 (DRB1 *0401, 
DRB1 *0301) were incubated with various inhibitors (0.5ng/ml Brefeldin A, 25J!M Leupeptin, 
25J!M Pepstatin A, 100J!M Cathepsin B inhibitor ll and 50J!M Calpeptin) or DMSO alone 
(vehicle control) for 18 hrs at 37°C. The expression of various MHC class ll epitopes were 
measured by cell surface cytofluorometry, and the results expressed as Treated/Untreated. 
Results shown are a representative example of three experiments. 
165 
4.4 Discussion 
In this study, we explored the intracellular pathway in which three HLA-
DRB1 *04-specific epitopes, defined by the mAbs NFLD.Dll and NFLD.D13, were 
formed in human BCL. In addition to identifying the subcellular location of these 
epitopes, we further ascertained which groups of proteases were required for their 
generation. We found that the D11 +0401 epitope co-localized with molecules found 
within late endosomal and lysosomal compartments. Upon further examination, this co-
localization occurred in multilamminar structures that resembled conventional MIIC as 
described by Kleijmeer et al, 1996 [43] and Robbins et al, 1996 (39]. We found that the 
D11 +0401 epitope was partially inhibited by cysteine protease inhibitors, whereas the 
Dl3+0404 epitope was not inhibited by protease inhibitors, although it did co-localize 
with molecules found within late endosomes and lysosomes. Also, similar to the 
Dll+0401 epitope, the D13+0401 epitope was inhibited by cysteine protease inhibitors. 
All three of these DRB1 *04 epitopes were inhibited by the ER-golgi transport inhibitor 
BfA. 
Since expression of the D 11 +040 1 epitope in human BCL is HLA-DM dependent 
[33], it was not surprising to observe co-localization of the Dll+0401 epitope with DM. 
However, the DM-independent D13+0404 epitope partly co-localized with DM, 
suggesting that both the D11+0401 and Dl3+0404 epitopes exists within D~ 
compartments in BCL. As DM is abundantly expressed within late endosomes and 
lysosomal compartments, such as MIIC [8, 16, 38, 39, 43], this implies that the D11 +0401 
and D13+0404 epitopes either form or traffic through late endosomes and lysosomes 
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within BCL. This is supported by the lack of co-localization of NFLD.Dll and 
NFLD.D13 with the transferrin receptor (CD71), a commonly used marker for recycling 
early endosomes [44, 45]. 
This being said, the co-localization patterns of the two epitopes with Ii differed, as 
very little D 11 +040 1 co-localized with Ii, compared to significant amounts of D 13+0404 
with Ii. This suggests that Ii may indeed be involved in D13+0404 epitope formation, 
either due to Ii intermediate peptides, or Ii-influenced trafficking ofD13+0404 molecules. 
Indeed, other studies suggest that a significant number of class lllli complexes may 
migrate directly to the cell surface [45]. Here, these molecules may either recycle 
through early endosomes to the plasma membrane, or alternatively, enter the endocytic 
pathway [45]. Therefore, although molecules that form the D13+0404 epitope are found 
within the endocytic pathway, the co-localization studies with Ii suggest that its 
intracellular trafficking route is different than the DRB 1 *04 molecules that form the 
Dl1+0401 epitope. The microscopical data with the D11+0401 epitope leads us to 
believe that the DRBI *0401 molecules responsible for forming this epitope enter the 
endocytic pathway and migrate directly to the cell surface via these compartments. 
Similarly, 16.23, a mAb which recognizes a DM-dependent epitope on DR3 
molecules has also been shown to be present primarily within late endosomal and 
lysosomal compartments within human BCL [46, 47], and similar to the D11+0401 and 
D13+0404 epitopes, 16.23 colocalized with DM, and CD63 within MIIC [46]. Zhong et 
al, 1997 [48] examined the subcellular location of the epitope recognized by C4H3, 
specific for 1-Ak molecules bound with exogenous HEL peptide 46-61. The C4H3 
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epitope was found within endosomal organelles expressing the lysosomal marker LAMP-
l within rat basophilic leukemia cells stably transfected with 1-Ak and pulsed with whole 
HEL. [48]. No co-localization was seen with C4H3 and antibodies recognizing the 
transferrin receptor, suggesting that this mAb-defined epitope, like the D 11 +040 1 and 
D13+0404 epitopes, does not travel through early endosomes. 
CD63, a tetraspan molecule that is present in copious amounts within MIIC, is 
also reported to be present in CDw78-defined supramolecular complexes, along with 
class II, CD82, DM and DO in MIIC within BCL [19]. Others have also reported the 
association of MHC class I, class il, DM and other tetraspanin proteins such as CD9, 
CD53, CD20, CD81 and CD82 [40, 49, 50]. These widely expressed tetraspanin 
molecules serve a wide variety of roles, including signal transduction, cell adhesion, 
motility, activation [51] and may structurally anchor molecules such as HLA-DR in order 
for proper intracellular and cell surface interaction to occur. These molecular complexes 
may also serve to concentrate specific MHC/peptide complexes, increasing the chance of 
TCR interaction. Our fmdings that D11+0401 and D13+0404 epitopes co-localized with 
CD63, CD82 and DM, suggests that these epitopes may result from DRB 1 *04 molecules 
that exist in such supramolecular tetraspan complexes. Supporting this, we observed that 
both the D11+0401 and D13+0404 epitopes on the cell surface were disrupted by the 
detergent saponin, which is reported to disturb tetraspan complexes at low concentrations 
[21 ]. Disruption of membrane lipid rafts did not change the expression levels of either of 
these epitopes. Similarly, the mAb, UL-5A1, which distinguishes DRB1 *0101 bound to 
HLA-A2 derived peptides on activated cells such as EBV-transformed B cells [52], co-
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localizes with CDw78 on the surface ofBCL and DC [21]. Like the UL-5A1 epitope, the 
D11+0401 and D13+0404 epitopes also appear to require additional factors present in 
activated P-APC, such as tetraspan microdomains for their expression. 
The association of Dll+0401 molecules with CD63, CD82 and DM was found 
within multilaminar MIIC compartments, which are thought to functionally most 
resemble lysosomes [53]. Unfortunately, immunoelectron microscopy studies using the 
NFLD.D13 mAb were unsuccessful, providing no further information into its 
ultrastructural location. Taken together, our data show that the D 11 +040 1 and D 13+0404 
epitopes in normal B cell lines are found associated with the tetraspan proteins CD63 and 
CD82 within the classical endocytic pathway, where they are most likely transported to 
the cell surface forming stable pMHC complexes. Our data imply that these two 
DRBl *04 epitopes do not use the alternative MHC class II pathway, in which class II 
molecules recycle to and from the cell surface through the early endosomal 
compartments. 
The use of several cell function inhibitors to further dissect the generation of the 
D11+0401 and D13+0404 epitopes in normal BCL revealed that both epitopes were 
partially inhibited by BfA, which blocks the movement of proteins from the ER to the 
golgi apparatus. This suggests that newly synthesized molecules are required for 
D11+0401 and Dl3+0404 epitope formation, either through the generation of new class II 
molecules, or through the formation of other molecules that are required for epitope 
generation, such as proteases and co-chaperone molecules such as DM, DO and Ii. 
Similarly, Griffin et al, 1997 [45] found differences in the compartments needed for the 
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processing of I-Ak and I-Ek-specific T cell epitopes from hen egg lysozyme and RNase. 
One complex, RNase-(42-56): I-Ak, was generated in early endosomal compartments and 
was inhibited by chloroquine but partially resistant to the effects of BfA. Another pMHC 
complex, RNase-(90-105): I-E\ was generated in late endocytic compartments and was 
resistant to the effects of chloroquine, though blocked by BfA. We found that the 
D11+0401 and D13+0404 epitopes were not inhibited by chloroquine and bafilomycin A, 
which block degradation in early endosomes (data not shown), providing further evidence 
that these class IT epitopes were generated in late endosomalllysosomal compartments 
within normal BCL. 
We speculated that the D11 +0401 epitope may require specific peptide(s) for its 
formation because although the D11 +0401 epitope is OM-dependent, other factors must 
be required for its generation since various NP-APC up-regulate DM, yet fail to express 
the D11+0401 epitope (Chapters 2 and 3). Thus the D11+0401 epitope is cell type and 
DM restricted, suggesting that specific peptides may be required for its generation. Other 
explanations could be that the protease arrays are different between cell types, or that 
specific protein complexes responsible for the generation of the D 11 +040 1 epitope differ 
between cell types. 
Our finding using protease inhibitors that exclusively impede either a particular 
protease, or class of protease revealed that the D11+0401 epitope requires both 
endosomal and cytopasmic cysteine proteases for its generation. Interestingly, although 
the intracellular trafficking pattern of the Dll+0401 and D13+0404 epitopes overlap, the 
Dl3+0404 epitope was not dependant on any protease group tested here, even though 
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leupeptin did cause a slight inhibition. This suggests that there may be redundancy in 
D 13 epitope generation, with several proteases compensating for the loss of function of 
another. Other explanations could be that one or more proteases, such as cathepsin S or 
L, are involved in D 13+0404 epitope formation. Alternatively, specific proteolytic events 
and specific subsets of peptides are not responsible for the generation of the D13+0404 
epitope, but NFLD.D13 recognizes a conformational determinant formed by the 
association ofDRB1 *0404 with other molecules such as CD82 or CD63. 
Recently, much attention has been paid to characterization of alternative class II 
processing pathways where peptides derived from class !-associated proteolysis, such as 
through the proteasome, are loaded onto class IT molecules. The dependence of 
D11 +0401 epitope generation on endosomal and cytoplasmic cysteine proteases is 
somewhat similar to studies described by Lich et al, 2000 [ 42], in which alternative 
processing was involved in the proteolysis of endogenous glutamic acid decarboxylase 
(GAD). For endogenously expressed GAD, cytoplasmic proteases such as the 
proteasome and calpain were required for the generation of an immunodominant peptide 
that binds to DRB1 *0401. Alternatively, lysosomal processing, blocked by BfA, was 
necessary for the processing of exogenous supplied GAD into the same immunodominant 
peptide. 
Inferring from these results, we hypothesize that the source of the putative 
peptide(s) involved in D11+0401 epitope formation may be cytoplasmic, since calpain 
inhibited NFLD.D11 binding to SA VC. Alternatively, the D11 +0401 epitope may be 
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formed from peptides derived from resident proteins within the endocytic pathway since 
leupeptin, CBI and BfA inhibited D11+0401 epitope expression. 
Without knowing whether specific peptides contribute to the D11+0401 epitope, 
one can only speculate that the source of the antigen is the same for the cytoplasmic and 
lysosomal generation of Dll +0401. It is possible that the Dll +0401 epitope could be 
derived from peptides generated from processing of an endogenous protein within both 
lysosomes and the cytoplasm, requiring cathepsin B and calpain, respectively. The 
involvement of cathepsin B, a protease with exopeptidase activity [42], leads to 
interesting speculation into the antigen source and mechanisms responsible for forming 
the D11+0401 epitope. Sercarz and Maverakis [54] have recently described two 
mechanisms how antigens are broken down and bound to class II molecules. The first 
involves a OM-mediated removal of CLIP for an appropriate sized peptide, while the 
second mechanism describes how a partially unfolded antigen attaches to the class II 
molecule, and the ends of the polypeptide are trimmed [54]. For the second mechanism, 
exopeptidases such as cathepsin B have an important role, and may explain the role of 
cathepsin B in the generation of the D 11 +040 1 epitope. Additionally, inhibition of the 
D 11 +040 1 epitope by calpeptin suggests that the source of the putative peptides that form 
the D11+0401 epitope are derived from the cytoplasm. The mechanism how 
cytoplasmicly derived peptides enter the lysosomal compartments of the endocytic 
pathway and whether pre-lysosomal processing followed by lysosomal processing occurs, 
is still to be resolved. Nimmerjahn and colleagues [55] however, recently provided 
evidence that this process may primarily occur through autophagy. They showed that 
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cytosolic proteins sequester to autophagosomes within EBV -transformed BCL, and these 
autophagosomes are subsequently delivered to the lysosomal compartments where the 
majority of intracellular class II molecules reside. 
Interestingly, the decrease in D11+0401 epitope expression on SAVC treated with 
cysteine protease inhibitors mirrored the loss of DR/CLIP complexes, suggesting the 
same proteases are involved in processing Ii. It is most unlikely that CLIP is involved in 
D11+0401 epitope formation for several reasons; a mAb directed against DR/CLIP 
complexes did not block the binding of NFLD.D11 to SAVC, CLIP peptides did not 
reconstitute the D11 +0401 epitope and cells that are negative for DM express significant 
amounts of CLIP, yet fail to express the D11+0401 epitope. This does not rule out that 
longer versions of the CLIP peptide, LIP and SLIP could somehow be responsible for 
epitope formation. There is evidence that treatment of cells with leupeptin causes the 
accumulation of LIP in post-golgi compartments [56], but these Ii intermediates exist at 
low levels within untreated cells, making them unlikely candidates for D11 +0401 epitope 
formation. 
The accumulation of LIP and SLIP within leupeptin-treated cells could however 
explain the presence of intracellular 013+0401 epitope in SAVC cells treated with the 
same cysteine protease inhibitors that inhibited D11 +0401 epitope formation. The level 
of intracellular DM was not affected by leupeptin, suggesting the loss of DM does not 
explain the generation of this D13+0401 ep_itope on SAVC. Although interesting, this 
leupeptin-induced DRB1 *0401 epitope may prove difficult to study since it is primarily 
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expressed intracellularly, and ts relatively scarce compared with the D11+0401 and 
D13+0404 epitopes. 
Finally, the effects of protease inhibitors on the Dl3+0401 epitope, which is 
expressed on DM negative BCL such as 9.5.3 0401 (34] were similar to the D11+0401 
epitope, in that this epitope was also inhibited by BfA, as well as by endosomal and 
cytoplasmic cysteine protease inhibitors. This would suggest that the peptides involved 
in both epitopes could actually be the same despite the opposite influence of DM. Of 
course, another explanation is that the same proteases are responsible for forming both 
epitopes, irregardless of the putative peptides. Alternatively, it is possible that the 
NFLD.Dll and NFLD.D13 mAbs are recognizing conformational epitopes that are 
influenced by the binding of certain set of peptides and/or the interaction with DM, 
similar to the epitopes recognized by the mAbs 16.23 [57] and 25-9-17 [58]. Analysis of 
the profiles ofpeptides eluted from DRB1*0401 molecules from SAVC, 8.1.6 0401 and 
9.5.3 0401 is underway and should yield useful information regarding the identity of 
these putative peptides. 
We have therefore described three DRB1 *04-specific epitopes recognized by the 
mAbs NFLD.D11 and NFLD.D13. The D11+0401 and D13+0404 epitopes differed in 
their requirements for cellular proteases, even though the intracellular pathways which 
form these epitopes in normal BCL appear to be similar. Both endosomal and 
cytoplasmic cysteine proteases are required for the generation of the D 11 +040 1 epitope 
and interestingly, the same proteases that prevent the appearance of this DM-dependant 
epitope also caused an intracellular generation of an epitope recognized by NFLD.D13. 
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Using DM negative cells, we also observed the loss of the D13+0401 epitope in the 
presence of cysteine protease inhibitors. Further analysis of the peptides eluted from the 
DRBl *04 molecules isolated from these DM positive and negative B cells is underway 
and should shed further light on the mechanisms of how these intriguing epitopes are 
formed. 
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5. Thesis Discussion 
The main focus of this thesis has been to characterize the generation and 
expression of epitopes defined by the mAbs NFLD.D11 and NFLD.D13. Both mAbs 
recognize epitopes on HLA-DRB1 *04 molecules that express an amino acid motif, 
QKRAA!QRRAA, also known as the shared epitope (SE) [1]. This sequence is found on a 
subset ofHLA-DR~1 *04, 01 and 14 molecules at ~-chain positions 70-74, and is associated 
with the development and disease severity of rheumatoid arthritis (RA) in Caucasians [2]. 
NFLD.D11 and NFLD.D13 were previously shown to bind DRB1 *0401 and DRBI *0404 
molecules, respectively, on EBV-transformed B cell lines (BCL) [3, 4]. In addition to 
binding strongly to BCL, NFLD.Dll and NFLD.D13 also bind weakly to peripheral 
blood B cells from normal controls and RA patients [3]. 
The formation ofthe D11+0401 epitope is dependent on the presence ofthe HLA-
DM, as it is not expressed on B cells that do not express DM [4, 5]. NFLD.D13 has an 
intriguing specificity as it is specific for DRB1 *0404, but not DRB1 *0401 in D~ BCL. 
However, in DM- B cells, NFLD.D13 recognizes an epitope on HLA-DRB1 *0401 
molecules [5]. As seen in Table 1 of Chapter 3, DRB1 *0401 and DRB1 *0404 differ at 
two amino acid positions, ~71 and ~86. NFLD.D11 binding absolutely requires a lysine 
at position ~71 but a glycine or valine at position f386 makes little difference. There are 
four key residues for NFLD.D13 binding to DRBI *0404; a tyrosine at ~37, aspartic acid 
at ~57, arginine at f371 and valine at ~86. These residues are key contact points forT cell 
and peptide recognition. For example, ~86 is located within pocket 1 of the class II 
peptide binding groove. Therefore the valine at ~86 in DRB1 *0404 means that it will be 
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able to accommodate slightly larger peptide side chains in pocket 1 compared to 
DRBl *0401. The same can be true for the difference between DRB1 *0404 and 
DRB1 *0401 at ~71, which along with amino acids 28, 47, 61 and 67 form pocket 7. ~57, 
which is important for NFLD.D13 binding to DRB1 *0404, is located in pocket 9 of the 
peptide binding groove. The location of these key residues within the peptide binding 
groove strongly suggests that class II-associated peptides are required for Dll +0401 and 
D13+0404 epitope formation. 
That the D11+0401 and D13+0404 epitopes are primarily expressed on EBv+ BCL 
but not on a wide variety of NP-APC, suggests that an activated cell phenotype is 
necessary for their formation. This may either be due to proteases that are specifically 
active within BCL or antigen processing compartments present only in P-APC. The 
critical role of DM in the formation of these DRBl *04 epitopes, the location of key ~ 
chain residues needed for NFLD.D11 and NFLD.D13 binding along with the cellular-
restricted expression of these epitopes suggest that a specific set of peptides are involved 
in their generation. This may be due to direct recognition of the class II peptide!MHC 
(pMHC) complex by these rnAbs, or alternatively, NFLD.D11 and NFLD.D13 may be 
recognizing conformational determinants on HLA-DRB1 *04 molecules similar to the 
recognition of DR3 by the rnAb 16.23 [6]. This putative conformational change in the 
DRB 1 *04 molecules may be influenced by the binding of certain peptides to the class II 
molecule, or by the interaction of the class II molecule with co-chaperone molecules such 
as DM or MHC class II-associated tetraspan molecules. 
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5.1 Summary of Major Findings 
D11+0401 Epitope 
• Strongly expressed on EBV -transformed B cells, IFN-y-induced M<l> and DC. 
• Not expressed on the cell surface ofmonocytes or DC, but expressed intracellularly on 
DC. 
• Weakly expressed on peripheral blood B cells and not expressed on PHA-stimulated T 
cells. 
• Requires HLA-DM for expression on BCL. 
• Not expressed on Daudi Dw4 or Daudi Dw4 DM. 
• Not expressed on synovial fibroblasts treated for up to 14 days with IFN-y, despite 
strong expression of DR, DM and Ii. 
• Not expressed on most carcinoma cell lines that have up-regulated DR and DM. 
• Weak to moderate expression on D~ melanoma cell lines, especially MDA MB 435 
Dw4. 
• Blocked by mAbs that map to the peptide binding site such as L243, NFLD.D2 and 
NFLD.DIO, but not by NFLD.Dl, which binds to the P2 domain. Also, not blocked by 
cerCLIP, which binds DR/CLIP complexes, indicating that the D11+nRB1 *0401 epitope 
exists on a different subset ofDRB1 *0401 molecules. 
• Requires a subset of cysteine proteases for its generation. 
• Requires newly synthesized molecules for its generation. 
• Co-localizes with markers for the endosomal pathway as well as markers for 
supramolecular complexes, such as CD82. 
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• Destroyed by tetraspan microdomain-disrupting chemical saponin, but not by methyl-
p-cyclodextrin, which disrupts lipid rafts. 
D13+0404 Epitope 
• Strongly expressed on EBV-transformed B cells, and peripheral blood M<l>. 
• Weakly expressed on peripheral blood B cells and negative on PHA-stirnulated T cells. 
• Does not require HLA-DM for its expression on BCL. 
• Not expressed on carcinoma, and fibroblast cell lines that have weakly up-regulated 
DRandDM. 
• Blocked by mAbs that map to the peptide binding site such as L243, NFLD.D2 and 
NFLD.DlO, but not by NFLD.Dl, which binds to the P2 domain. Also, not blocked by 
cerCLIP, which binds DR/CLIP complexes, indicating that the D13+DRB1 *0404 epitope 
exists on a different subset ofDRBl *0404 molecules. 
• Does not require proteases for its generation. 
• Requires newly synthesized molecules for its generation. 
• Co-localizes with markers for the endosomal pathway as well as markers for 
supramolecular complexes, such as CD82. 
• Destroyed by tetraspan microdomain-disrupting chemical saponin, but not by methyl-
p-cyclodextrin, which disrupts lipid rafts. 
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D13+0401 Epitope 
• Expressed on HLA-DM negative BCL such as 9.5.3 0401, 5.2.4 0401, SJO Dw4, BLS 
Dw4 and T2 Dw4. 
• Lost after DM reconstitution. 
• Blocked by mAbs that map to the peptide binding site such as L243, NFLD.D2 and 
NFLD.D10, but not by NFLD.D1, which binds to the Jh domain. Also, not blocked by 
cerCLIP, which binds DR/CLIP complexes, indicating that the D13+DRB1 *0401 epitope 
exists on a different subset ofDRB1 *0401 molecules. 
• Requires a subset of cysteine proteases for its generation. 
• Requires newly synthesized molecules for its generation. 
• Expressed on cells that are CDw78-, a marker for tetraspan microdomains. 
I will now discuss and examine in detail these main fmdings as they relate to 
current immunological research, and explain the basis for future hypotheses with regards 
to the generation of these mAb-defmed eptiopes. 
5.1.1 D11+0401 Epitope 
The Dl1+0401 epitope was the most intensely studied in this thesis, and yielded 
several fascinating insights in regards to the proteases needed for its generation, its 
intracellular location within BCL and its expression on P-APC and NP-APC. The use of 
protease inhibitors showed that the cysteine protease inhibitors leupeptin, calpeptin and 
cathepsin B inhibitor II blocked the formation of this epitope on BCL. In contrast, the 
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aspartyl protease inhibitor pepstatin A as well as the proteasome inhibitor lactacysin did 
not have an effect. This indicates that cysteine proteases are critical in generating the 
peptide repertoire that binds to DRB 1 *040 1 peptide binding cleft to form the D 11 +040 1 
epitope. 
However, without knowing these peptides, it is difficult to conclude that this 
epitope is peptide-specific with absolute certainty. Certainly, the dependence of this 
epitope on DM, along with the involvement of cysteine proteases does suggest that the 
D 11 +040 1 epitope could be dependent on a particular set of peptides. Evidence that the 
D11 +0401 epitope is on or near the peptide binding groove comes from data showing that 
NFLD.D11 binding was not blocked by mAb NFLD.D1, which binds to the ~2 domain of 
DRB1 *04 molecules. In contrast, mAbs L243, NFLD.D2 and NFLD.D10, which bind to 
residues in the peptide binding groove, did block NFLD.D11 binding to SAVC. Having 
said this, this data only provides evidence that the residues that these mAbs recognize are 
important for NFLD.Dl1 binding and does not implicate any class 11-associated peptide. 
Another explanation is that a set of structurally related peptides generated by 
cysteine proteases, bind to DRBI *0401 molecules and cause a conformational change 
that is detected by NFLD.D11. Charles Janeway's group showed, using the l-Ab-specific 
mAb, 25-9-17, that peptides can impose subtle structural changes in MHC class II 
molecules, which can be differentiated by certain mAbs [7]. Conformationally-induced 
changes may also be peptide-independent as was shown for the 16.23-defined DR3 
epitope, which is influenced by the interaction between HLA-DR3 and DM [6]. This 
epitope, like the D11 +0401 epitope also disappears in the absence of DM. Although DM 
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interaction with DRB1 *0401 molecules in a peptide-independent manner could possibly 
generate Dll +0401 epitope, we do not think this is the case because it is not present on 
DRB1 *0401+ cells that have up-regulated DM, such as IFN-y treated synovial fibroblasts 
(Chapter 2). This suggests that although DM is necessary for D11+0401 expression, 
other factors are required. These may include P-APC specific proteins or proteases that 
are differentially up-regulated in NP-APC compared to P-APC. 
This differential protein expression may explain why, although there are 
similarities in the expression patterns of the D 11 +040 1 and 16.23 epitopes, there are also 
notable differences. Unlike the D11+0401 epitope, the 16.23 epitope was up-regulated on 
IFN-y treated fibroblasts after 5 days [8]. We did not observe D11 +0401 expression on 
various fibroblast cell lines as well as other NP-APC treated with IFN-y, even when the 
cells were treated for 14 days, although these cells expressed copious amounts of HLA-
DR and DM. This expression pattern of the D11+0401 epitope on various cell types, 
which will be further discussed later, suggests that although a similar DR-DM interaction 
may be forming the D11 +0401 epitope, other cell-specific factors are also required for its 
expression. 
5.1.1.2 Proteolytic Events Involved in D11+0401 Epitope Formation 
The requirement of both endosomal and cytoplasmic cysteine proteases for 
D11+0401 epitope expression may help explain the additional factors required for 
D 11 +040 1 epitope expression in addition to providing further insights into how certain 
MHC class II epitopes are formed. Others have shown that cytoplasmic processing is a 
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prerequisite for the generation of particular class II epitopes [9, 10]. More recently a 
proposed mechanism of how peptides derived from cytosolic antigens can enter the lytic 
compartments and bind to class II molecules has been described [11]. Lich et al, 2000 
showed that alternative processing was involved in the proteolysis of endogenous 
glutamate decarboxylase (GAD). For endogenously expressed GAD, cytoplasmic 
proteolysis by the proteasome and calpain were required for the generation of an 
immunodominant peptide that binds to DRB1 *0401. However, lysosomal processing, 
blocked by brefeldin A, was necessary for the processing of exogenous supplied GAD 
into the same immunodominant peptide. Similarly, Mukheijee et al, 2001 showed that 
processing by the proteasome was required for the class II presentation of peptides 
derived from cytoplasmically expressed OVA and conalbumin [10]. The same authors 
also showed that class II presentation of an endogenous 1-E\7' peptide was also inhibited 
by inhibitors of cytosolic proteolysis. 
These results infer that the source of the putative peptide( s) involved in D 11 +040 1 
epitope formation may be cytoplasmically-derived, since calpain inhibited NFLD.Dll 
binding to SAVC, or due to peptides derived from resident proteins within the endocytic 
pathway since cathepsin B inhibitor II and brefeldin A also inhibited'D11+0401 epitope 
expression. Involvement of the exopeptidase cathepsin B leads to interesting speculation 
into possible mechanisms that form the D11 +0401 epitope. Sercarz and Maverakis [12] 
have recently described two mechanisms for how antigens are broken down and bound to 
class II molecules. The first involves a DM-mediated removal of CLIP for an appropriate 
sized peptide, while the other describes how a partially unfolded antigen attaches to the 
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class II molecule, and is trimmed into peptides while bound [12]. For the second 
mechanism, exopeptidases such as cathepsin B have an important role, and may explain 
.-
the role of cathepsin B in the generation of the D 11 +040 1 epitope. 
Of course, it is possible that the D 11 +040 1 epitope could be derived from peptides 
generated from processing of an endogenous protein within both the lysosomes and 
cytoplasm. The mechanism by which cytoplasmicly derived peptides enter the lysosomal 
compartments of the endocytic pathway is still to be fully resolved, although Nimmerjahn 
et al, 2003 recently provided evidence that this process primarily occurs through 
autophagy. They showed that cytosolic proteins sequester to autophagosomes within 
EBV -transformed BCL, and these autophagosomes are subsequently delivered to the 
lysosomal compartments where the majority of intracellular class II molecules reside. 
Therefore it may be useful to test whether autophagy is related to the calpain inhibition of 
D11 +0401 epitope expression on SAVC. One could imagine that calpain pre-processes a 
putative antigen in the cytoplasm, where it is then transported into the lysosomes by 
autophagy, and further processed by lysosomal cysteine proteases such as cathepsin B. 
To determine whether autophagy is important for Dll+0401 epitope expression, cells 
could be treated with wortmannin, a known inhibitor of autophagy [11]. 
The differential expression ofproteases required for D11+0401 epitope expression 
could explain why it is not expressed in most D~ NP-APC such as synovial fibroblasts 
(Chapter 2). Having said this, cultured fibroblast-like synoviocytes from RA patients 
have been shown to express and secrete copious amounts of cathepsin B, S and L after 
stimulation with inflammatory cytokines such as IFN-y [13, 14]. The seemingly 
190 
ubiquitous expression of these cysteine proteases within NP-APC suggests that the 
protein source of the putative D11+0401 peptides may differ between P-APC and NP-
APC. Therefore, although DM and cysteine proteases are required for D 11 +040 1 epitope 
formation, another cell type-specific factor is likely also necessary. 
5.1.1.3 Cellular Expression of the D11+0401 Epitope 
Since the D11+0401 epitope was strongly expressed on B cells, M<l>, DC and not 
on a wide variety of NP-APC tested, this suggests that a factor specific to P-APC is 
influencing its production. Together with the protease inhibitor results, differential 
expression of certain pro teases between D 11 +040 1 + and D 11 +040 1- cells is a possibility 
and requires further testing. In regards to the D 11 +040 1 epitope expression on myeloid 
cells, DC are known to increase proteolysis [15] and lysosomal function [16] after 
activation with inflammatory stimuli such as LPS and TNF-a.. However, because the 
D11+0401 epitope was expressed equally on DC before and after stimulation, this 
suggests that a ubiquitous protein/pathway within these DC is responsible for forming 
this epitope. 
Another explanation for differential expression of the D11 +0401 epitope could 
be intracellular compartmentalization and cellular organization differences between P-
APC and NP-APC. For example, the putative melanoma cell line MDA MB 435 Dw4 
expressed significant amounts of D 11 +040 1 epitope before and after IFN-y stimulation. 
We do not think this is simply because of high DM levels, as several other D~ NP-APC 
failed to express Dl1+0401; more likely, there is a shared factor or mechanism causing 
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the expression of the D11 +0401 epitope in MDA MB 435 Dw4, B cells, M<l> and DC. 
Further studies on MDA MB 435 Dw4 such as co-localization studies with markers of 
intracellular compartments or by he treatment with protease inhibitors should further 
define the factors responsible for generating the D 11 +040 1 epitope on BCL compared to 
MDA MB 435 Dw4. 
Our studies described in Chapter 4 clearly show that the D11 +0401 epitope co-
localizes with DM as well as the tetraspan molecules CD63 and CD82. Since the 
intracellular distribution of CD63 is restricted to lysosomes, its co-localization with 
NFLD.D11 suggests that the D11 +0401 epitope exists within the lysosomallendosomal 
pathway. Furthermore, as shown by immunoelectron microscopy, D11+0401 colocalized 
with CD63, CD82 and DM was located within multilaminar MIIC compartments, which 
are thought to functionally most resemble lysosomes [17]. Since the D11+0401 epitope 
was also sensitive to brefeldin A treatment, which inhibits ER-Golgi as well as transport 
of molecules to lysosomal compartments [11 ], this suggests molecules bearing the 
D11 +0401 epitope traffics through the classical MHC class II pathway to traffic through 
BCL and is generated in post-Golgi compartments. 
CD63, which is present in copious amounts in MIIC and lysosomes, is also 
present in large complexes that include MHC class I, class II, DM, DO and other 
tetraspanin proteins such as CD9, CD53, CD20, CD81 and CD82 [18-20]. Related to 
this, Hammond et al, 1998 [21] also found an enrichment of supramolecular complexes 
involving HLA class I, class II, CD63, CD82, DM and DO in MIIC within B cell lines. 
These widely expressed tetraspanin molecules serve a wide variety of roles, including 
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signal transduction, cell adhesion, motility, activation and may structurally anchor 
molecules such as HLA-DR in order for proper intracellular and cell surface interactions 
to occur [22]. These tetraspan molecular complexes have also been suggested to 
concentrate specific MHC/peptide complexes, increasing the chance of TCR-MHC 
interaction [23]. 
Our finding that the Dll +0401 epitope co-localized with CD63, CD82 and DM 
also raises the possibility that the D11+0401 epitope requires DRBl *04 molecules 
existing within such supramolecular tetraspan complexes. Since HLA class I molecules 
are also reported to be located within these microdomains, further indirect evidence that 
the Dll +0401 epitope is located within tetraspan microdomains is partial blocking of 
NFLD.Dll binding to BCL with the HLA-B specific mAb NFLD.M15 (data not shown). 
Related to this, CD82 has been found associated with HLA class I within normal BCL 
[24], so it is conceivable that a complex between either of these molecules with 
DRBl *0401 results in an epitope recognized by NFLD.Dll. 
Supporting this, we observed that cell surface NFLD.Dll binding was disrupted 
by the detergent saponin, which, when used at low concentrations is reported to disturb 
tetraspan complexes [25]. Many groups, including Roche and colleagues have also 
suggested that class II molecules located within lipid raft domains are important for the 
presentation of peptides when antigen is at limiting concentrations, in addition to 
concentrating relevant pMHC complexes into the central immunological synapse 
interface, better enabling T cell activation [26, 27]. We did not observe a loss in 
NFLD.D11 binding to BCL in the presence of the lipid raft disrupting chemical methyl-
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~-cyclodextrin, suggesting that the D11+0401 epitope likely does not require lipid raft 
microdomains for its expression. A similar mAb, designated UL-5A1, distinguishes 
DRB1 *0101 bound to I-ll.,A-A2 derived peptides only on activated cells such as EBV-
transformed B cells [28]. This suggests that an activated phenotype, either by the 
expression of cellular-specific proteins or the mobilization of necessary 
compartmentalization and antigen processing mechanisms is also important for UL-5A1 
epitope expression. The UL-5A1 epitope is reported to co-localize with CDw78, a 
marker for tetraspan microdomains, on the surface of BCL [23] and DC [25]. Like the 
UL-5A1 epitope, the D11+0401 and Dl3+0404 epitopes also require a factor present in 
activated P-APC, such as tetraspan microdomains for their expression. 
Taken together, we conclude that the Dl1+0401 epitope in BCL requires DM, 
cysteine proteases, and is located within the classical MHC class ll pathway, in particular 
within late endosomes and lysosomes. Here, the D11+0401 epitope may be located 
within tetraspan protein aggregates that include CD63 and CD82. As will be discussed 
later, immunoprecipitation of D11+DRB1 *04 molecules has proven technically difficult, 
thus, a potentially useful experiment would have been to immunoprecipitate CD82 or 
CD63-positive complexes using mild detergents that do not destroy the tetraspan 
microdomains, such as n-octylglucoside [25], and test for the presence of the Dll+0401 
epitope. Comparison of these aggregates between a Dl1+0401 epitope positive cell line 
such as SA VC or MDA MB 435 DW 4 and a D 11 +040 1 epitope negative cell line such as 
T2.0401, or 9.5.3 0401, which do not express CDw78, should answer whether such 
tetraspan microdomains are required for D 11 +040 1 expression. 
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5.1.2 D13+0404 Epitope 
The second epitope, D 13+0404 is somewhat similar to the D 11 +040 1 epitope, in 
that its expression is restricted. For example, it is more strongly expressed on BCL than 
peripheral blood B cells [3], but unlike D11+0401, it is more strongly expressed on 
resting and activated M<D (data not shown). Because of the lower frequency of 
DRBl *0404 compared to DRBl *0401 in the general population, fewer cell lines were 
available for testing the D13+0404 epitope. From those DRBl *0404+ cells tested, we 
found that like the Dll+0401 epitope, the D13+0404 epitope appears to be preferentially 
expressed on P-APC. Thus, this pattern of expression suggests that a cell-specific 
mechanism is responsible for the generation of the D13+0404 epitope. 
Although, like the Dll+0401 epitope, the D13+0404 epitope co-localized with 
molecules found within late endosomes and lysosomes such as CD82, LAMP-l and 
CD63, but not with CD71, a marker for early endosomes, its strong co-localization with 
Ii suggests that Ii may be involved in D13+0404 epitope formation, either due to Ii 
intermediate peptides, or through Ii-influenced trafficking ofD13+ DRBl *04 molecules. 
Indeed, data suggests that a significant number of class II/Ii complexes migrate directly to 
the cell surface [29]. Here these molecules may either recycle through early endosomes 
to the plasma membrane, or alternatively, enter the endocytic pathway from the cell 
surface directly to the MIIC [29]. Therefore, although the D13+0404 is found within the 
endocytic pathway, the co-localization studies with Ii suggest that its intracellular 
trafficking route may be different from the molecules that form the D11+0401 epitope. 
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The partial loss in Dl3+0404 expression in the presence ofbrefeldin A indicates that this 
epitope is formed in post-golgi compartments, and provides further evidence that 
NFLD.Dl3 recognizes DRB1 *0404 molecules within the classical MHC class II 
pathway. Unfortunately, the NFLD.Dl3 mAb could not be used in the immunoelectron 
microscopy assays and therefore we can not conclude anything about the ultrastructural 
location of this epitope with BCL. 
Searching for other factors that influence the generation of the Dl3+0404 epitope, 
we found that unlike the D 11 +040 1 epitope, none of the protease inhibitors used in this 
study significantly affected the expression of the Dl3+0404 epitope. Our finding that the 
Dl3+0404 epitope was not significantly altered by inhibiting proteases such as cathepsin 
B and calpain, suggests, along with it being less DM-dependent, that the Dl3+0404 
epitope is probably peptide-independent and is conformationally determined. When 
compared to DRB1 *0401, DRB1 *0404 differs in two residues; positions P71 and P86. 
DRBI *0401 has lysine and glycine, whereas DRBI *0404 has arginine and valine at 
positions P71 and P86, respectively. The arginine at position p71, in particular is a likely 
key residues responsible for the ability of NFLD.Dl3 to specifically recognize 
DRB 1 *0404 since it has an extra methyl group compared with lysine, which points up 
and out, and is thought to contact the TCR as well as the bound peptide [1, 2]. Having 
said this, this does not explain the absence of the Dl3+0404 epitope on NP-APC. 
Since the Dl3+0404 epitope co-localized with the CD63 and CD82 mAbs within 
MT14b, another possibility is that these tetraspan molecules are somehow influencing the 
binding of NFLD.Dl3 to DRBI *0404. One can imagine that the Dl3+0404 epitope 
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could be formed by DRBl *0404 molecules located within tetraspan microdomains in a 
manner similarly suggested for the Dll+0401 epitope. This prospect is supported by data 
in which the D13+0404 epitope on the surface of MT14b was dramatically disrupted by 
the tetraspan microdomain disrupting chemical saponin, but not by methyl-~­
cyclodextrin, which · disrupts lipid rafts by dispersing cholesterol aggregations on the cell 
surface. If the D13+0404 epitope requires DRBI *0404 molecules expressed in 
supramolecular complexes, this may explain its absence on NP-APC such as synovial 
fibroblasts. For example, although synovial fibroblasts express CD63, CD82 and DM, it 
is possible that they do not express other proteins seemingly required for proper tetraspan 
microdomain formation, such as CD20, CD40, CD9 or CD81 [23]. 
5.1.3 D13+0401 Epitope 
The third epitope (D13+0401) under investigation in this thesis is present on DM 
negative BCL and disappears after DM expression is restored [4]. Since the Dl3+0401 
epitope is inhibited by DM, this suggests that certain peptides, present in the DRBl *0401 
peptide binding groove, somehow influence the binding of NFLD.D13, either through 
direct interaction of the mAb with the peptide/MHC complex or through a 
conformational change in these molecules. Since DM negative cells express abundant 
amounts of CLIP in the class II peptide-binding groove, CLIP was considered a prime 
candidate to either form or influence the expression of the D13+0401 epitope. However, 
evidence against this included failure to reconstitute the epitopes with CLIP in peptide 
binding assays and failure of cerCLIP to block the D13+0401 epitope. Alternatively, the 
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absence ofDM could be creating a conformational change in the DRB1*0401 molecules 
that is detected by NFLD.D13. This could be explained by the previously discussed, 
DR3-reactive mAb 16.23, which is not expressed in DM negative BCL, and thus is 
similar to the D 11 +040 1 epitope. It has been shown that DM alters the conformation of 
the DR3 molecules in a peptide-independent manner such that 16.23 binding is 
obliterated in its absence [ 6]. 
Although we have not tested it here, it is possible that the opposite situation is 
occurring with the D13+0401 epitope, where the absence of DM induces a 
conformational change in the DRBI *0401 molecules that is recognized by NFLD.D13. 
After the introduction of DM into these D13+0401 epitope negative cells, this required 
conformation would be lost and result in the loss ofNFLD.D13 binding. This putative 
conformational change may or may not involve specific peptides in the DRBI *0401 
peptide binding groove. To test whether peptides might be involved, we used NFLD.DIO 
to purified DRBI *04-derived peptides from the mutant BCL 9.5.3 0401, which is DM 
negative and D13+0401 [5], and peptides from the parent BCL, 8.1.6 0401, which 
expresses the D11+0401 epitope and not the D13+0401 epitope. It is expected that 
differential display of these peptides (ongoing work that is being carried out in 
collaboration with Drs Englehard and Hunt at the University of Virginia) will yield major 
peptide-population differences since these cells are genetically identical with the 
exception of a deletion on chromosome 6, which includes DMB [30]. Using peptide 
binding algorithms, we will select and synthesize the most promising peptides for 
reconstitution in peptide binding assays. It is expected that peptide fractions that differ 
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between 8.1.6 0401 and 9.5.3 0401 could then be used in more functional assays such as 
epitope reconstitution assays. 
Unfortunately, confocal microscopy, immunoelectron microscopy and CELISA 
based experiments that were erformed on normal BCL could not be done on 9.5.3 0401. 
L243 (HLA-DR), NFLD.D1 (HLA-DRB1 *04), as well as NFLD.D13 (D13+0401) 
binding was effected by the fixatives acetone and paraformaldehyde when these 
experiments were repeated with 9.5.3 0401 (data not shown). Therefore the data on the 
D 13+040 1 epitope presented in this thesis is restricted to cell surface expression. I feel 
that it would have been valuable to compare the intracellular generation of the D13+0401 
epitope by confocal microscopy with the D11 +0401 epitope in DM positive BCL, 
especially with the knowledge that both epitopes are influenced by the same proteases. 
5.2 Usefulness of D11+0401 and D13+0404 Epitopes in the Field of Immunological 
Research. 
Although the basic mechanisms and molecules involved in MHC class II antigen 
processing and presentation are well known, some questions still remain unresolved. 
First, recruitment of peptide-loaded class II molecules to the cell surface, whether it is 
through specific tetraspan or lipid microdomains still remains a mystery. Several lines of 
evidence point towards both structures being involved in MHC class II antigen 
processmg and presentation [23, 25-27]. The differences m internal 
compartmentalization between P-APC and NP-APC and how this relates to the 
presentation of class 11/peptide complexes is another active field of research. For 
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example, recently melanocytes have been reported to contain unique melanosomes that 
resemble conventional MHC class II antigen processing compartments and function in 
the storage, synthesis and secretion of melanins [31, 32]. Many of these melanins are 
tumor-associated antigens and therefore the generation and functioning of these 
lysosome-like compartments within melanocytes as well as similar compartments within 
other non-conventional APC is of great importance for tumor immunology and 
autoimmunity. If the compartmentalization within MDA MB 435 Dw4 is shown to be 
more like that of P-APC, this could explain the presence of the Dll +0401 epitope on 
these cells. Similarly, differences in compartmentalization within other NP-APC would 
explain the lack ofthe D11+0401 epitope. 
Although we have known for years through biochemical studies that MHC class II 
molecules contain peptides derived from endogenous proteins within their binding clefts 
[33-36], the process of how these peptides are generated within the cell is only recently 
being resolved. These peptides may be derived from either lysosomal and/or cytoplasmic 
proteolysis, and recent data strongly suggests that proteasomal proteolysis can generate 
certain MHC class II-associated peptides [9, 10]. Therefore, the proteolytic events 
leading to the generation of mature class II molecules are another active field of research. 
Although many of the individual proteases involved in class II processing have been 
defined [37-39], the exact interplay between proteases in the development of mature class 
11/peptide complexes, and how this may differ between cell types still needs further 
unravelling. 
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5.3 Future Studies 
(1) The interesting finding that endosomal and cytoplasmic proteolysis by cysteine 
proteases is important for optimal expression of the D 11 +040 1 epitope within BCL, these 
proteolytic events could be further defmed. Inhibiting cathepsin L had little effect on the 
D11+0401 epitope (data not shown). However, the effects of an abundant lysosomal 
cysteine protease cathepsin S, was not rigorously examined. For this, the inhibitor LHVS 
or the more recently developed specific inhibitor of cathepsin S, Clik60 [ 40] would be 
useful. 
(2) The strong expression ofthe D11+0401 epitope within the melanoma cell line MDA 
MB 435 DW4, but not within other NP-APC, is tantalizing. It would be insightful to 
compare its intracellular location as well as the proteolytic events that form the D11+0401 
epitope in MDA MB 435 DW4 to normal BCL. Related to this, I believe that the cellular 
restriction of the D 11 +040 1 epitope makes it a useful tool in investigating the antigen 
processing differences between P-APC and NP-APC, which may be due to 
compartmentalization and association with tetraspan molecules as well as proteolytic 
activity within the cell. Of course, the possibility that cellular-specific peptides bound to 
the DRB1 *0401 peptide binding groove are necessary for this epitope needs to be 
resolved. 
(3) To resolve this issue of peptide dependence, it would be ideal to purify D11+0401 
epitope positive DRB1 *0401 molecules by immunoprecipitation and acid elute the 
peptides from the peptide binding groove. The ability of these peptides to reconstitute 
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the D 11 +040 1 epitope in cells that do not normally express this epitope may answer if it 
is peptide-dependent. Unfortunately, the NFLD.D11 mAb has not proven to be useful for 
such biochemical assays in the past. In fact, analysis of BCL lysates by western blots 
using the NFLD.D11 mAb yields a band the size ofthe HLA-DR ~chain. Knowing this, 
we have purified DRB1 *04 molecules from SAVC using NFLD.DlO, which requires a Q 
at position 70 ofthe DR~ chain and blocks NFLD.D11 binding to SAVC. 
It is expected that the pool of DRB1*04 molecules that form the D11+0401 
epitope will lie within this NFLD.DlO-defmed DRB1 *04 population. Although not 
presented in the context of this thesis, I have purified DRB1 *0401-associated peptides 
from several BCL in order to address the issue of peptide dependence of these epitopes. 
Analysis of peptides derived from 8.1.6 0401 (D 11 +040 1 epitope positive) and 9.5 .3 0401 
(D13+0401 epitope positive) is underway within the lab and hopefully should answer 
whether or not the D11+0401 epitope is peptide dependent. If this proves to be the case, 
comparing whether these putative peptides are generated within BCL, MDA MB 435 and 
NP-APC that do not express the D11+0401 epitope could provide valuable information 
about differences in the generation of class II pMHC complexes between cell types. 
Alternatively, if the Dll +0401 and D13+0404 epitopes do prove to contain nested sets of 
peptides, it would be interesting to analyze their expression in the thymus and other 
lymphoid organs. 
(4) From the cumulative data on the D13+0404 epitope, I feel that it is important to 
investigate factors responsible for its P-APC specificity. This will hopefully lead to 
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insights into the factors responsible for its generation and also could hold valuable 
information into the differences in DRBI *04 epitope expression between P-APC and NP-
APC. For the Dl3+0404 epitope, these differences may be due to the organization of 
tetraspan protein complexes and therefore this needs further attention. As proposed for 
the D11+0401 epitope, immunoprecipitation of CD82 or CD63 in the presence of 
chemicals that either disrupt or preserve tetraspan microdomains followed by 
immunoblotting with NFLD.D13 may answer whether or not the D13+0404 epitope is 
found on DRB 1 *0404 molecules within these protein complexes. 
5.4 Concluding Statements 
In summary, I feel that studies with the mAbs NFLD.Dll and NFLD.D13 have 
yielded interesting information into numerous immunological processes. The cell type-
restricted nature of these epitopes has been useful in detecting differences in HLA-
DRBl *04 complexes in cells that would not be detected using pan-DRBl *04 mAbs such 
as NFLD.Dl. For the D11+0401 and D13+0404 epitopes, their expression on BCL and in 
the case ofD11+0401, M<l> and DC, also makes them useful tools for examining antigen 
processing and presentation differences between P-APC and NP-APC. For example, 
their absence on synovial fibroblasts indicates that the peptide repertoire on these cells is 
different from BCL even though they have a similar class II pathway with respect to 
chaperones. Similarly, other MHC class II specific mAbs have been used to dissect the 
basic mechanisms of antigen processing and presentation [41-43]. Another mAb, Y-Ae, 
which recognizes l-Ab molecules complexed with a major self-peptide, Eas2-6S [44, 45] 
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has been used to address a variety of questions, including the expression of this self 
peptide in the thymus and peripheral lymphoid organs [41, 42, 46, 47]. Also, the role of 
self peptides in positive and negative selection ofT cells has also been investigated using 
Y-Ae [48, 49], and mAb, designated G35 [50]. Of course the advantage ofworking with 
these mAbs is that they recognize murine MHC class II molecules, which makes the 
design and ethics of the appropriate experiments more reasonable. Also, the epitopes 
recognized by these mAbs are known to require specific peptides, which we do not know 
is the case for the D 11 +040 1 and D 13+0404 epitopes. 
Since NFLD.Dll and NFLD.D13 are located on the same DRBI *04 molecules 
that carry the SE, which is associated with severe RA, these mAbs might be useful to 
compare the levels of expression ofDRBl *04 on P-APC in healthy controls and patients 
presenting with RA. This may lead to some insight into the cells and HLA-DRBI *04 
molecules that are responsible for disease progression. Similarly, studies with the MK16 
mAb, which is specific for HLA-DR2 bound with the immunodominant myelin basic 
protein (MBP) peptide 85-99 have been used to study the presence of this pMHC 
complex in multiple sclerosis lesions, as well as identifying the predominant APC 
responsible for presenting this immundominant pMHC complex [51]. 
The potential involvement of tetraspan microdomains in the generation of these 
DRBI *04 epitopes makes them useful tools for studying how these microdomains 
function compared to lipid raft microdomains. Little is known about how these tetraspan 
microdomains traffic, are organized on the cell surface, and how they function to 
concentrate pMHC complexes, so ifthe DRBl *04 molecules that form the D11+0401 and 
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D13+0404 epitopes are tetrapan-associated, the NFLD.D11 and NFLD.D13 mAbs could 
be useful for answering these questions. Furthermore, the tetraspan environment on the 
surface of different cell types could explain why these epitopes are absent on synovial 
fibroblasts. 
The involvement of endosomal and cytoplasmic cysteine proteases m the 
formation of the Dl1+0401 and D13+0401 epitopes also provides information into how 
cytoplasmic proteases function in the generation of mature class II pMHC complexes. 
From a clinical perspective, the role of lysosomal cathepsins in human cancers has 
recently been under investigation. This may be due to over expression of certain 
cathepsins which may either lead to breakdown of the surrounding tissues [52], or 
through the inappropriate breakdown of antigens, which could play an active role in the T 
cell dependent anti-tumor immune response through MHC class II molecules. Therefore 
the role of lysosomal cysteine proteases in the formation ofthe D11+0401 and D13+0401 
epitopes may be important in our general knowledge of the role of these proteases in 
MHC class II maturation and functioning. 
The involvement ofDM and the inhibition of these epitopes by protease inhibitors 
only indirectly implies that peptides are involved in the expression of these epitopes. 
Comparison of the DRB1*04-associated peptides derived from 8.1.6 0401 (Dl1+0401 
epitope positive) and 9.5.3 0401 (D13+0404 epitope positive) in addition to testing if 
these peptides will be able to reconstitute these epitopes on other cells is likely to answer 
the question of peptide dependence. A potential problem to this approach could be the 
nature of the class II peptides, which are of variable lengths. Lippolis et al, 2002 [53] 
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purified peptides from DRB1 *0401 molecules and subjected them to mass spectrometry 
analysis. They found that of the 700 peptides analyzed, there appeared to be an 
abundance of nested sets of peptides sharing the same core sequence. This core sequence 
can be flanked by numerous and different amino acids, resulting in peptides with various 
lengths and charges. Because of this, peptides with the same core sequence may not elute 
in the same fractions making it difficult to obtain enough peptides to reconstitute the class 
II epitope. 
Alternatively, the NFLD.D11 and NFLD.D13 mAbs may be recognizing 
conformational epitopes on DRB 1 *04 molecules that are influenced by tetraspan 
complexes, or DM as is the case with the 16.23 epitope. Another possibility could be that 
cysteine proteases are normally generating groups of peptides that once bound to the 
DRB1 *0401 molecule, changes its conformation such that a subset of DRB1 *04 
molecules are recognized by either NFLD.D11 or NFLD.Dl3, in a similar manner to how 
25-9-17 recognizes a conformational epitope on I-A b molecules [7]. This putative 
conformation could also be influenced by the presence of DM. This, of course is mere 
speculation, but these open-ended questions may spark future research involving the 
NFLD.Dll and NFLD.D13 recognized HLA-DRBl *04 epitopes. 
Whether or not these epitopes are generated by specific peptides in the class II 
peptide binding grooves, through direct pMHC complex recognition or conformational 
changes induced by these peptides, or through protein-protein interaction between class II 
molecules and tetraspan molecules, these :mAbs will still prove useful for studying basic 
immunological processes. 
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